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RESUMO 
O câncer é o nome dado a um conjunto de mais de 100 doenças que tem 
em comum, o crescimento desordenado de células (maligno), que 
invadem os tecidos e órgãos podendo espalhar-se (metástase) para 
outras regiões do corpo e o câncer benigno, que significa simplesmente 
uma massa localizada de células que se multiplicam vagarosamente e se 
assemelham ao seu tecido original e raramente constitui risco de vida, 
dependendo do tempo de diagnóstico. Dados da Organização Mundial 
de Saúde (OMS) mostram que o câncer é a segunda principal causa de 
mortes em todo o mundo. Estima se que no ano de 2030, o câncer 
poderá matar 17 milhões de pessoas contra os 7,6 milhões de óbitos que 
provocou em 2007. Um grande esforço na busca de novos tratamentos 
para o câncer, como um tratamento mais seletivo das células 
cancerígenas vem ganhando destaque na literatura. A busca de novas 
formulações farmacêutica utilizando como ferramenta a nanotecnologia 
pode melhorar a eficácia terapêutica de fármacos já existente no 
mercado e consequentemente diminuir seus inúmeros efeitos adversos. 
Nanopartículas poliméricas (NPs) com propriedades 
superparamagneticas e superfície modificada com ácido fólico (FA) 
podem direcionar o fármaco encapsulado a uma célula tumoral alvo, no 
qual, melhora sua internalização celular (endocitose) e eficácia 
terapêutica, diminuindo assim seus efeitos tóxicos. Outra vantagem 
destes sistemas com propriedades superparamagnéticas, é que estas 
podem induzir a morte das células por hipertermia (HPT) (aumento da 
temperatura), sendo este tratamento muito mais eficaz quando associado 
a terapias convencionais, como a quimioterapia e a radioterapia. Tendo 
em conta as vantagens e desvantagens de diferentes estratégias 
terapêuticas, a ideia de combinar vários tratamentos, pode ser um 
atrativo para a próxima geração do tratamento do câncer. Com isso, o 
objetivo deste trabalho foi a síntese, caracterização e estudos in vitro das 
NPs de poli (metacrilato de metila) (PMMA) com propriedades 
superparamagnéticas, obtidas via polimerização em miniemulsão. A fim 
de verificar a eficácia das NPs como sistemas carreadores de fármacos, 
dois compostos antitumorais foram utilizados: a ftalocianina de zinco 
(ZnPc), um fotossensibilizante de segunda geração utilizado no 
tratamento do câncer via Terapia Fotodinâmica (PDT) e o lauril galato 
(G12), um derivado do ácido gálico. Com o intuito de melhorar a 
vetorização das NPs de PMMA, o AF foi usado como modificador de 
 
 
 
  
superfície. Por fim, ensaios de citotoxicidade e internalização celular 
foram realizados em células que expressam receptores folatos, com o 
objetivo de avaliar o mecanismo de entrada dos sistemas preparados. As 
NPs de PMMA obtidas via polimerização em miniemulsão 
apresentaram um tamanho nanométrico, com potencial zeta negativo e 
biocompatibilidade em células tumorais e não tumorais. A partir destes 
excelentes resultados de biocompatibilidade, a ZnPc foi incorporada nas 
NPs de PMMA (PMMAZnPc). Ensaios de citotoxicidade em células 
leucêmicas (K562 e Jurkat) mostraram um maior efeito citotóxico da 
ZnPc encapsulada em NPs que ZnPc livre, sugerindo que a morte das 
células leucêumicas foi mediada por apoptose. Em outro estudo, NPs de 
PMMA com propriedades superparamagnéticas (MNPs-PMMA) foram 
obtidas via polimerização em miniemulsão. MNPs-PMMA NPs 
apresentaram biocompatibilidade em células tumorais e não tumorais, e 
induziram a morte das células U87MG (~50%) por HPT. O tratamento 
simultâneo (PDT e HPT) sobre as mesmas células (U87MG) com o 
encapsulamento simultâneo da ZnPc e NPMs em NPs de PMMA 
(MNPsZnPc-PMMA),  apresentaram um efeito sinérgico. Os resultados 
in vitro mostraram que a aplicação da PDT e HPT simultaneamente 
podem ser mais eficazes quando aplicados simultaneamente. Por fim, 
visando uma melhor vetorização das NPs de PMMA quando o FA foi 
usado como agente ligante (FA-MNPsPMMA). A adsorção do FA nas 
NPs de PMMA com propriedades superparamagnéticas aumentou a 
internalização das NPs nas células que expressam receptores folatos 
(células K562). Em outro estudo o G12 foi incorporado nas NPs de 
PMMA. O encapsulamento simultâneo do G12 e NPMs em NPs de 
PMMA com superfície modificada, apresentou um maior efeito 
citotóxico sobre as células HeLa, quando comparado com as NPs sem 
FA. Ensaios de captação celular e citometria de fluxo demostraram uma 
maior internalização das NPs de PMMA com superfície modificada, 
sugerindo que estas são internalizadas via receptor folato mediado pelo 
mecanismo de endocitose. Além disso, o encapsulamento do G12 em 
NPs de PMMA diminui possíveis efeitos citotóxicos do G12, em células 
não tumorais e células do sangue. 
Palavra chave: ácido fólico, poli(metacrilato de metila), nanopartículas 
poliméricas, polimerização em miniemulsão, superparamagnetismo.  
 
 
 
 
 
  
ABSTRACT 
 
Polymeric nanoparticles (NPs) with superparamagnetic properties and 
surface modified with folic acid (FA) can targeted drug delivery to 
tumors, which increase their cellular uptake (endocytosis) and 
therapeutic efficacy. Furthermore, NPs with superparamagnetic 
properties can induce cell death by hyperthermia (increasing cell 
temperature), and the combination of hyperthermia (HPT) with other 
methods like chemotherapy and radiotherapy turns these treatments 
much more effective. Having regard to the advantages and 
disadvantages of different therapeutic strategies, the idea of combining 
various treatments can be attractive for the next generation of cancer 
treatment. Thus the aim of this work was to synthesize by miniemulsion 
polymerization poly(methyl methacrylate) (PMMA) NPs with 
superparamagnetic properties for biomedical applications. In order to 
verify the effectiveness of NPs as drugs carrier systems, two antitumor 
compounds were used: zinc phthalocyanine (ZnPc), a second generation 
photosensitizer used in the treatment of cancer via photodynamic 
therapy (PDT) and lauryl gallate (G12), a derivative of gallic acid. With 
the aim to improve the drug delivery, the FA was used as a surface 
modifier of NPs. Finally, cytotoxicity and cellular uptake assay were 
performed in cells that express folate receptors (HeLa) to evaluate the 
entered mechanism of the prepared systems. The NPs obtained by 
minimeulsion polymerization presented a nanometric size, negative zeta 
potential and biocompatibility in tumor and non-tumor cells. From these 
excellent results of biocompatibility, ZnPc was encapsulated in PMMA 
NPs (PMMAZnPc). Cytotoxicity assays on leukemic cells (Jurkat and 
K562) showed a higher cytotoxic effect of PMMAZnPc than free ZnPc, 
suggesting that the death leukemic cells were by apoptosis. In another 
study, NPs with superparamagnetic properties (MNPs-PMMA) were 
obtained by miniemulsion polymerization. MNPs-PMMA NPs 
presented biocompatibility in tumor and non-tumor cells inducing the 
death of U87MG cells (~50%) by HPT. Simultaneous treatment by PDT 
and HPT in U87MG cells, with the simultaneous encapsulation of ZnPc 
and NPMs in PMMA NPs (PMMA-MNPsZnPc), showed a synergic 
effect when the treatments were combined. The in vitro results showed 
that the application of PDT and HPT together can be more effective than 
each of the two treatments applied separately. Finally, aiming to 
 
 
 
 
  
improve the drug delivery efficacy, the surface of NPs were modified 
with folic acid (FA). The adsorption of the FA on PMMA NPs with 
superparamagnetic properties (FA-MNPsPMMA) increased 
internalization of NPs on cells that express folate receptors of type β 
(K562). In another study, the G12 was encapsulated in 
superparamagnetic PMMA NPs (MNPsG12PMMA-FA). The 
simultaneous encapsulation presented a higher cytotoxic effect of FA-
MNPsG12PMMA than NPs without FA, when incubated in HeLa cells. 
Cellular uptake assays and flow cytometry demonstrated a higher 
cellular uptake of FA-MNPsG12PMMA than NPs without FA, 
suggesting that these are internalized by folate receptor-mediated 
endocytosis mechanism. Furthermore, the encapsulation of G12 in 
PMMA NPs decreases possible cytotoxic effects of G12, in non-tumor 
cells and blood cells.   
 
Keywords: folic acid, poly(methyl methacrylate), polymeric 
nanoparticles, miniemulsion polymerization, superparamagnetic  
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CHAPTER 1 
1. INTRODUCTION 
 
Magnetic nanoparticles (MNPs) have been extensively studied 
for a variety of biological applications, such as, targeted drug delivery, 
in which can be guided by external magnetic field (ZHAO et al, 2011; 
ZHENG et al, 2005) and in cancer treatment by hyperthermia (FEUSER 
et al,. 2015a; KUMAR et al, 2011; SIMIONI et al, 2007). Cancer 
treatment by hyperthermia involves raising the temperature of tumor-
loaded tissues to 40–43 °C (BASE et al, 2012; DANHIER et al, 2010; 
GUPTA and GUPTA 2005). Solid tumors have been shown to have 
increased susceptibility to small temperature rises compared to healthy 
tissue due to their increased rate of cell cycling, increased hypoxia, 
reducing fluid exchange, increased acidity (pH 2-4) (BASEL et al, 2012; 
ZEE, 2002). The combination of hyperthermia with radiotherapy, 
chemotherapy and photodynamic therapy (PDT) turns these much more 
effective. However, for application in biomedical field, MNPs must 
have combined properties of high magnetic saturation, biocompatibility 
and superparamagnetic properties, in order to improve the efficacy of 
thermal therapy as a cancer treatment (HAUSER et al, 2016; KUMAR 
et al,. 2011; ZHENG et al, 2005). The use of free MNPs for these 
applications are challenging due to the high surface to volume ratio and 
strong dipole–dipole interaction between the particles, which makes 
MNPs agglomeration possible (KUMAR et al, 2014; TANG et al, 
2013). The agglomeration of MNPs can be attenuated with the 
encapsulation of MNPs in polymeric nanoparticles (NPs). The 
encapsulation of MNPs in polymeric NPs improves their chemical and 
physical stability, solubility, biological stability, target delivery and 
reduces the side effects of the encapsulated material (FAN et al, 2009; 
ZHANG et al, 2011; AKBARZADEH et al, 2012). The preparation of 
polymeric nanoparticles (NPs) with superparamagnetic properties can 
increase the site-specific drug concentration and reduce toxic effects on 
non-tumor cells or tissues, in which, it can be attracted by external 
magnetic field (targeted drug delivery) and also induce cell death by 
hyperthermia, as illustrated in Figure 1.1.  (FEUSER et al, 2015a, 2015b 
GUPTA and GUPTA, 2005; XU and SU, 2013).  
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Figure 1.1 Illustration of targeted drug delivery and treatment by hyperthermia 
when polymeric NPs are systemically administered (adapted from Mody et al, 
2013)  
NPs are drugs carrier systems able of improve pharmacokinetic 
profile and decreased drugs toxic effects. Additionally, drugs carriers 
system can control the drugs release maintaining drug levels within the 
therapeutic window, decrease risk of toxicity and acting as controlled 
release system. Today, many studies have been developed in search of 
new carrier systems to the chronic diseases treatment, such as cancer, 
tuberculosis and Leishmania. The use of polymeric NPs to cancer 
treatment is a strategy excellent mainly due to physiological difference 
of non tumor and tumor cells, as can be seen in Figure 1.2.  
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Figure 1.2 Anatomic and physiological difference of non-tumor and tumor cells 
(adapted from Chin et al, 1999) 
 
The procedure to encapsulate drugs in polymeric NPs presents 
many advantages when compared with the use of free drugs, such as: 
protective effect against drug degradation controlled or sustained 
release, possibility of drug delivery within the target tissue, and 
reduction of side effects (DE JONG and BORN, 2008; FELICE et al, 
2014; FEUSER et al, 2014; REN et al, 2013). NPs can be prepared by in 
situ polymerization (miniemulsion polymerization) and pre-formed 
polymer method (nanoprecipitation and miniemulsification solvent 
evaporation) and they can be classified, as nanocapsules (oil core) and 
nanospheres (polymeric matrix). The main advantage of the in situ 
polymerization when compared with the pre-formed polymer technique 
is the ability to produce complex nanostructures, including inorganic 
nanoparticle encapsulation in a single reaction step with fast 
polymerization rates and high drug encapsulation efficient 
(MAHDAVIAN et al, 2008; QUIU et al, 2007; ROMIO et al, 2009). In 
this work polymeric NPs were obtained from methyl methacrylate 
(MMA) monomer. Poly(methyl methacrylate) (PMMA), a polymer 
biocompatible and non-biodegradable, has been used in many 
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application in biomedical field, such as, adjuvant in vaccines and as 
carrier for many drugs including antioxidants, anti-inflammatories, 
antihistamines, antihypertensives, antidiabetics and antibiotics 
(BETTENCOURT and ALMEIDA, 2012; FEUSER et al, 2014; 
SCHADE and ROUKIS, 2010; SIVAKUMAR and RAO, 2000). Recent 
publications have shown an increasing interest in its applications as a 
drug carrier (GYERGYEKA et al, 2010; FU and KAO, 2010).    
Another strategy used to improve the pharmacokinetic profile 
and drugs cellular uptake is the functionalization or surface modification 
of NPs with ligands, such as folic acid, that has been shown to result in 
uptake of NPs by endocytosis. Folic acid (FA) (Figure 1.3) is a water-
soluble vitamin and it has been used in targeted therapy drugs in 
oncology (SAHOO et al, 2013; JIA-JYUN et al, 2009). The folate 
receptor (FR) is significantly overexpressed on the surface of different 
human tumor cells and limited expression on non-tumor cells (YANG et 
al, 2014; SAHOO et al, 2013; SALTAN et al, 2011; JIA-JYUN et al, 
2009). FR-mediated drug delivery is facilitated by endocytosis, which 
may enable drug delivery (SUDIMACK and LEE, 2000; PENGCHENG 
et al,. 2009; CHEN et al,. 2013). The NPs can be internalized across a 
plasmatic membrane (passive diffusion) and through endocytosis (NPs 
are engulfed by endocytic vesicles) (WANG et al, 2012). Several in 
vitro studies have demonstrated that the modified surface of 
nanoparticles with FA increases the cellular uptake in tumor cells that 
overexpressed FR (ZHANG et al,. 2009; DUAN et al, 2012; SAHOO et 
al, 2013; YANG et al,. 2014). However, the functionalization or 
adsorption of the ligands cannot ensure targeted drug delivery when it is 
intravenously administered (in vivo). When the functionalized NPs enter 
the bloodstream they need to cross the blood vessel endothelial cells, 
which do not express FR, in order to reach the interstitial space of tumor 
sites (CHIN and FERREIRA, 1999; ANDHARIYA et al,. 2013). To 
overcome this, a drug delivery system with superparamagnetic 
properties was proposed that could be guided by external magnetic field 
and uptake in vivo by FR mediated by endocytosis (Zheng et al,. 2005; 
Xu et al,. 2014). Furthermore, MNPs can also induce cell death by 
hyperthermia (HPT), when external alternating magnetic fields are 
applied (XU et al,. 2014, MODY et al,. 2014; FEUSER et al,. 2015a and 
2015b).  
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Figure 1.3 Chemical structure of folic acid 
 
In this work two antitumor drugs models were  used: Zinc (II) 
phthalocyanine (ZnPc) and dodecyl gallate (G12). ZnPc is a promising 
second-generation photosensitizer for PDT that belongs to the 
phthalocyanine class due to its high optical absorption coefficient (in the 
range of 600-800 nm). PDT has also been used in the treatment of solid 
tumors in the esophagus, lungs, larynx, and uterine cervix (DALMONS 
et al, 2003; DIES et al, 2013; WEN et al, 2012; ZHEN et al, 2013). 
Furthermore, there are several studies that show the use of PDT in the 
treatment of leukemia in vitro (FEUSER et al, 2015; FURRE et al, 
2005) and  a few studies that report the efficacy of in vivo PDT on 
leukemic cells (HUANG et al, 2009; WEN et al, 2012). NPs are 
promising delivery systems for use in PDT and HPT. PDT consists of 
therapeutic approaches involving the activation of photosensitized drugs 
by a visible light source, always associated with the generation of 
cytotoxic reactive oxygen species (ROS) and other free radicals, by type 
I or type II photochemistry pathway (FOOTE, 1991), to promote the 
selective destruction of target tissues (MARANHO et al, 2009; 
NAWALANY et al, 2012; RICCI-JÚNIOR and MARCHETTI, 2006; 
TRIESSCHEIJN et al, 2006). The combination of HTP and PDT has 
produced promising results indicating synergistic interaction and 
significant tumor regression (BOLFARINI et al, 2012; PRIMO and 
TEDESCO, 2013; XU and SU, 2013).The heat released by HPT induces 
changes in cell cycle, causing faster denaturation of malignant cells 
through aggregation of nuclear proteins, thereby enhancing the 
sensitivity of cells denatured previously with PDT (KUMAR and 
MOHAMAD, 2011). 
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Gallic acid (GA) is an important polyphenol compound 
presenting various biological activities. (ALVES et al, 2016; OW and 
STUPANS, 2003; WANG et al, 2007). The biological activity of GA 
and its derivatives has been described in the literature as antimalarial 
(KLEIN and WEBER, 2001), antioxidant (GRUNDHOFER and 
NIEMETZ, 2007; OW and STUPANS, 2003), antitumor (ZHAO and 
HU, 2013) and antibacterial (MANNA and KUO, 1999). G12 is an ester 
derivative of GA, with twelve carbon atoms in the side-chain, more 
efficient than GA in antiviral, antifungal, antioxidant and antitumoral 
activities (CORDOVA et al, 2011; LOCATELLI, 2013). These high 
biological activities have been correlated to the amphipathic character 
by increasing cell membranes affinity and permeability (SAEKI et al, 
2000; LOCATELLI et al, 2013). Although some of these ester 
derivatives showed a high cytotoxic activity, the chemical derivatization 
decrease their water solubility, constituting a disadvantage for 
intravenous administration (STELLA et al, 2007). Other disadvantage 
involving in vivo administration of GA is poor pharmacokinetic profile 
(low bioavailability) (ALVES et al, 2016). Therefore the encapsulation 
of drugs in polymeric NPs with superparamagnetic properties and 
modified surface can increase site-specific drug concentration (increased 
bioavailability), reduce toxic effects on non-tumor cells or tissues, 
protecting and preventing possible aggregation of encapsulated drugs 
with suitable release profile. In addition, it can improve the intravenous 
administration, when it is dispersed in aqueous medium, providing an 
excellent strategy for cancer treatment and other disease (ORTEAG et 
al, 2011).  
1.1 Objectives 
1.1.1 General objective 
 
The main goal of this work was the synthesis, characterization 
and in vitro cytotoxicity assay of MNPs and antitumor drugs 
simultaneous encapsulated in folic acid-poly(methyl methacrylate) 
nanoparticles obtained by miniemulsion polymerization.  
1.1.2 Specific objectives: 
 in vitro cytotoxicity studies of PMMA NPs obtained via 
miniemulsion polymerization; 
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 in vitro cytotoxicity studies by PDT of ZnPc loaded in PMMA 
NPs obtained via miniemulsion polymerization; 
 in vitro cytotoxicity studies by HPT of PMMA NPs with 
superparamagnetic properties obtained via miniemulsion 
polymerization; 
 in vitro cytotoxicity studies by PDT and/or HPT (simultaneous 
treatment) of ZnPc loaded in superparamagnetic PMMA NPs 
obtained via miniemulsion polymerization; 
 synthesis and characterization superparamagnetic PMMA NPs 
with  FA-surface modified obtained via miniemulsion 
polymerization and in vitro studies on cell that overexpress FR 
type β 
 synthesis and characterization of G12 loaded in 
superparamagnetic PMMA NPs with  FA-surface modified. In 
vitro cytotoxicity and cellular uptake assay on cell that 
overexpress FR type α.  
 
The next chapters of this Thesis will be present as articles. 
Chapter 2 presents the article entitled: “In vitro cytotoxicity of 
poly(methyl methacrylate) nanoparticles and nanocapsules obtained by 
miniemulsion polymerization for drug delivery application”, published 
in Journal of Nanoscience and Nanotechnology (doi: 
10.1166/jnn.2015.11610). The Chapter 3 presents the article entitled: 
“Synthesis of Znpc loaded poly(methyl methacrylate) nanoparticles via 
miniemulsion polymerization for photodynamic therapy in leukemic 
cells”, published in Materials and Engineering C (doi: 
10.1016/j.msec.2015.11.063). The Chapter 4 presents the article 
entitled: “Encapsulation of magnetic nanoparticles in poly(methyl 
methacrylate) by miniemulsion and evaluation of hyperthemia in 
U87MG cells”, published in European Journal Polymer 
(doi: 10.1016/j.eurpolymj.2015.04.029). The Chapter 5 presents the 
article entitled: “Simultaneous encapsulation of magnetic nanoparticles 
and zinc phthalocyanine in poly(methyl methacrylate) nanoparticles by 
miniemulsion polymerization and in vitro studies”, published in 
Colloids an Surfaces B: Biointerfaces (doi: 
10.1016/j.colsurfb.2015.07.067). The articles presented in Chapter 6 
entitled: “Superparamagnetic poly(methyl methacrylate) nanoparticles 
surface modified with folic acid presenting cell uptake mediated by 
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endocytosis” was published in the Journal of Nanoparticles Research. 
The article presented in Chapter 7 entitled “Synthesis of folic acid-
superparamagnetic poly(methyl methacrylate) nanoparticles loaded with 
lauryl gallate by miniemulsion polymerization and in vitro studies” was 
submitted. Lastly, in Chapter 8 a general conclusion of the work 
performed in this Thesis is presented.  
It is also important to mention that the method of simultaneous 
encapsulation of MNPs and drugs by miniemulsion polymerization was 
patented (BR 1020140133887) by Feuser et al. (2015). 
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CHAPTER 2 
IN VITRO CYTOTOXICITY OF POLY(METHYL 
METHACRYLATE) NANOPARTICLES AND NANOCAPSULES 
OBTAINED BY MINIEMULSION POLYMERIZATION FOR 
DRUG DELIVERY APPLICATION 
 
Abstract: With the objective to develop a new drug delivery systems 
without secondary effects, this study evaluated in vitro cytotoxicity in 
fibroblast cells, macrophage uptake and hemocompatibility of 
poly(methyl methacrylate) (PMMA) nanoparticles and nanocapsules 
obtained by miniemulsion polymerization. PMMA nanoparticles and 
nanocapsules presented spherical morphology, mean size 102 ± 4.2 nm 
and 211 ± 3.8 nm and  negative zeta potential - 27 ± 3.2mV, - 41 ± 4.3 
mV. In vitro cytotoxicity in fibroblast cells lines L929 and NIH-3T3 
caused no significant reduction of cells viability, which, is critical 
regarding the biocompatibility of those carriers. Assay macrophages 
uptake showed that PMMA nanoparticles presented a significant 
increase (67%) in the phagocytic uptake, when compared with PMMA 
nanocapsules (44%), indicated that higher negative zeta potential and 
small mean size influenced in the macrophages uptake. Both polymeric 
systems, presented excellent blood biocompatibility. Finally, our results 
indicate, that these polymeric systems obtained by miniemulsion 
polymerization, have the potential to be used as drug delivery system in 
the treatment of diseases, in which, macrophages act as host cells.  
 
Keywords: biomaterials, poly(methyl methacrylate); miniemulsion 
polymerization, in vitro cytotoxicity. 
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The manuscript was published in the Journal of Nanoscience and 
Nanotechnology 
doi: 10.1166/jnn.2015.11610 
2. INTRODUCTION 
 
Polymeric nanoparticles and nanocapsules obtained by 
miniemulsion polymerization have been studied extensively as carriers 
for the drug delivery systems, whose main advantages are the protection 
of the drug, controlled release, the possibility of site-specific-site drug 
delivery in the target tissue and reduction of side effects 
(LANDFESTER et al, 2009; LANDFESTER and MAILANDER, 2013; 
MORA-HUERTAS et al, 2010). Nanoparticles are matrix-type systems 
composed of an entanglement of oligomer or polymer units, while 
nanocapsules are reservoir type systems, inside of which active 
components may be confined in a cavity which consists of a liquid 
nucleus (an oil which may dissolve lipophilic agents) and surrounded by 
polymer shell in the order of nanometers. Miniemulsion is defined as 
dispersions of relatively stable oil droplets with a size range 50–500 nm, 
prepared by shearing a system containing oil, water, surfactant and 
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costabilizer (AL-GHAMDI et al, 2006; ANTONIETTI and 
LANDFESTER, 2002; ROMIO et al, 2013; TEIXEIRA et al, 2005;   
The development of biocompatible polymers, as poly(methyl 
methacrylate) (PMMA) obtained by miniemulsion polymerization has 
drawn much attention in the last decades due to their excellent 
physicochemical properties, and the potential value has been discussed 
for a variety of pharmaceutical, medical, and cosmetic applications, 
such as, medium for drug release and carries system (BETTENCOURT 
et al, 2010; FEUSER et al, 2013; LEKSHMI et al, 2010). An important 
factor in the preparation of polymeric systems for biomedical 
application is synthesis conditions and their physical-chemical 
characteristics, that will determine the type of application and the 
therapeutic level to be achieved (CHELLAT et al, 2005)
 
 
However, the most important in the preparation of polymeric 
systems for biomedical application, is their biocompatibility, preventing 
toxic effects on the physiological system (DESHAYES and KASKO, 
2013). To verify the in vitro biocompatibility of these polymeric 
systems, fibroblast cells lines are useful models for research since they 
provide large amounts of consistent cells for prolonged use and because 
most cellular characteristics are maintained reliable experimental data 
can be compared among research reports, in which, the same cell lines 
are used. Mouse fibroblast (L929) is a popular cell line in many 
experiment aspects such as material biocompatibility testing 
(BRETAGNOL et al, 2008; Zange et al, 1997) drug cytotoxicity testing 
(Faria et al, 2009; NORDIN et al, 1991) and cell biology studies 
(CARTWRIGHT et al, 1996; Taniguchi et al, 2006). Macrophage 
uptake assays, is another important study, to evaluate the accumulation 
of polymeric systems into macrophages.  
The interaction between polymeric system and macrophages, 
cells that specialize in the internalization of foreign particles is of 
interest. Macrophages enact rapid clearance of particles from the 
circulation, decrease circulating half-life of a drug. One the other hand, 
nanoparticles targeted to macrophages can be attractive, especially for 
treatment of diseases, in which, macrophages act as host cells, as for 
example, in the treatment of leishmaniasis and inflammatory diseases 
(CHELLAT et al, 2005; JAIN et al, 2015; LUNOV et al, 2011; 
SHARMA et al, 2010) 
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In order to develop new drug delivery systems without 
secondary effects, the final purpose of this study was to evaluate the in 
vitro cytotoxicity in murine fibroblast (L929) and normal human 
fibroblast (NIH-3T3), hemocompatibility and in vitro macrophage 
uptake (J774) of PMMA nanoparticles and nanocapsules, obtained by 
miniemulsion polymerization with the final goal of evaluate the 
biological activities of these nanostructured systems 
2.1 MATERIALS AND METHODS 
2.1.1 MATERIALS 
 
For PMMA nanoparticles and nanocapsules preparation the 
following reagents were used: monomer methyl methacrylate (MMA) 
from Arinos chemistry, azobisisobutylonitrile (AIBN), sodium 
phosphate monobasic (NaH2PO4) and sodium phosphate dibasic 
(Na2HPO4) were purchased from Vetec chemistry, lecithin of Alpha 
Aesar, as co-stabilizer Crodamol (Croda) and distilled water was used 
throughout the experiments. 
2.2.2 METHODS 
2.2.1.1 Synthesis of PMMA nanoparticles 
 
The preparation of PMMA nanoparticles via miniemulsion 
polymerization was the same described by FEUSER and collaborates 
(2013). In a beaker containing 20mL distilled water (aqueous phase) 
added the organic phase containing: 79 wt% MMA, 3.6 wt% Lecithin, 4 
wt% Miglyol and 14 wt% AIBN (in relation organic phase). The organic 
phase was added dropwise under higher shear with amplitude of 70% 
(Fisher Scientific, Sonic Dismembrator, 500 W). The higher shear was 
kept for 5 min (10 s on, and 1 s off) in a beaker immersed in an ice bath 
to avoid the temperature increase during sonication. The miniemulsion 
was transferred to glass tubes (10 mL) at 70 °C where the 
polymerization took place for 3 hours under light protection. 
Afterwards, the material was cooled, centrifuged and washed several 
times with phosphate buffered saline (PBS) at pH 7.4. Subsequently 
nanoparticles were transferred to glass vials, frozen in liquid nitrogen 
and lyophilized (Lyophilizer, FreeZone 4.5-L Benchtop Freeze Dry 
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System; Labconco, Kansas City, MO). The lyophilized powder was 
stored at room temperature (25 °C) before analysis. 
2.2.1.2 Synthesis of PMMA nanocapsules  
 
In a beaker containing 20mL distilled water (aqueous phase) 
added the organic phase containing: 44.4 wt% MMA, 2wt% Lecithin, 44 
wt% Miglyol and 8 wt% AIBN (in relation organic phase). The organic 
phase was added dropwise under higher shear with amplitude of 70% 
(Fisher Scientific, Sonic Dismembrator, 500W). The higher shear was 
kept for 5 min (10 s on and 1 s off) in a beaker immersed in an ice bath 
to avoid the temperature increase during sonication. The miniemulsion 
was transferred to glass tubes (10 mL) at 70 °C where the 
polymerization took place for 4 hours. Afterwards, the material was 
cooled, centrifuged and washed several times with phosphate buffered 
saline (PBS) at pH 7.4 and lyophiolized. 
2.2.1.3 Preparation of PMMA nanoparticles and nanocapsules 
labeled with 6-coumarin 
 
6-coumarin, a highly fluorescent molecule, was dissolved in 
Miglyol to form a uniform solution (0.5mg.mL
-1
). This solution (6-
coumarin/Miglyol) was used in the preparation of the miniemulsion. In a 
beaker containing 20mL distilled water (aqueous phase) added the 
organic phase containing: 79 wt% MMA, 3.6 wt% Lecithin, 4 wt% 
Miglyol and 14 wt% AIBN or 44.4 wt% MMA, 2 wt% Lecithin, 44wt% 
6-coumarin/Miglyol and 8 wt% AIBN (in relation organic phase) to 
preparation of nanoparticles and nanocapsules, respectively. The organic 
phase was added dropwise under higher shear with amplitude of 70% 
(Fisher Scientific, Sonic Dismembrator, 500W). The higher shear was 
kept for 5 min (10 s on and 1 s off) in a beaker immersed in an ice bath 
to avoid the temperature increase during sonication. The miniemulsion 
was transferred to glass tubes (10 mL) at 70 °C where the 
polymerization took place for 4 hours under light protection. 
Afterwards, the material was cooled, centrifuged and washed several 
times with phosphate buffered saline (PBS) at pH 7.4 and lyophiolized.  
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2.3 Characterization of PMMA nanoparticles and nanocapsules 
 
Average diameters (intensity averages) PMMA nanoparticles 
and nanocapsules were measured by dynamic light scattering (DLS-
Malvern Instruments, Zeta Sizer Nano S). Surface charge of the 
nanoparticles was investigated through zeta potential measurements 
(Zetasizer, Malvern Instruments, U.K.). All samples were analyzed five 
times, from which were calculated the average and standard deviation. 
The analysis was performed at 28 
o
C.  PMMA nanoparticles and 
nanocapsules morphology were observed using Transmission Electronic 
Microscopy (TEM), model JEM 2100 F 100 kV. 
2.4 In vitro studies 
2.4.1 Cell culture 
 
Mouse fibroblasts cells L929 (kindly provided by Dr. Jamil 
Assreuy, Federal University of Santa Catarina, Florianopolis, SC, 
Brazil) and NIH-3T3 (kindly provided by Dr. Antônio Cláudio Tedesco, 
University of Sao Paulo, São Paulo, SP, Brazil) were cultivated in 
Dulbecco’s Modified Eagle Medium (DMEM) (GIBCO, São Paulo, SP, 
Brazil) and supplemented with 10% fetal bovine serum (FBS) (GIBCO, 
São Paulo, SP, Brazil), 100 U/mL penicillin-streptomycin (GIBCO, São 
Paulo, SP, Brazil) and 10 mM HEPES (GIBCO, São Paulo, SP, Brazil) 
incubated at 37 
o
C in a humidified atmosphere with 5% CO2, in plastic 
culture flasks. 
2.4.2 In vitro cytotoxicity assay 
 
In order to determine PMMA nanoparticles and nanocapsules 
cytotoxicity, in vitro cytotoxicity MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide) assay (purchased from Amresco LLC, 
Solon)  was performed using L929 mouse fibroblasts (ATCC, Manassas, 
VA). Cells were arranged in flat bottom 96-well tissue culture plates 
(starting concentration: 5.0x10
4
 cells/mL, 200 mL/well). PMMA 
nanoparticles and nanocapsules were dispersed in phosphate buffered 
saline (PBS) (Laborclin, Pinhais, PR, Brazil) at final concentration of 
micrograms per millimeter. For treatment were made different dilution 
in culture media starting with concentration of 2 mg/mL. After 
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incubation, cells were exposed to different dilutions test samples for 24 
h at 37 
o
C in a humidified atmosphere with 5% of CO2. 
Cells viability was measured by MTT assay. MTT solution was 
added to cell cultures in a final concentration of 0.5 mg/mL and cells 
were incubated for 3 h. Thereafter, 100 mL of lysis solution (20% 
sodium dodecyl sulphate in 50% n,n-dimethylformamide, 0.4% acetic 
acid, and 0.04 N HCl) was added and the conversion of MTT to 
formazan by metabolically viable cells was measured by a Organon 
Teknika microplate reader (Organon Teknika, Brussels, Belgium) at 540 
nm. Each dilution was tested in three replicates. 50% of inhibition 
concentration (IC50) was determined by GraphPad Prism version 5.01 
(GraphPad Software Inc, La Jolla, CA, USA). 
2.4.3 Cell analysis by fluorescence microscopy   
 
The intracellular fate of carrier systems marked with 6-
coumarin (nanoparticles and nanocapsules labeled) were evaluated with 
fluorescence microscopy. L929 and NIH-3T3 cells (starting 
concentration: 1.0x10
6
 cells/mL, 200 mL/well) were incubated with 
carrier systems, at concentration of 250 µg/mL. After 24 h of 
incubation, cells were washed with PBS and the coverslips covering the 
bottom of the plate were removed and placed on a glass slide. Cells 
were analyzed under a fluorescence microscope (Olympus BX41). The 
cell morphology was evaluated by optical microscopy and the 
fluorescence of 6-coumarin was monitored by fluorescence microscopy. 
Cells images were acquired using emission mode with 20 x objectives 
after exciting the sample from 450 to 490 nm using barrier filter. 
Fluorescence imaging in wavelength of 505 nm was collected. In order 
to quantify the 6-coumarin fluorescence, image analysis was performed 
using ImageJ software. 
2.4.4 Macrophage Uptake Studies 
 
Phagocytic uptake and intracellular fate of fluorescent free 6-
coumarin, PMMA nanoparticles and nanocapsules labeled with 6-
coumarin at concentration 300 µg.mL
-1
 were monitored by fluorescence 
microscopy upon incubation with murine macrophage-like J774 cells. 
Cell uptake was determined in cells grown near to confluence on 
coverslips in 24-well plates. After 60 minutes of incubation with free 6-
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coumarin, PMMA nanoparticles and nanocapsules labeled with 6-
coumarin at 37 ºC, the treatment solutions were removed, and cells were 
washed with phosphate buffered saline (PBS). For uptake analysis by 
fluorescence microscopy, the coverslips were mounted on a 
fluorescence microscope (Olympus BX-FLA) and the fluorescence of 6-
coumarin was monitored. Cells images were acquired using emission 
mode with 40x objectives after exciting the sample from 450 to 490 nm 
using barrier filter. Fluorescence imaging in wavelength of 505 nm was 
collected. In order to quantify the macrophage uptake, image analysis 
was performed using ImageJ software. 
2.4.5 Hemolysis assay 
 
Citrate-stabilized human blood was freshly collected according 
to an approved University of Utah Institutional Review Board protocol 
used within 3 hours of being drawn. 4 mL of whole blood was added to 
8 mL of a sterile solution of sodium chloride in water (saline) and the 
RBCs were isolated from serum by centrifugation at 10,000 × g for 5 
minutes, this method was previous described in the literature (WANG et 
al, 2009; YU et al, 2011). The RBCs were further washed five times 
with saline solution. Following the last wash, the RBCs were diluted to 
2 mL of saline. 120 µL of the diluted RBC suspension was added to 880 
µL of water or saline. Samples were treated with PMMA nanoparticles 
and nanocapsules at 10 µl (70 µg.mL
-1
), 25µl (150 µg.mL
-1
 and 50 µl 
(300 µg.mL
-1
) volume. All samples were prepared in triplicate and the 
suspension was briefly vortexed before leaving under gentle stirring at 
37 °C for 60 minutes. After that, the mixture was briefly vortexed again 
and centrifuged at 10.000 × g for 5 minutes. 100 μL of supernatant was 
transferred to a 96-well plate. The absorbance value of hemoglobin at 
570 nm was measured with the reference wavelength at 540 nm. 120 µL 
of the diluted RBC suspension incubated with 880 µL of water and 
saline were used as the positive and negative control, respectively. 
Hemolysis percent was calculated as:  
Hemolysis (%) = [(Sample absorbance – negative control)/(positive 
control – negative control)] × 100 
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2.5 Statistical Analysis 
 
The results are presented as means ± SEM. The statistical 
significance between groups was determined by analysis of variance 
(ANOVA) followed by Bonferroni’s multiple comparison test. P-values 
less than 0.05 were considered indicative of significance. IC50 values 
were determined by graphical interpolation from individual 
experiments.  
2.6 RESULTS AND DISCUSSIONS 
 
The evaluation of the morphology and particle size is of 
fundamental importance, when it is desired obtain polymeric systems 
for biomedical application, which, may have important biological 
implications on cellular uptake and biological processes (HE et al, 2010; 
ZHANG et al, 2008; DANHIER et al, 2010). Figure 2.1 shows mean 
size determinate by DLS and TEM analysis. The results obtained by 
DLS showed that PMMA nanoparticles and nanocapsules exhibited low 
polydispersity index (PdI) and mean diameter of approximately 
102 ±4.2 nm and 211 ±3.8 nm respectively, for PMMA nanoparticles 
and nanocapsules. TEM analysis corroborate with results obtained by 
DLS. PMMA nanoparticles and nanocapsules presented spherical 
morphology and regular size distribution of nanoparticles and 
nanocapsules.   
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Figure 2.1 Dynamic light scattering (left) and transmission electron microscopy 
images (right) of PMMA nanoparticles and PMMA nanocapsules. 
 
Other important factor in the polymeric systems preparation is 
the surface charge, which gives information about the colloidal stability, 
blood time circulation and possible interactions between nanoparticles 
and biological medium (HE et al, 2010; ZHANG et al, 2008; DANHIER 
et al, 2010). PMMA nanoparticles and nanocapsules presented negative 
surface charge, - 40 ± 4.3 mV and - 27 ± 3.2mV, respectively. The 
negative charge is associated with the presence of surfactants (lecithin) 
adsorbed in the PMMA nanoparticles and nanocapsules surface. 
Lecithins have compounds, such as, free acids or negatively charged 
phospholipids, which confer a negative charge (ROMIO et al, 2013). 
The difference of zeta potential, between PMMA nanoparticles and 
nanocapsules, can be related with the lecithin, located on the core oil of 
polymer, wherein, the polymeric wall formed around the oil droplets 
very thick and consequently decreasing the surface charge (LOSA et al, 
1993; CALVO et al, 1996).    
Cytotoxic effect of PMMA nanoparticles and nanocapsules 
were analyzed in L929 and NIH-3T3 mouse fibroblast cells by MTT 
assay for 24 hours (Figure 2.2).  When the L929 and NIH-3T3 cells 
were exposed with PMMA nanoparticles and nanocapsules both cells 
presented a slightly reduced of cell viability, approximately 81% and 
84% in the L929 cells and 84% and 81% in the NIH-3T3 cells 
respectively at concentration 750 µg.ml
-1
 (Figure2.2). 
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Figure 2.2 In vitro cytotoxicity of PMMA nanoparticles and nanocapsules in 
L929 and NIH3T3 cells exposed 24 h. (*p>0.05 Bonferroni’s multiple 
comparison test) 
 
The effect of polymeric systems on fibroblasts morphology was 
evaluated by optical microscopy, and fluorescence microscopy using 6-
coumarin as fluorescent dye. It can be seen in Figure 2.3 that there were 
no significant changes in cell morphology even after the incorporation 
of 6-coumarin. The use of L929 cells are recommended by ISO 10993-5 
to in vitro cytotoxicity assay of news materials for biomedical 
application. According to ISO 10993-5, cell viability <70% compared to 
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untreated cells are considered cytotoxic. Therefore it can be said that the 
nanoparticles and nanocapsules obtained in this work via miniemulsion 
polymerization exhibit biocompatibility. 
 
Figure 2.3 Optical and fluorescence microscopy images of L929 and NIH-3T3 
cells after 24 hours of incubation with PMMA nanoparticles and nanocapsules 
labeled with 6-coumarin. (*p <0.001) using one-way ANOVA followed by 
post-test Bonferroni’s. 
 
 Uptake of 6-coumarin-loaded nanoparticles by macrophages 
was monitored by morphologic observation of the cells after 60 min of 
incubation (Figure 2.5). Green fluorescence indicates the intracellular 
accumulation of 6-coumarin. PMMA nanoparticles and nanocapsules 
labeled with 6-coumarin seemed scarcely captured by cells, as can be 
observed by the weak fluorescence in the cytoplasm of the 
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macrophages. On the other hand, free 6-coumarin was actively 
phagocytized and accumulated into the cells, as evidenced by their 
bright fluorescence. The quantification of intracellular fluorescence 
(Figure 2.4) to the PMMA nanoparticles (67%) showed a higher 
phagocytic uptake when compared with PMMA nanocapsules (44%). 
This increase in the phagocytic uptake of PMMA nanoparticles, can be 
related, with the mean size, morphology, surface charge and surface 
chemistry of polymeric systems (HE et al, 2010; KIM et al, 2011; 
SHANG et al, 2014). In this study, PMMA nanoparticles were 
phagocytized more efficiently by J774 cells. This difference in the 
macrophages uptake is attributed with surface charge and surface 
chemistry of polymeric systems, as previously discussed. Our results 
indicated PMMA nanoparticles and nanocapsules can be used as a 
platform for drug transport, especially for treatment of diseases, in 
which, macrophages act as host cells (CHELLAT et al, 2005). 
Macrophages play a central role in inflammation and act as reservoirs 
for bacterium and parasites, which are involved with infectious diseases, 
as tuberculosis and leishmanisis (JAIN et al, 2015; LUNOV et al, 2011; 
SHARMA et al, 2010).
  
 
Figure 2.4 Macrophages Uptake Assay. Optical and fluorescence microscopy 
images of J774 cells  after 60 minutes incubation in the dark with free 6-
coumarin, PMMA nanoparticles and nanocapsules labeled with 6-coumarin. (*p 
<0.001) using one-way ANOVA followed by post-test Bonferroni’s. 
49
 
 
 
  
 
Figure 2.5 Effects of nanoparticles systems on 6-coumarin macrophages 
uptake. Optical and fluorescence microscopy images of J774 cells upon 60 
minutes incubation in the dark with free 6-coumarin, PMMA nanoparticles and 
nanocapsules labeled with 6-coumarin (* p <0.001) using one-way ANOVA 
followed by posttest Bonferroni’s. 
50
 
 
 
  
The impact of nanoparticle and nanocapsules on human red 
blood cells (RBCs) was evaluated by hemolysis assay. The quantitation 
of hemoglobin in the supernatant of nanoparticle-RBC mixture was 
done recording the absorbance of hemoglobin at 540 nm. Treatment 
with 10 µl, 25 µl and 50 µl of PMMA nanoparticles and nanocapsules 
was not able to cause hemolysis of RBCs suggesting that these systems 
do not have hemolytic capacity, even when administered at high 
concentrations (Figure 2.6). In others words are similar to the original 
plasma, which indicates that the materials have no obvious activation to 
coagulation factors and thrombin generation (ZHOU et al, 2011). The 
hemolysis assay is considered to be a supplementary assay for 
assessment of cytotoxicity and plays an important role in evaluation of 
biosafety.  The results showed that PMMA nanoparticles and 
nanocapsules obtained by miniemulsion polymerization have high blood 
biocompatibility, which can be an alternative for drugs carrier systems 
administered systemically. The results showed that the hemolytic ratio 
of the nanoparticles and nanocapsules are within the range of less than 
5%, the critical safe hemolytic ratio for biomaterials according to 
ISO/TR 7406, which indicated that the damage of the sample on the 
erythrocytes was little. 
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Figure 2.6 Hemolysis assay. Relative rate of hemolysis in human RBCs upon 
incubation with PMMA nanoparticles and nanocapsules respectively at 10 µl, 
25 µl and 50 µl volume. Data were mean ± SD (n=3). (*p <0.001) using one-
way ANOVA followed by posttest Bonferroni’s. 
2.7 CONCLUSIONS 
 
The synthesis of PMMA nanoparticles and nanocapsules 
obtained by miniemulsion polymerization resulted in a stable polymeric 
system in aqueous dispersion, with low polydispersity index and good 
biocompatibility using high concentrations of nanoparticles. Hemolysis 
assay showed that polymeric systems can be systemically administered 
without causing any damage to the blood system. Altogether, this study 
showed that PMMA nanoparticles can be used as drug delivery, in the 
diseases treatments, in which, macrophages act as host cells. PMMA 
nanocapsules proved to be less efficient in macrophages uptake, may 
increasing blood circulating half-life.  Finally, conclude that polymeric 
systems obtained by miniemulsion polymerization, can be used as drug 
delivery system in macrophages. Future studies, such as, encapsulation 
of drugs for leishmaniasis treatment and internalization assay in 
leishmaniasis parasites will be underway. 
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CHAPTER 3 
SYNTHESIS OF ZNPC LOADED POLY(METHYL 
METHACRYLATE) NANOPARTICLES VIA MINIEMULSION 
POLYMERIZATION FOR PHOTODYNAMIC THERAPY IN 
LEUKEMIC CELLS 
 
Abstract: The goal of this work was to synthesize and characterize 
ZnPc loaded poly(methyl methacrylate) (PMMA) nanoparticles (NPs) 
by miniemulsion polymerization. Biocompatibility assays were 
performed in murine fibroblast (L929) cells and human peripheral blood 
lymphocytes (HPBL). Finally, photobiological assays were performed in 
two leukemic cells: chronic myeloid leukemia in blast crisis (K562) and 
acute lymphoblastic leukemia (Jurkat). ZnPc loaded PMMA NPs 
presented an average diameter of 97 ± 2.5 nm with a low polydispersity 
index and negative surface charge. The encapsulation efficiency (EE %) 
of ZnPc PMMA NPs was 87 % ± 2.12. The release of ZnPc from 
PMMA NPs was slow and sustained without the presence of burst 
effect, indicating homogeneous drug distribution in the polymeric 
matrix. NP biocompatibility was observed on the treatment of peripheral 
blood lymphocytes and L929 fibroblast cells. Phototoxicity assays 
showed that the ZnPc loaded in PMMA NPs was more phototoxic than 
free ZnPc after activation with visible light at 675 nm, using a low light 
dose of 2 J/cm
2
 in both leukemic cells (Jurkat and K562). The results 
from fluorescence microscopy (EB/OA) and DNA fragmentation 
suggest that the ZnPc loaded PMMA NPs induced cell death by 
apoptosis.  Based on presented results, our study suggests that PDT 
combined with use of polymeric NPs, may be an excellent alternative 
for leukemia treatment.   
 
Keywords: leukemia, miniemulsion, polymeric nanoparticles, 
photodynamic therapy. 
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3. Introduction 
 
The development of polymeric nanoparticles (NPs) as drug 
carriers has been drawing significant interest in recent years, due to their 
promising applications in cancer therapy. The procedure to encapsulate 
drugs in NPs presents many advantages when compared with the use of 
free drugs, such as: protective effect against drug degradation controlled 
or sustained release, possibility of drug delivery within the target tissue, 
and reduction of side effects (DE JONG and BORN, 2008; FELICE et 
al, 2014; FEUSER et al, 2014; REN et al, 2013). Poly(methyl 
methacrylate)  (PMMA), a biocompatible and non-biodegradable 
polymer, has been used as an adjuvant in vaccines and is a carrier for 
many drugs (BETTENCOURT and ALMEIDA, 2012; FEUSER et al, 
2014), including antioxidants, anti-inflammatories, antihistamines, 
antihypertensives, antidiabetics and antibiotics (BETTENCOURT and 
ALMEIDA, 2012; SCHADE and ROUKIS, 2010; SIVAKUMAR and 
RAO, 2000). Polymeric NPs can be prepared by miniemulsion 
polymerization or preformed polymers (GUTERRES et al, 2007; 
SCHAFFAZICK et al, 2003; HUANG et al, 2007; MORA-HUERTAS, 
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2010). Miniemulsion polymerization allows the synthesis of polymeric 
NPs with unique characteristics, great commercial interest, and 
possibility of incorporation of drugs with low solubility in the 
continuous phase. In general, miniemulsions consist of small droplets 
(50-500nm) dispersed in an aqueous phase. In order to stabilize such a 
direct miniemulsion, droplet coalescence is suppressed by the surfactant 
that stabilizes the particles electrostatically or sterically. Since the 
miniemulsion features a distribution in droplet size, the bigger droplets 
can grow due to a mass flux from the smaller ones as Laplace pressure 
increases with decreasing droplet size, this phenomenon is known as 
molecular diffusion degradation or Ostwald ripening. The 
ultrahydrophobe prevents diffusion degradation by introducing a 
counterforce to the Laplace pressure, since the smaller particles would 
contain a higher concentration of the ultrahydrphobe, which increases 
the osmotic pressure (ASUA, 2014; HIGUCHI and MISRA, 1962). The 
main advantage of the miniemulsion polymerization process is the 
ability to produce complex nanostructures, including inorganic 
nanoparticle encapsulation in a single reaction step with fast 
polymerization rates (MAHDAVIAN et al, 2008; QIU et al, 2007).  
PDT is a current therapy that involves the administration of a 
non-toxic dye and the activation of photosensitizers with visible light 
(SIQUEIRA-MOURA et al, 2007). The activated photosensitizers are 
able to react with tissue oxygen producing reactive oxygen species 
(ROS) and other free radicals. ROS and free radicals are cytotoxic and 
formed by photochemical reactions type 1 or 2, respectively (FOOTE, 
1991). Tumor cells are selectively eliminated after visible light 
application in the lesion site (DALMONS et al, 2003); MARANHO et 
al, 2009; OLEINEICK et al, 2002; RICCI-JÚNIOR and MARCHETTI, 
2007; SAVOLAINEN et al, 2008; TRIESSCHEIJN et al, 2007; ZHEN 
et al, 2013). Efficient photosensitizers should have high absorbance at a 
wavelength suitable for the desired application (RAI et al, 2010), 
generally, near the maximum absorbance wavelength of the PS, 
avoiding interference from natural endogenous molecules. PDT has 
been widely used for treating superficial tumors such as skin, head, and 
neck tumors (PRIMO and TEDESCO, 2013; RAI et al, 2010; ROCHA 
et al, 2012). PDT has also been used in the treatment of solid tumors in 
the esophagus, lungs, larynx, and uterine cervix (DALMONS et al, 
2003; DIES et al, 2013; ie et al, 2012; ZHEN et al, 2013). Furthermore, 
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there are several studies that show the use of PDT in the treatment of 
leukemia in vitro (FEUSER et al, 2015; FURRE et al, 2005). However, 
there are a few studies that report the efficacy of in vivo PDT on 
leukemic cells (HUANG et al, 2009; WEN et al, 2012). In an in vivo 
study, Wen and collaborators (2014), evaluated the efficacy of PDT on 
(A20) murine B-lymphoma leukemia cells, where microphotofibers 
(200 μm diameter) were inserted into tail veins and irradiated with a 
laser. The results showed an excellent efficacy of PDT on leukemic 
cells, resulting in cell death by apoptosis. This study showed that PDT 
could be an excellent alternative for leukemia treatment. According to 
Barth and collaborators (2011) leukemia only presents a challenge to 
photosensitizer or nanoparticle uptake when compared with solid 
tumors. Moreover, manifestation of leukemia throughout the body 
creates added challenges to the successful light delivery necessary for 
PDT. Currently, the development of optical fibers and laser devices with 
high light diffusion, associated with endoscopic minimum invasive 
treatment, allows us to use T-cell lymphoma and B-cell lymphoma, not 
only as model to understand the interaction and cellular behavior of the 
photosensitizers with this kind of cell, but also to imagine the use of 
PDT in the future treatment of these diseases, which is supported by 
previous reported studies (BICALHO et al, 2013; LONGO et al, 2013; 
TANAKA et al, 2001). 
Zinc (II) phthalocyanine (ZnPc) is a second-generation 
photosensitizer for PDT. It belongs to a class of lipophilic 
phthalocyanines and has high optical absorbance coefficient within the 
600-800 nm range. These photosensitizers are insoluble in water and 
prone to self-aggregation in aqueous solutions, which drastically reduces 
the photosensitizing efficiency restricting its direct use in biological 
fluids (RICCI-JÚNIOR and MARCHETTI, 2007). Many drug delivery 
systems containing photosensitizers have been described in the 
literature, and the results demonstrate a higher therapeutic efficacy by 
PDT than free photosensitizers, in which these drug delivery systems 
tend to prevent aggregation and photosensitizers toxicity (RICCI-
JÚNIOR and MARCHETTI, 2007; ROCHA et al, 2012; SIQUEIRA-
MOURA et al, 2007). Finally, the goal of this study was to synthesize 
and characterize ZnPc loaded poly(methyl methacrylate) (PMMA) 
obtained by miniemulsion polymerization (PMMAZnPc). 
Biocompatibility assays were performed in murine fibroblast (L929) 
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cells and human peripheral blood lymphocytes (HPBL). Finally, 
phototoxicity activity was evaluated in two leukemic cells: chronic 
myeloid leukemia in blast crisis (K562) and acute lymphoblastic 
leukemia (Jurkat).   
3.1 MATERIALS AND METHODS 
3.2 Materials 
 
For the synthesis of ZnPc loaded PMMA NPs the following 
reagents were employed: the monomer methyl methacrylate (MMA), 
purchased from Arinos; azobisisobutylonitrile (AIBN), sodium dodecyl 
sulfate (SDS), NaH2PO4 (sodium phosphate monobasic) and Na2HPO4 
(sodium phosphate dibasic), purchased from Vetec; lecithin (Alpha 
Aesar); miglyol 812 (Sazol) and zinc (II) phthalocyanine (ZnPc) and N-
methylpyrrolidone (NMP), both purchased from Sigma Aldrich. 
Distilled water was used throughout the experiments. 
3.3 Methods 
3.3.1 Synthesis of ZnPc loaded in PMMA NPs via miniemulsion 
polymerization (PMMAZnPc) 
 
ZnPc loaded in PMMA NPs was obtained by miniemulsion 
polymerization. Briefly, 1 mL of NMP containing 6 mg of ZnPc was 
added dropwise in a beaker containing 20 mL of distilled water 
(aqueous phase) under sonication with a 70% amplitude (Fisher 
Scientific, Sonic Dismembrator, 500 W). Next, the organic phase 
(containing 2 g of MMA, 0.1 g of lecithin, 0.1 g of miglyol and 0.04 g 
of AIBN) was added dropwise under high shear to the previous aqueous 
ZnPc dispersion. The sonication was continued for five minutes (10 s on 
and 1 s off) in a beaker immersed in an ice bath to avoid temperature 
increases during sonication. The miniemulsion was transferred to glass 
tubes (10 mL) at 70°C, where the polymerization took place for three 
hours under the protection from light. Afterwards, the material was 
cooled, centrifuged and washed several times with PBS at pH 7.4. 
Subsequently, NPs were transferred to glass vials, frozen in liquid 
nitrogen and lyophilized (FreeZone 4.5-L Benchtop Freeze Dry System; 
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Labconco, Kansas City, MO). The lyophilized powder was stored at 
room temperature (25°C) before analysis.  
3.3.2 Characterization  
 
Monomer consumption was followed by gravimetric analysis as 
described by Bernardy nd collaborates (2010). Latex samples taken at 
different time intervals were put into aluminum capsules that contained 
0.3 g of 1 wt % hydroquinone aqueous solution. The NPs were dried at 
60 °C until weight was constant. Conversion was determined as the ratio 
between experimental and theoretical polymer content, disregarding the 
fraction of non-volatile components, such as emulsifiers, co-stabilizers, 
photosensitizers and hydroquinone that was added to stop the 
polymerization reaction. The final residual monomer content was 
determined by GC (GC2010AF Shimadzu). Intensity mean diameters of 
the monomer droplets and polymeric NPs were measured by dynamic 
light scattering (DLS-Malvern Instruments, Zeta Sizer Nano S, UK). 
The surface charge of the NPs was investigated through zeta potential 
measurements (Zetasizer, Malvern Instruments, U.K.). All samples were 
analyzed five times at room temperature (28
o
C) and the results were 
presented as mean and standard deviation. The NPs morphology was 
analyzed using transmission electron microscopy (TEM) (model JEM 
2100F, 100 Kv). For this analysis, several drops of the diluted samples 
were placed on a 200-mesh Formvar/carbon copper grid (Electron 
Microscopy Science). After drying, samples were sputter-coated with a 
thin carbon film to avoid PMMA degradation under the electron beam 
and observed at 100 kV. 
UV-vis analysis was performed in order to evaluate the 
photochemical properties of ZnPc loaded PMMA NPs. A known 
amount of ZnPc loaded PMMA NPs were extracted with NMP 
(3µg.mL
-1
) and the wavelength was analyzed in the visible range (500 –
 800 nm). The ZnPc release and the encapsulation efficiency (EE%) 
were determined by UV-vis spectrophotometry. NPs (10 mg) were 
dissolved in NMP, which is an excellent solvent for both drug and 
polymer. The ZnPc concentration was measured at 675 nm (region 
visible spectrum) using a calibration curve with different concentrations 
of ZnPc dispersed in NMP. The coefficient of determination (r
2
) 
exceeded 0.999, with excellent linearity (20-200 ng). The EE% was 
calculated from Eq 1: 
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where EE (%) is the ZnPc encapsulation efficiency, M1 is the mass of 
ZnPc loaded NPs, and Mt is the ZnPc mass used in formulation. The 
experiments were conducted in triplicate (n = 3). 
The crystalline phase of the ZnPc and NPs were identified by 
measurements of X-ray diffraction (XRD) using Cu-Kα (1.54056 Å) at 
45 kV/40 mA in an XRD model Xpert-Pro. NP chemical 
characterization was performed by Fourier transform infrared 
spectroscopy (FTIR) using KBr pellets.  
3.4 In vitro studies 
3.4.1 In vitro release of ZnPc from PMMA NPs  
 
The in vitro release followed studies described by Ricci-Junior 
and Marchetti (2006). NPs (5 mg) were weighed and added to 30 mL of 
the receptor medium, composed of PBS (pH 7.4) and 2 wt.% SDS. The 
NPs suspension was continuously stirred (100 rpm) and the temperature 
was maintained at 37 
o
C in a thermostatically controlled water bath. At 
given time intervals, six samples (n = 6) of 3 ml were withdrawn and 
centrifuged at 10,000 × g for 30 min (Beckman J-25 centrifuge, USA). 
The precipitates were re-suspended in 3 ml of fresh medium and placed 
in the respective dissolution vessels. The drug released in the receptor 
medium was quantified by spectrophotometry using the visible region of 
the spectrum (670 nm). The release profile was obtained by associating 
the percentage of drug released with time. The release data were fitted 
utilizing the zero order, first order and Higuchi mathematical models 
described by Costa and Lobo (2001).
 
 
3.4.2 Photobiological activity  
 
Two human leukemia cell lines were used in this study: chronic 
myeloid leukemia in blast crisis (K562) and acute lymphoblastic 
leukemia (Jurkat). Cells were cultured in Roswell Park Memorial 
Institute Medium (RPMI) (GIBCO, São Paulo, SP, Brazil) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 
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100 U/ml penicillin, 100µg.mL
-1
 streptomycin and 10 mM HEPES 
under 5% CO2 humidified atmosphere in 75 cm
2
 flasks at 37°C. Cell 
lines were purchased from American Type Culture Collection (ATCC, 
Rockville, MD, USA). Cell viability counts were obtained using the 
Trypan blue exclusion assay.  In order to assess the cytotoxic effect, 
K562 and Jurkat cells were cultured at a density of 5 x 10
4
 and 1 x 10
5
, 
respectively, in 96-well plates. Cells were incubated (1 h) with PMMA 
NPs at concentrations of 10, 20, 40 and 100 µg.mL
-1
 of PMMA, and 
free and loaded ZnPc in PMMA NPs at concentrations of 24.50, 30.62, 
49.00 and 61.25 ng of ZnPc. The incubation time was determined 
according to the experimental protocol described in PDT cell culture 
literature (LONGO et al, 2013). Following the incubation time, cells 
were centrifuged, resuspended with 200µL of RPMI, exposed to a 
visible light (675 nm) dose of 2 J/cm
2
 (Photon Lase I, DMC, Brazil), 
and incubated for 24 h. Cell viability was assessed using the classic 
MTT assay (Sigma, MO, USA). Cells without treatment were irradiated 
with a visible light (675 nm) dose of 2 J/cm
2
, and used as a negative 
control, in order to evaluate light cytotoxicity. The viability of the 
control group was considered as 100%. The half maximal inhibitory 
concentration (IC50) was determined for ZnPc loaded in PMMA NPs. In 
order to verify the cytotoxic effect of ZnPc loaded PMMA NPs without 
light exposure, cells were incubated for 1h and submitted to the same 
protocol described above.  
Murine fibroblast cells (L929) were cultivated in Dulbecco’s 
Modified Eagle Medium (DMEM) (GIBCO, São Paulo, SP, Brazil) and 
incubated (5% CO2, 37°C) for 24 h. DMEM was supplemented with 
10% fetal bovine serum (FBS) (GIBCO, São Paulo, SP, Brazil), 
100 U/mL penicillin-streptomycin (GIBCO, São Paulo, SP, Brazil) and 
10 mM HEPES (GIBCO, São Paulo, SP, Brazil). After 24 h, cells L929 
were treated with ZnPc loaded PMMA NPs at concentrations near IC50 
and free PMMA NPs at a final concentration of 50µg.mL
-1
 and 
incubated (5% CO2, 37°C) for 1 h. After incubation, the medium 
containing the NPs was discarded and the cells were washed with PBS. 
Afterwards, the cells were incubated with fresh medium for an 
additional 24 h, until the cell viability assay (MTT) was performed.  
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3.4.3 MTT assay 
 
The cell MTT proliferation method was used to assess cell 
viability after both the cytotoxic assays. Briefly, aliquots of 100 μl MTT 
solution (5 mg.mL
-1
) and 100 μl medium were added to each well. The 
cells were then incubated for 4 h (37°C and 5% CO2) to allow the 
formazan formation reaction. Following incubation, the medium 
containing the MTT solution was removed and the formazan crystals 
were dissolved in dimethyl sulfoxide (DMSO). The optical density was 
measured at 550 nm using a Safire
2
 microplate reader (Tecan Group 
Ltd.). Results are presented as survival percentage, considering the 
control (untreated cells) as 100%.  
3.4.4 Human peripheral blood lymphocytes (HPBL) 
 
This study was approved by the Medical Ethics Committee 
238/03. Five non-smoking healthy volunteers, who had never been 
treated with any cancer drugs, participated in this study between August 
2011 and September 2011 at the Polydoro Ernani de São Thiago 
University Hospital (Florianópolis, Brazil). Blood samples were 
collected and human peripheral blood lymphocytes were isolated using 
the Ficoll-Hypaque method. After diluting blood with PBS, 
lymphocytes were isolated by centrifugation over a Ficoll-Hypaque 
density gradient (density = 1.070 g/ml) for 30 min at 2000 rpm. Cells 
were washed twice with PBS and subsequently suspended in RPMI with 
10% fetal bovine serum. The isolated lymphocyte viability was 
measured using the Trypan blue exclusion assay and found to be around 
95%. The HPBL cells (1 x 10
6 
cells/200 µL) were incubated for 1 h with 
ZnPc loaded PMMA NPs at final concentrations of 35.07 and 46.88 
ng.mL
-1
 (concentrations near IC50) at 37
o
C in a humidified atmosphere 
with 5% CO2. After incubation for 1 h, cells were centrifuged, 
resuspended with 200 µL of RPMI, exposed to a visible light (675 nm) 
dose of 2 J/cm
2
 and incubated again for 24 h. Two controls were used: a 
non-treated group and a group treated with 25 µg.mL
-1
 of taxol, a 
compound already used in leukemia treatment clinical protocols. The 
protocol used for cytotoxic activity evaluation is the same as previously 
described. 
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3.4.5 Acridine orange – ethidium bromide (AO-EB) staining and 
DNA fragmentation  
 
Apoptotic cells were stained with acridine orange - ethidium 
bromide (AO-EB) and examined with a fluorescence microscope. For 
morphological observations, K562 and Jurkat, with concentrations of 
5 x 10
5 
and 1 x 10
6 
cells/well respectively, were treated with ZnPc 
loaded NPs at concentration near IC50. After 1 h incubation, cells were 
centrifuged, resuspended with 200 µL of RPMI, exposed to a visible 
light (675 nm) dose of 2 J/cm
2
 and incubated again for 24 h. The 
supernatant was removed and the cells were stained with a 1% AO-EB 
(1:1) solution and observed under a fluorescence microscope (Olympus 
BX41). Fields were photographed with a digital camera. 
DNA fragmentation assay is another technique used to evaluate 
apoptotic cells. K562 and Jurkat cells were treated with ZnPc loaded 
PMMA at concentrations of IC50 (6x10
6
 cells/well, IC50) with an 
incubation time of 1 h.  Subsequently, the cells were washed with PBS 
and separated by centrifugation. Cells were exposed to a visible light 
(675 nm) dose of 2 J/cm
2
 and incubated for 24 h. After incubation, the 
cells were separated by centrifugation and lysed cells were suspended in 
PBS solution. The genomic DNA was obtained using the mini 
preparation kit with a spin column. The genomic DNA was separated on 
a 2% agarose gel stained with 1 µg.mL
-1
 ethidium bromide for 40 min at 
80 V. 
3.5 Statistical analysis 
 
Data are presented as the mean±standard deviation of three 
determinations. One-way ANOVA followed by the Bonferroni post-hoc 
test were used to compare the cytotoxicity of the samples at different 
concentrations. Statistical analyses were performed using the Statistical 
Package for Social Sciences for Windows (SPSS Inc. version 13.0, 
USA). The statistical significance level was set at p <  0.05 for all 
analyses. 
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3.6 RESULTS AND DISCUSSION 
 
Measurements of the conversion reaction (Figure 3.1) indicated 
that after 170 minutes of reaction the conversion reached almost 100%. 
The reactions kinetics showed that ZnPc presence did not affect the 
polymerization rate. The final conversion was slightly below 100%, 
probably due to the loss of monomer (MMA) by evaporation during the 
stages of emulsification and polymerization. Monomer evaporation may 
occur due to high vapor pressure of the MMA (FEUSER et al, 2014). 
Residual monomer (MMA) was not detected by GC analysis after 
lyophilization of ZnPc loaded PMMA NPs. The non-presence of MMA 
is an important factor when the focus for these NPs is their biomedical 
application. MMA presence can cause serious toxicity problems. The 
zeta potential is another important characteristic of the NPs and it 
provides information about the colloidal stability and the possible 
interactions between the NPs and the biological medium. ZnPc loaded 
PMMA NPs exhibited a high negative charge surface (-45 ±0.09 mV at 
pH 7.4 ±0.1), contributing to a higher colloidal stability of NPs 
(ANTONIETTI and LANDFESTER, 2002; SIQUEIRA-MOURA et al, 
2013). The negative charge is associated with the presence of surfactants 
adsorbed on the nanoparticle surface.  
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Figure 3.1 Conversion gravimetric of the PMMA, ZnPc loaded PMMA NPs. 
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Figure 3.2 shows the TEM images and the particle size 
distribution (PSD) obtained by DLS. ZnPc loaded PMMA NPs 
presented nanometric size with a narrow size distribution and spherical 
morphology, as can be seen clearly in Figure 3.2b and c. Table 3.1 
shows the mean diameter and polydispersity index (PdI) obtained by 
DLS. The DLS results corroborate with the TEM analysis. The low 
polydispersity index (PDI), around 0.1, indicates that both samples have 
a narrow size distribution. In addition, the osmotic pressure would be 
sufficient to prevent Ostwald ripening, which increases the stability of 
the miniemulsion (ANTONIETTI and LANDFESTER, 2002; SHORK, 
2005). It is likely that the dominant nucleation mechanism was the 
polymerization of the monomer (ANTONIETTI and LANDFESTER, 
2002; BERNARDY et al, 2010; FEUSER et al, 2014). Both morphology 
and particle size have important biological implications on cellular 
uptake and biological processes (DANHIER et al, 2010; HE et al, 2010).  
 
 
Figure 3.2 Particle size distribution obtained by dynamic light scattering (a) and 
transmission electron microscopy image (b and c) of ZnPc loaded PMMA NPs. 
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Table 3.1 Intensity mean diameter: droplets (DPg) and Nps (DPNP); 
Polydispersity index:  droplets (PdIg) and NPs (PdINP) obtained by DLS. 
Samples DPg (nm) DPNps  (nm) PdIg PdINP 
PMMA NPs 85 ±2.3 89 ±1.9 0.09 ±0.04 0.09 ±0.05 
ZnPc loaded PMMA 92 ±2.2 97  ±2.5 0.10 ±0.05 0.11 ±0.02 
 
For encapsulation of the photosensitizer, ZnPc, into PMMA 
NPs using miniemulsion polymerization, a solution of ZnPc in NMP 
was added to the aqueous phase under high shear using a sonic 
dismembrator.  Subsequently, the organic phase was added to the 
aqueous phase with continuous homogenization during five minutes 
using a sonic dismembrator. The addition of the organic phase, which 
contains the monomer and ZnPc, coalesced with the monomer droplets. 
The dispersion was stabilized by the lecithin present in the organic 
phase. This technique showed a high EE% (87 ±2.1 %). Tests performed 
with a high HLB (Hydrophilic-Lipophilic Balance) surfactant dispersed 
in the aqueous phase, such as SDS (sodium dodecyl sulphate), presented 
low encapsulation efficiency (> 20%) (data not shown). The presence of 
the surfactant with high HLB stabilized the photosensitizer dispersion in 
the aqueous phase, and reduced the coalescence between the 
photosensitizer and monomer droplets resulting in low encapsulation 
efficiency. UV-vis analysis showed that the ZnPc loaded PMMA NPs 
did not suffer changes in its spectroscopic properties after encapsulation 
(Figure 3.3). The soret and Q bands remained in the same position. Free 
ZnPc and ZnPc loaded PMMA NPs have similar spectroscopic behavior 
with wavelength of maximum absorbance at 675 nm for one of the Q 
bands (FEUSER et al, 2015).  
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Figure 3.3 Absorption spectra in the UV-vis: free ZnPc, PMMA and ZnPc 
loaded in PMMA Nps. 
 
X-ray diffraction (XRD) of free ZnPc, PMMA NPs, ZnPc 
loaded PMMA NPs is exhibits in Figure 3.4a. XRD profile of Free ZnPc 
exhibited a diffraction profile of crystalline material (β-phase of 
monoclinic structure) with several intense peaks (Figure 3.4). Free ZnPc 
has three different polymorphic forms (α, β and γ phases), where the β-
form is thermodynamically stable (SHOCK et al, 1988). Our results are 
similar to the results reported by Iwatsu and collaborates (1980) and 
Choi and collaborates (2014) for the polymorphic β-form of ZnPc.  
However, these peaks were not observed in the diffractograms from 
NPs. Therefore, the diffractograms of the NPs (Figure 3.3a) indicated 
that the drug (ZnPc) can be molecularly dispersed in the polymeric 
matrix. Similar results have been reported in literature (HONG et al, 
2008; LEKSHMI et al, 2010; WANG et al, 2014). FT-IR spectrum 
(Figure 3.4b) of ZnPc loaded PMMA NPs (Figure 4b) showed signals in 
1736 cm
-1
 corresponding to the PMMA C=O groups. In addition, the 
bands in the 3000 – 2800 cm
-1
 region are attributed to the stretching of 
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C
_
H bonds of the PMMA saturated alkane. The free ZnPc presented 
peak characteristics (718, 747 and 783 cm
-1
) of β-ZnPc (HUSSEIN, 
2011), corroborating with XRD analysis. The FTIR spectrum of free 
ZnPc, PMMA, ZnPc loaded PMMA NPs confirmed that there was no 
significant interaction between drug and polymer. These results 
corroborate with XRD analysis, indicating that the drug, ZnPc, can be 
molecularly dispersed in the polymeric matrix (LEKSHMI et al, 2010).  
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Figure 3.4 X-ray powder diffraction patterns (a) and FTIR analyses (b) of: free 
ZnPc, PMMA, ZnPc loaded PMMA NPs. 
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3.7 In vitro studies 
3.7.1 In vitro ZnPc release study 
 
Release study was performed in order to evaluate the release 
profile of ZnPc encapsulated in PMMA NPs. ZnPc loaded PMMA NPs 
presented a slow and sustained release profile. As can be seen in Fig. 
3.5, the amount of ZnPc released from PMMA NPs reached 20% in 
120 h. After 120 h of contact with the aqueous medium, the polymer 
matrix becomes less resistant to diffusion of the drug (LEKSHMI et al, 
2010). Consequently, a linear increase can be observed in the drug 
release after 120 h.  Eighty-five percent of the drug was released in the 
acceptor solution in 300 h. In addition, no burst effect was detected, 
indicating that ZnPc was entrapped within the PMMA NPs and possibly 
homogeneously dispersed in the polymeric matrix of the NPs and not at 
the surface (KUMARI et al, 2010; MADERUELO et al, 2011), 
corroborating with the results from the XRD and FTIR analyses.  
The extended release may be attributed to the slow diffusion of 
ZnPc through the polymeric matrix of the PMMA NPs that present slow 
rate of disintegration aqueous medium (FU and KAO, 2010; LEKSHMI 
et al, 2010; VAN DER ENDE et al, 2010). Furthermore, the low 
solubility of ZnPc could contribute with the reduction the drug diffusion 
through the polymeric matrix, and consequently slowing the drug 
release (GAO et al, 2011). Sustained release systems are able to 
maintain the constant drug concentration in the blood plasma for a 
prolonged period, improving patient compliance (decreases the number 
of daily administrations) and therapeutic efficacy (GAO et al, 2011; 
HUANG et al, 2001). 
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Figure 3.5 Release profiles of ZnPc loaded PMMA NPs. Data refer 
mean ± standard deviation (n =3) different experiments (pH 7.4). 
 
The zero order, first order, and Higuchi mathematical models 
were used in this study to evaluate the release kinetics (Table 3.2). 
Mathematical models were applied to the release data. The choice of the 
model was based on the highest coefficient of determination (r
2
). As 
shown in Figure 5, release kinetics was best explained by the zero order 
model, with the highest value of r
2
 (0.9699), followed by the Higuchi 
model (0.8833) and the first order (0.7895). According to Costa and 
Lobo (2001) the zero order model is adequate for drug dissolution from 
delivery systems that do not disintegrate. The release profile showed 
that ZnPc flux is constant and it was released almost immediately from 
PMMA NPs with a small Lag Time as can be seen in the Table 3.2. Lag 
time is the time required for initial drug release (LEOPOLD et al, 2001; 
ROTHEN-WEINHOLD et al, 2000). The release of drugs from 
non-degradable polymeric delivery systems is more likely to be 
diffusion driven, which is associated with concentration gradient, 
diffusion distance and the swelling degree (FU and KAO, 2010). 
Finally, our results suggest that release of ZnPc from PMMA NPs was 
by diffusion, typical of non-biodegradable polymer (GAO et al, 2011; 
RAO AND GECKELER, 2011).  
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3.7.2 Biocompatibility assays 
 
The cytotoxic effects of PMMA NPs on K562 and Jurkat cells 
were found by MTT assay. Figure 3.6 shows the cytotoxicity profile of 
K562 and Jurkat cells incubated for 1 h with various NPs 
concentrations, in the absence of visible and red light exposure there 
was no cytotoxic effect when compared with the control group. The 
HPBL and L929 cells incubated with ZnPc loaded PMMA NPs and 
exposed to red light, also didn’t present any cytotoxic effect. Other 
studies showed that PMMA NPs obtained by miniemulsion 
polymerization presented biocompatibility in human leukemic (THP1) 
and human lung adenocarcinoma cell lines (A549) (FEUSER et al, 
2014). The non-cytotoxicity of the L929 cells is an important factor; 
ISO 10993-5 recommends the in vitro cytotoxicity assay of new 
material (MADERUELO et al, 2011). The non-cytotoxicity in HPBL 
cells is another key factor to leukemia and solid tumor treatment, where 
ZnPc loaded PMMA NPs can be systemically administered without 
causing a toxicity effect on human blood cells (DEDA et al, 2009). 
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Figure 3.6 Cytoxicity effect of different concentrations of free PMMA NPs 
(10 - 100 µg.mL
-1
) on leukemia cell lines (K562 and Jurkat) without and with 
red light. *p <0.05 compared to control groups, using ANOVA followed by the 
Bonferroni post-hoc test. Cytotoxic effects of ZnPc loaded PMMA in Nps on 
normal peripheral blood mononuclear human (HPBL) cells and normal mouse 
fibroblast (L929) cells, after red light exposure. ***p < 0.001 compared with 
control group, using ANOVA followed by the Bonferroni post-hoc test. 
3.7.3 Photobiological activity 
 
The phototoxicity assay (Figure 3.7) of free ZnPc and ZnPc 
loaded PMMA NPs on Jurkat and K562 cells was performed. The 
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results presented in Figure 7, showed that in the absence of red light, 
free ZnPc and ZnPc loaded PMMA NPs did not present cytotoxic 
effects on the leukemic cells (Figure 3.7). However, after irradiation 
with red light free ZnPc and ZnPc loaded PMMA NPs induced cell 
death in a concentration-dependent manner when compared with the 
control group (only cells) (Figure 3.7). The IC50 values of free ZnPc and 
ZnPc loaded PMMA Nps for Jurkat and K562 cells were 39.05 ±0.96 
(Figure 3.7a), 47.43 ±1.20 (Figure 3.7b), 28.24 ±0.97 (Figure 3.7c) and 
28.52 ±1.06ng/mL (Figure 3.7d), respectively. The phototoxicity assay 
showed that the ZnPc loaded PMMA NPs that incubated for 1 h were 
more phototoxic than the free ZnPc. The low incubation times (1 h) used 
in this study reflect the amount of photosensitizer delivered to the cells. 
The increase in phototoxic activity of ZnPc loaded PMMA NPs may be 
related to a higher delivery of ZnPc into cells. The non-aggregation of 
ZnPc in biological mediums also contributes to a higher phototoxicity. 
The photobiological activity is highly dependent on the 
photosensitizer’s cellular uptake mechanism. In an aqueous medium, a 
free ZnPc is generally absorbed by diffusion across the plasmatic 
membrane (lipophilic) leading to a low intracellular concentration. 
Moreover, lipophilic ZnPc tends to aggregate in aqueous mediums, 
which reduce the photodynamic activity (CHARTTEJEE et al, 2008; 
DEDA et al, 2009; DOLMANS et al, 2003; RICCI-JÚNIOR and  
MARCHETTI, 2006). The results showed that the encapsulated ZnPc in 
polymeric NPs (PMMA) is an excellent strategy for leukemia treatment 
by PDT.  
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Figure 3.7 Phototoxicity assay of free ZnPc using Jurkat (a) and K562 (b) cells, 
and ZnPc loaded in PMMA Nps using Jurkat (c) and K562 (d) cells. *** p<0.05 
compared to control groups, using ANOVA followed by the Bonferroni post-
hoc test. 
3.7.4 Evaluation of cell death by AO-EB staining and DNA 
fragmentation  
 
PDT can induce cell death by apoptosis and/or necrosis after 
visible light exposure. To evaluate the cell death pathway, cell 
morphology was examined using fluorescence microscopy by AO-EB 
staining (Figure 3.8). K562 and Jurkat cells were treated with ZnPc 
loaded PMMA NPs, irradiated with red light (675 nm, light dose 
2 J/cm
2
) and incubated for 1 h. Viable cells exhibit green fluorescence 
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due to dye uptake. On the other hand, apoptotic cells exhibit orange-red 
fluorescence in the nucleus due to intercalation of ethidium bromide into 
damaged DNA (SHAO et al, 2012). As can be clearly seen in Figure 
3.8, Jurkat and K562 cells presented orange fluorescence due to loss of 
membrane integrity, condensed or fragmented chromatin and presence 
of apoptotic bodies (white arrow) (ELMORES, 2007; GOSWAMI et al, 
2014). Initial apoptosis can be observed in K562 cells, which present 
intact membranes and green fluorescence (yellow arrow), with 
condensed chromatin and nuclear fragmentation. This study’s results 
were similar to the work of Goswasmi and collaborators where PDT was 
used to induce cell death by apoptosis in Hela and MCF-7 cells. The cell 
death by apoptosis was observed in a variety of tumor cell lines after 
PDT application with different photosensitizer derivatives (MARANHO 
et al, 2009; SHAO et al, 2012; SIQUEIRA-MOURA et al, 2009). 
Apoptosis is an intrinsic physiological event, which can also be 
triggered by external stimuli like oxidative stress attributable to PDT. 
Light absorption by the dye in the presence of oxygen, triggers 
photophysical and biological processes that result in the formation of 
ROS capable of damaging cellular components and causes cell death by 
apoptosis or necrosis (DOLMANS, 2003; FABRIS et al, 2001; 
OLEINEICK et al, 2002. The low light dose and low drug concentration 
used in the PDT is an important factor to induce cell death by apoptosis 
(DOLMANS, 2003; FABRIS et al, 2001; OLEINEICK et al, 2002; 
SHAO et al, 2012). Our results suggest that low ZnPc concentration and 
low light dose induced cell death by apoptosis. These results were 
corroborated with DNA fragmentation assays, as can be seen in Figure 
3.9. DNA fragmentation assay induced the "staircase" fragmentation 
pattern characteristic of cell death by apoptosis.  
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Figure 3.8 Acridine orange–ethidium bromide (AO-EB) staining of Jurkat and 
K562 cells at concentration of IC50 of ZnPc loaded PMMA NPs. The group 
without treatment was taken as the control group. 
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Fig. 3.9 DNA fragmentation analysis of ZnPc loaded PMMA NPs on K562 and 
Jurkat cells. The level of DNA fragmentation was determined using the 
genomic DNA mini preparation kit to obtain the genomic DNA. This was then 
separated in 2 % agarose gel with 1 mg.mL
-1
 ethidium bromide for 40 min at 
80 V. 
3.8 CONCLUSIONS 
 
The encapsulation method of ZnPc loaded PMMA NPs by 
miniemulsion polymerization showed high encapsulation efficiency of 
ZnPc (87 % ±2.1), and resulted in stable aqueous dispersion with an 
average size diameter around 100 nm. The release profile test and 
mathematical models used in this study showed that the ZnPc loaded in 
PMMA NPs had a sustained release, maintaining drug release for 
extended periods of time. Cytotoxicity and phototoxicity studies in 
leukemic cells (K562 and Jurkat) associated with non-cytotoxic activity 
in human peripheral blood lymphocyte cells and on normal fibroblast 
cells (L929) showed that the ZnPc loaded PMMA NPs can be 
considered an effective strategy for treatment of leukemic cells by PDT, 
based on low IC50 values and light dose. All the photobiological studies 
performed allow us conclude that ZnPc loaded PMMA NPs are 
promising drug carrier systems, improving the photobiologycal activity 
of the ZnPc on leukemic cells. 
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CHAPTER 4 
ENCAPSULATION OF MAGNETIC NANOPARTICLES IN 
POLY(METHYL METHACRYLATE) BY MINIEMULSION AND 
EVALUATION OF HYPERTHEMIA IN U87MG CELLS 
 
Abstract: Magnetic nanoparticles (MNPs) are promising materials for 
hyperthermia treatment and magnetic targeting systems. The objective 
of this work was to synthesize and characterize magnetic nanoparticles 
coated with oleic acid (MNPsOA) loaded with poly(methyl 
methacrylate) prepared by miniemulsion polymerization (MNPs-
PMMA) and evaluate their cytotoxicity in murine fibroblast (L929) 
cells, blood biocompatibility (hemolysis assay) and hyperthermia (HPT) 
in human glioblastoma (U87MG) cells. The MNPs-PMMA 
nanoparticles presented average mean diameter of 99 ±1.9 nm with a 
polydispersity index (PdI) of 0.13 ±0.015 and saturation magnetization 
(Ms) value of 34emu/g of iron oxide, as well as superparamagnetic 
properties. The MNPs-PMMA nanoparticles did not present cytotoxicity 
in murine fibroblast (L929) and U87MG cells. HPT assays were 
applied, demonstrating that AC magnetic field application (1 MHz and 
40 Oe) for 3 min or 6 min reduced the viability cells by 75% and 52% 
respectively. Morphological analyses showed that U87MG cells treated 
with 0.1 µg.mL
-1
 of MNPs-PMMA nanoparticles shrank after AC 
magnetic field application for 6 mim, resulting in a region of hypoxia. 
Hemolysis assay showed that MNPs-PMMA nanoparticles presented 
high blood biocompatibility. Our results indicate that MNPs-PMMA 
nanoparticles obtained by miniemulsion polymerization have the 
potential to be used as carrier systems for HPT.  
 
Keywords: biomaterials, hyperthermia, polymers, superparamagnetic 
nanoparticles. 
 
The manuscript was published in the European Polymer Journal 
doi: 10.1016/j.eurpolymj.2015.04.029 
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4. INTRODUCTION  
 
Magnetic nanoparticles (MNPs) have been widely used in 
various biomedical applications (FERREIRA et al, 2012; GUPTA and 
GUPTA 2005; LAURENT et al, 2010; TEJA and KOH, 2009), such as 
targeted drug delivery (DORNIANI et al, 2012; KUMAR and 
MOHAMAD, 2011; SHI et al, 2013; ZHA et al, 2013; ZHAO et al, 
2005; ZHENG et al, 2005), hyperthermia (FERREIRA et al, 2012; 
LATTUADA and  HATTON, 2007; SAHOO et al, 2013; SIMIONI et 
al, 2007; TEJA and KOH, 2009) and magnetic resonance imaging 
(MRI) (ABULATEEFEH et al, 2011; FERREIRA et al, 2012; GUPTA 
and GUPTA 2005; LAURENT et al, 2010; TEJA and KOH, 2009). For 
these applications, MNPs must have combined properties of high 
magnetic saturation, superparamagnetic properties and biocompatibility 
(KUMAR and MOHAMAD, 2011; ZHENG et al, 2005). MNPs are 
promising materials for hyperthermia treatment and have been used in 
cancer therapy for decades, usually applied as an adjuvant to 
radiotherapy and chemotherapy. Additionally, induced hyperthermia for 
cancer treatment involves raising the temperature of tumor-loaded 
tissues to 40–43 °C (BASE et al, 2012; DANHIER et al, 2010; GUPTA 
and GUPTA 2005). Solid tumors have been shown to have increased 
susceptibility to small changes in temperature compared to healthy 
tissue due to their increased rate of cell cycling, increased hypoxia, 
reduced fluid exchange and increased cellular acidity (pH 2-4) 
(DANHIER et al, 2010; TANG et al, 2013).  
In cancer therapy, the major difficulty is to destroy tumor cells 
without harming the surrounding normal tissue. The use the polymeric 
nanoparticles (Nps) for drug delivery results in increased local drug 
concentrations, reducing toxic effects on healthy cells or tissues, 
providing a new strategy for cancer treatment. Nps are solid spherical 
structures ranging around 100 nm in size and can be prepared from 
natural or synthetic polymers (LANDFESTER and MAILANDER, 
2013). Nps have the function of protecting and preventing aggregation 
of MNPs (TANG et al, 2013). On the other hand, MNPs can ensure the 
mobility of the Nps when a magnetic field is applied, enabling their use 
for drug transport. A large number of strategies have been proposed in 
the literature to encapsulate MNPs in polymeric colloidal particles 
including emulsion polymerization (BOURGEOUT-LAMI E, 
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LANSALOT, 2010), inverse miniemulsion polymerization (ROMIO et 
al, 2012) and direct miniemulsion polymerization (HE et al, 2008; 
STAUDT et al, 2013). 
Poly(methyl methacrylate) (PMMA) is widely used in 
biomedical materials due to its biocompatibility. Recent publications 
have shown an increasing interest in its applications as a drug carrier 
(GYERGYEKA et a, 2010; FU and KAO, 2010). PMMA, since it is not 
biodegradable, can increase the circulation time in the blood and 
therapeutic index of encapsulated drugs (FU and KAO, 2010). PMMA 
based particulate carriers can be prepared either by polymerization in 
dispersed phase or from preformed polymer-based techniques 
(BETTENCOURT and ALMEIDA, 2012; ZHENG et al, 2005). 
Miniemulsion polymerization allows the production of polymeric 
nanocapsules or nanospheres with unique characteristics of great 
commercial interest. Miniemulsion polymerization produces stable 
aqueous dispersions of droplets (50-500 nm) containing monomer, 
surfactant, ultrahydrophobe, initiator and water insoluble compounds 
(e.g., hydrophobic MNPs) by applying high shear stress (ASUA, 2014; 
CRESPY and LANDFESTER, 2010; HIGUCHI and MISRA, 1962; 
LANDFESTER, 2009; QIU et al, 2007). In order to stabilize such a 
direct miniemulsion, droplet coalescence is suppressed by the surfactant 
that stabilizes the particles electrostatically or sterically. As the 
miniemulsion features a distribution in droplet size, the bigger droplets 
can growth due to a mass flux from the smaller ones as Laplace pressure 
increases with decreasing droplet size, this phenomena is known as 
molecular diffusion degradation or Ostwald ripening. The 
ultrahydrophobe prevents diffusion degradation by introducing a 
counterforce to the Laplace pressure as the smaller particles would 
contain a higher concentration of ultrahydrphobe increasing the Osmotic 
pressure (HIGUCHI and MISRA, 1962). As the colloidal stability is 
attained, monomer droplets act as the primary polymerization loci and 
behave as "nano-reactors" and thus lead to a similar concentration of 
hydrophobic MNPs inside the polymeric particles if a high adhesion 
interaction between the polymer and the shells of metal nanoparticles is 
attained (ASUA, 2014). The main advantage of the miniemulsion 
polymerization process is the ability to produce complex nanostructures, 
including the encapsulation of inorganic nanoparticles, in a single 
81
 
 
 
  
reaction step with fast polymerization rates (MAHDAVIAN et al, 2008; 
LANDFESTER K, MAILANDER, 2013; QIU et al, 2007). 
The goals of this work were to synthesize and characterize 
MNPs loaded in poly(methyl methacrylate) (PMMA) by miniemulsion 
polymerization and to evaluate in vitro the cytotoxicity in murine 
fibroblast (L929) cells, hemolysis and the efficacy of HPT treatment 
using human glioblastoma (U87MG) cells. 
4.1 MATERIALS AND METHODS 
4.1.1 Materials 
 
For synthesis of magnetic nanoparticles coated with oleic acid 
(MNPsOA), the following reagents were employed (high purity grade): 
ferrous sulfate (FeSO4⋅4H2O), iron (III) chloride hexahydrate 
(FeCl3⋅6H2O), ammonium hydroxide (99%), and oleic acid (OA), all 
purchased from Vetec Química Fina. For the encapsulation of 
MNPsOA, the following reagents were employed: methyl methacrylate 
(MMA), obtained from Arinos Química Ltda., azobisisobutyronitrile 
(AIBN), purchased from Vetec, lecithin, obtained from Alpha Aesar, 
and Miglyol 812 (as co-stabilizer), purchased frolm Sasol. Distilled 
water was used throughout the experiments. 
4.2.2 Methods  
4.2.2.1 Synthesis of magnetic nanoparticles coated with oleic acid 
(MNPsOA) 
 
MNPsOA nanoparticles were prepared by co-precipitation 
(MEIORIN et al, 2014). Briefly, FeCl3.6H2O and FeSO4.7H2O (mole 
ratio of 1:1.2) were dissolved in a beaker containing distilled water 
under mechanical stirring in the range of 800 rpm. Then an ammonium 
hydroxide solution (11 mL) was rapidly added to the solution. After 1 h, 
30 mL was added to the OA and the stirring process was continued (800 
rpm) for 30 min. The MNPsOA produced was centrifuged and washed 
three times with ethanol to remove the unreacted OA.  
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4.2.2.2 Encapsulation MNPs in PMMA nanoparticles by 
miniemulsion polymerization (MNPs-PMMA)  
 
For encapsulation of MNPs by miniemulsion polymerization, an 
organic phase containing 2 g of MMA with 1 g of MNPsOA, 0.1 g of 
lecithin, 0.1 g of Miglyol and 0.4 g of AIBN was added to a beaker 
containing 20 mL of distilled water (aqueous phase). The organic phase 
was added dropwise under higher shear with amplitude of 70% (Fisher 
Scientific, Sonic Dismembrator, 500 W). The high shear was maintained 
for 5 min (10 s on and 1 s off) in a beaker immersed in an ice bath to 
avoid increased temperature during sonication. The miniemulsion 
product was transferred to glass tubes (10 mL) at 70 °C for 
polymerization during 3 h. Afterwards, the material was cooled, 
centrifuged and washed three times with phosphate buffered saline 
(PBS) at pH 7.4. Subsequently, Nps were transferred to glass vials, 
frozen in liquid nitrogen and lyophilized (FreeZone 4.5-L Benchtop 
Freeze Dry System; Labconco, Kansas City, MO). The lyophilized 
powder was stored at room temperature (25 °C) before analysis. The 
magnetic fluid concentration used to produce the MNPs-PMMA was 
about 1.2x10
17
 particles/mL. 
4.2.3 MNPsAO and MNPs-PMMA nanoparticles characterization  
 
Average diameters (intensity averages) of monomer droplets 
(Dg) and of polymer particles were measured by dynamic light 
scattering (DLS-Malvern Instruments, Zetasizer Nano S). The Nps 
morphology was observed using transmission electron microscopy 
(TEM), with a JEM 2100F microscope operating at 100 kV. The XRD 
experiments were performed to identify the crystallographic structure of 
Nps. The crystalline phase of Nps was identified by measurements of X-
ray diffraction using Cu-Kα (1.54056 Å) 45 kV/40 mA in an Xpert-Pro 
diffractometer. The average crystal size is calculated according to the 
Debye-Scherrer equation, D = Rλ/ßcos θ (where D is the particle 
diameter, R is the Scherrer constant (0.89),   λ is the incident light 
wavenumber, β is the peak width of half-maximum, and θ is the 
diffraction angle. The average crystallite size is obtained from the most 
intense peak (311). Fourier-transform infrared spectroscopy (FT-IR) 
was used to confirm the chemical structure of the MNPs and PMMA 
using a KBr pellet. The MNPsOA and MNPs-PMMA nanoparticles 
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were measured through TGA runs under a nitrogen atmosphere at a 
heating rate of 10 °C/min. A MicroSense model EV9 vibration sample 
magnetometer (VSM) was used to measure the hysteresis loops of 
MNPsOA and MNPs-PMMA nanoparticles. 
4.3 In vitro studies 
4.3.1 In vitro cytotoxicity assay of MNPs-PMMA nanoparticles on 
L929 cells  
 
The murine fibroblast (L929) cell lines were selected to 
evaluate cytotoxicity as a direct contact test, as recommended by ISO 
10993 for in vitro toxicity. The cells were cultured in Dulbecco’s 
Modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum, penicillin (100 units/ml), streptomycin (100 mg/mL), and 
4 mM/L of glutamine at 37 °C in tissue culture flasks with 5% CO2. For 
experimental purposes, trypsinized cells were adjusted to a 
concentration of 1x10
4
 cells/well and plated in a 96 well flat bottom 
culture plate. For cytotoxicity study, the cells were incubated with three 
concentrations of MNPs-PMMA nanoparticles (10, 20, 50µg.mL
-1
) for 
24 h at 37 °C in a humidified 5% CO2 incubator and cell viability was 
measured by the MTT (3-(4, 5-dimethiazolzyl)-2-5-diphenyltetrazolium 
bromide) assay. 
4.3.2 Cytotoxicity assay of MNPs-PMMA nanoparticles without 
hyperthermic application on U87MG cells  
 
 U87MG cells were seeded at 1x10
4 
cells/well in a 96-well plate 
to assess the intrinsic cytotoxic effect of the MNPs-PMMA 
nanoparticles. After 24 h, the cells were kept in the dark and incubated 
with a mixture of fresh medium and MNPs-PMMA. Nps at a final 
concentration of 0.05 and 0.1µg of MNPs were maintained for 3 h at 37 
°C and 5% CO2. After incubation, the medium containing the MNPs-
PMMA nanoparticles was discarded and the cells were washed with 
sodium phosphate buffered saline (PBS). In the next step, the cells were 
incubated with fresh medium for an additional 24 h, after which the cell 
viability assay (MTT) was performed. Control cells were incubated with 
culture medium alone (untreated cells) or medium containing unloaded 
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MNPs-PMMA nanoparticles, both in the dark. Toxicity experiments in 
darkness were carried out in triplicate, with 36 wells for each condition. 
4.3.3 MNPs-PMMA nanoparticles hyperthermia effect on U87MG 
cells 
 
In order to evaluate the MNPs-PMMA nanoparticles 
hyperthermia effect on U87MG cells in vitro, the cells were seeded at 
1x10
5 
cells/well in 24-well plate. After 24 h, the cells were treated with 
a medium containing MNPs-PMMA nanoparticles at two 
concentrations: 0.05 µg and 0.1 µg (5% CO2, 37 °C). Following 
incubation (3 h), the medium loaded with Nps was removed, the cells 
were rinsed with PBS (1X) and incubated with conditioned medium. 
After 24 h, the cells were treated during 6 minutes with alternating 
magnetic fields operating at 1 MHz and 40O e amplitude, in fresh 
medium without bovine serum. After the hyperthermic application, the 
cells were incubated (5% CO2, 37 °C) in fresh conditioned medium for a 
further 24 h, after which the MTT cell viability assay was performed. 
Control cells were incubated with culture medium alone without 
MNPsOA encapsulation and magnetic field, or encapsulated MNPsOA 
mixed with medium (encapsulation control). The cytotoxicity assay was 
carried out in triplicate, with 36 wells for each condition. 
4.3.4 MTT viability assay 
 
The MTT cell proliferation assay was employed to assess cell 
viability after both the cytotoxic assays. Briefly, 80-μl aliquots of MTT 
solution (5 mg.ml
−1
) and 420 μl of medium without phenol red were 
added to each well. The cells were then incubated for 4 h, at 37 °C and 
5% CO2 to allow the formazan-formation reaction. Following 
incubation, the medium containing the MTT solution was removed, and 
the formazan crystals were dissolved in 2-propanol. The optical density 
was measured at 570 and 690 nm using a Safire2 microplate reader 
(Tecan Group Ltd.). The results are presented as survival percentage, 
taking the control (untreated cells) as 100%.  
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4.3.4 Morphological analyses  
 
Morphological analyses, consistent with observation of changes 
in cells morphology, were carried out by inverted microscopy. Cells 
were treated with MNPs-PMMA nanoparticles at MNPs concentration 
of 0.1µg.mL
-1
. As negative controls, cells were incubated with culture 
medium alone without magnetic field (control cells), MNPs-PMMA 
nanoparticles mixed with medium without magnetic field (control 
group), or medium alone with magnetic field (hyperthermia control). 
The morphological changes of the cells were observed 1 h and 24 h after 
treatment. 
4.3.5 Hemolysis assay 
 
This study was approved by the medical ethics committee of 
Polydoro Ernani de São Thiago University Hospital (Florianopolis, 
Brazil). Citrate-stabilized human blood was freshly collected and used 
within 3 h of being drawn. 4 mL of whole blood was added to 8 mL of a 
sterile solution of sodium chloride in water (saline) and the human red 
blood cells (RBCs) were isolated from serum by centrifugation at 
10,000 × g for 5 minutes. The RBCs were further washed five times 
with saline solution. Following the last wash, the RBCs were diluted in 
2 mL of saline solution and then 120 µL of the diluted RBC suspension 
was added to 880 µL of water or saline. The MNPs-PMMA 
nanoparticles coated with 0.1µg.mL
-1
 were treated at 10 µl, 25 µl and 50 
µl volume. All samples were prepared in triplicate and the suspension 
was briefly vortexed before gentle stirring at 37 °C for 60 minutes. After 
that, the mixture was briefly vortexed again and centrifuged at 10,000 × 
g for 5 minutes. 100 μL of supernatant from the sample tube was 
transferred to a 96-well plate. The absorbance value of hemoglobin at 
570 nm was measured with the reference wavelength at 540 nm. 120 µL 
of the diluted RBC suspension incubated with 880 µL of water and 
saline were used as the positive and negative control, respectively. The 
hemolysis percent (%) was calculated from Equation 1:  
 
Hemolysis (%) 
(sample absorbance-negative control) 
(positive control-negative control)
 100%                                                
(1)    
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4.4 RESULTS AND DISCUSSION   
4.4.1 MNPs-PMMA nanoparticles characterization     
 
The MNPsOA and MNPs-PMMA nanoparticles were examined 
by transmission electron microscopy (TEM) to determine their shape, 
size, and uniformity under optimum conditions. This analysis is very 
important to verify the presence of secondary nucleation and 
degradation mechanisms, especially when the final material will have 
biomedical use (FEUSER et al, 2014). Figure 4.1(a)-(b) show that these 
MNPsOA particles had a very small size, of around 5-13 nm in 
diameter, with narrow size distribution.   
 
Figure 4.1 Transmission electron micrographs (TEM) of (a and b) MNPsOA 
and (c and d) MNPs-PMMA nanoparticles. 
Figure 4.1c and d, shows some darker regions, which is 
attributed to the core formed by MNPs in PMMA with an approximate 
value of 100 nm, with spherical morphology and relatively narrow size 
distribution. Table 4.1 shows average droplets (DpI) and particles (DpF) 
87
 
 
 
  
and polydispersity index (PdI) given by DLS. These results corroborate 
those of the TEM analysis (Figure 4.1). The low PdI indicates that both 
samples have narrow average size distribution and that the osmotic 
pressure would be sufficient to prevent Ostwald ripening (ASUA, 2014; 
LANDFESTER and MAILANDER, 2009; SHORK et al, 2015). The 
TEM and DLS showed that the size distribution of the MNPs-PMMA 
nanoparticles is uniform and it is likely that the dominant nucleation 
mechanism was polymerization of monomer droplets in preference to 
other possible mechanisms, such as micellar or homogeneous 
nucleation, as would be expected when employing a hydrophobic 
initiator (LANDFESTER and MAILANDER, 2009).    
 
Table 4.1 Analysis of average droplet (Dg) and particle (Dp) diameter and 
initial and final polydispersity index (PdIg and PdIp) of NP miniemulsion 
polymerization by DLS 
Samples Dg(nm) Dp(nm) PdIg PdIp 
MNPs-PMMA 92±2.3 99±1.9 0.11±0.011 0.13±0.015 
 
The powder X-ray diffraction (XRD) patterns for the naked 
MNPsOA and MNPs-PMMA nanoparticles are shown in Figure 4.2. For 
both samples (MNPsOA and MNPs-PMMA), six characteristic peaks 
can be observed at 2θ: (220), (311), (400), (422), (511) and (440) 
(DALLAS et al, 2006; DORNIANI et al, 2012; HONG et al, 2008; 
SAHOO et al, 2013). The XRD patterns of MNPsOA and MNPs-
PMMA nanoparticles (Figure 4.2a and c respectively) indicate that the 
diffraction peaks’ intensity weakened but did not disappear. The 
weakness of diffraction intensity of MNPs-PMMA nanoparticles may be 
due to the lower content of MNPs. During the synthesis process, the 
structure of MNP nanoparticles was unchanged. Therefore, the results 
demonstrated that the MNPs-loaded PMMA nanoparticles have the 
expected crystalline structure of Fe3O4 (HONG et al, 2008; ZHENG et 
al, 2005). Using the XRD results and Debye-Scherrer equation, the 
average crystallite sizes of MNPs and MNPs-PMMA nanoparticles were 
estimated to be 8 nm and 10 nm, respectively, similar to the result from 
TEM (Figure 4.1). According to Mody and collaborates (2014), when 
MNPs have a critical diameter of about 5-10 nm, they can become 
superparamagnetic nanoparticles. 
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Figure 4.2 Powder x-ray diffraction (XRD) patterns for (a) MNPsOA, (b) 
PMMA and (c) MNPs-PMMA nanoparticles. 
FT-IR analysis (Figure 4.3) can verify the presence of the 
absorption bands of the functional groups present in samples. In 
Figure3a, the peak at about 577cm
-1
 is related to the vibration of the 
Fe-O bond, which matches well with the characteristic peak of MNPs 
(SAHOO et al, 2013). The spectrum of MNPs-PMMA nanoparticles is 
shown in Figure 4.3c. The adsorption peak at 577cm
-1
 was the 
characteristic absorption of Fe-O bond, confirming the presence of 
MNPs in PMMA nanoparticles (HONG et al, 2008). A new adsorption 
at 1736 cm
-1
 corresponds to C=O groups of PMMA. In addition, the 
bands in the 3000–2800 cm
-1
 region are attributed to the stretching of C-
H bonds of the saturated alkane in PMMA, indicating the existence of 
PMMA (Figure 4.2b) (FEUSER et al, 2014). On the basis of the above 
analysis, the MNPs and MNPs-PMMA nanoparticles were confirmed to 
be present in the composite particles
 
(HONG et al, 2008). 
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Figure 4.3 FTIR spectra of MNPsOA (a), PMMA (b) and MNPs-PMMA 
nanoparticles (c). 
 
The thermal decompositions of pure MNPsOA and MNPs-
PMMA nanoparticles were studied using thermogravimetry. Figure 4a 
and b show there was no mass loss in the temperature range 0 to 100 °C, 
which can indicate the material is free of impurities (LANDFESTER an 
RAMIREs, 2003). Figure4a shows two mass loss events, the first, of 
30%, observed between temperatures of 200 and 280 °C, and the 
second, of 13%, observed between 300 and 410 °C. According to 
Landfester and Ramires (2003), the presence of two peaks indicates that 
different species of OA are present in the sample. In the case of MNPs 
in PMMA nanoparticles (Figure 4.4b), mass loss is gradual and it can be 
clearly seen that the PMMA nanoparticles are completely degraded 
when reaching about 410 °C. The residual concentration of 20% 
corresponds to the MNPs. The other 80% corresponds to the PMMA 
and AO present in MNPs. This analysis is very important to determine 
the total concentration of MNPs in the formulation.  
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Figure 4.4 TGA analysis of MNPsOA (a) and MNPs-PMMA nanoparticles (b). 
The magnetic properties of MNPsOA and MNPs-PMMA 
nanoparticles were characterized by vibrating sample magnetometry 
(VSM). Figure 4.5 shows the hysteresis loops as a function of the 
magnetic field at room temperature. The magnetic parameters, including 
saturation magnetization and remnant magnetization, are shown in Table 
4.2. Saturation magnetization values in emu/g were obtained 
considering the iron oxide mass obtained from TGA analysis. 
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Figure 4.5 Magnetic properties of MNPs(AO) and MNPs-PMMA, magnetic 
field of 20 KOe (a)-(b) and magnetic field of 4 KOe (c)-(d), respectively. 
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Table 4.2 Magnetic properties of MNPs(OA) and MNPs-PMMA nanoparticles 
Samples Ms (emu/g) Mr (emu/g) Hc (Oe) Mr/Ms  
MNPs(OA) 66 0.0058 2.0 8.7 x10
-5
 
MNPs-PMMA 34 0.0138 0.2 3.8 x10
-5
 
 
The saturation magnetization of the MNPs-PMMA 
nanoparticles was about 34 emu/g of MNPs (Figure 4.5a and c), while 
that of the MNPs(AO) was about 66 emu/g of MNPs (Figure 4.5b and 
d). The decrease in saturation magnetization relative to the bulk value 
Ms=100 emu/g may be due to oxidation processes during sonication, 
which leads to the formation of some iron oxides without magnetization 
or with low saturation magnetization (Ms), such as maghemite (𝛾-
Fe2O3), which has a lower Ms of 60–80 emu/g compared to 92-100 
emu/g for Fe3O4 (LANDFESTER and RAMIREs, 2003). It also can be 
attributed to the dense coating of the non-magnetic polymer, or because 
during the polymerization, some of the Fe3O4 converts to another iron 
oxide, like 𝛾-Fe2O3, due to the presence of the oxidizing initiator 
fragments (DALLAS et al, 2006; HONG et al, 2008; MODY et al, 2014; 
RAMIRES and LANDFESTER, 2003). However, the nanoparticles 
presented a significantly lower Ms compared with the bulk values, due 
to finite-size effects (BATLLE and LABARTA, 2002). All of the 
ferrofluids showed typical superparamagnetic behavior at room 
temperature, with absence of hysteresis loop, low Mr/Ms ratio and small 
Hc values (Table 4.2) (CHANDRASEKHARANA et al, 2011; MODY 
et al, 2014). The superparamagnetic properties of Nps are very 
important for biomedical applications. Therefore, without an external 
magnetic field, their overall magnetization value is randomized to zero, 
preventing active behavior of the particles when there is no applied field 
(DALLAS et al, 2006; GUPTAab, 2005; ZHENG et al, 2005).             
Figure 4.6 shows that the amount of MNPs in PMMA 
nanoparticles does not influence the Ms (Figure 4.6a and b) and the 
general shape of the magnetization curve (Figure 4.6c and d), indicating 
non-observable interacting effects among MNPs. This clearly indicates 
that the MNPs with a diameter of 10 nm are still well separated in the 
polymer matrix (XU et al, 2014). This Ms value is enough for 
encapsulated MNPs to move quickly and be easily separated from the 
aqueous phase by the action of an external magnetic field gradient, as 
can be seen in Figure 4.7. MNPs-PMMA nanoparticles can be directed 
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towards a specific target in the human body, with application of an 
external magnetic field, such as, after intravenous administration.  
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Figure 4.6 Magnetic properties with different concentrations of MNPs in 
PMMA (10% and 20%), magnetic field of 20 KOe (a)-(b) and magnetic field of 
4 KOe (c)-(d), respectively. 
 
 
Figure7 MNPs-PMMA nanoparticles in PBS (7.4) without application of an 
external magnetic field and with application of an external magnetic field. 
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4.4.2 In vitro antitumor activity of MNPs-PMMA nanoparticles on 
L929 and U87MG cells 
 
The cytotoxic effects of MNPs-PMMA nanoparticles on L929 
cells were examined by the MTT assay. Figure 4.8 shows the 
cytotoxicity profile of L929 cells incubated with various concentrations 
of MNPs-PMMA nanoparticles. The nanoparticles did not show any 
cytotoxic effect on L929 cells. Cell viability of nearly 99% can be 
observed after treatment with the control group. This test with L929 
cells is very important as it will facilitate innovative research using 
nanomaterials for hyperthermia based treatment and drug release 
systems (ABULATEEFH et al, 2011; SIMIONI et al, 2007). 
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Figure 4.8 Cytotoxicity effects of different concentrations of MNPs-PMMA 
nanoparticles on L929 cells. 
ns
p <0.05 compared to control group, using 
ANOVA followed by the Bonferroni post-hoc test. 
 
The viability of U87MG cells treated with MNPs-PMMA 
nanoparticles under AC magnetic field activation is shown in Figure 4.9. 
The viability of U87MG cells decreased (p < 0.05) after AC magnetic 
field application, reaching 52% (0.05µg.mL
-1
) and 54% (0.1µg.mL 
-1
). 
The temperature change caused by the AC magnetic field induced HPT. 
This observation can be attributed to the local heating caused by the 
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HPT process (DORNIANI et al, 2012; GUPTAab, 2005; ZHAO et al, 
2013). The viability of U87MG cells with HPT for 1 min, 3 min and 6 
min presented significant differences (p<0.05). However, different 
concentrations (0.05µg.mL
-1
 and 0.1µg.mL
-1
) of MNPs used in the 
cytotoxicity assays did not present significant differences (p<0.05).  
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Figure 4.9 Cytotoxicity effect of two concentrations (0.05µg and 0.1µg of 
MNPs loaded in PMMA nanoparticles) on U87MG cells, 24 h after induced 
hyperthermia for 1, 3 and 6 min (40 Oe – 1 MHz) exposure. ***p <0.05 
compared to control groups, using ANOVA followed by the Bonferroni post-
hoc test. 
 
The morphology of U87MG cells treated with MNPs-PMMA 
nanoparticles and the corresponding induction of hyperthermia is shown 
in Figure 4.10. Figure 4.10b shows that after 1 h, U87MG cells treated 
under AC magnetic field resulted in a region of hypoxia. According to 
Zee (2002), the architecture of the vasculature in solid tumors is chaotic, 
resulting in regions with hypoxia, which is not found in normal tissues 
in undisturbed conditions. The results of the MNPs-PMMA 
nanoparticles in the control group demonstrate that the 
superparamagnetic nanoparticles themselves (without AC magnetic 
field) do not have any treatment effect (Figure 4.10a). Figure10c show 
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the significantly reduced viability of U87MG cells, to 54% (0.1µg.mL
-1
) 
after 24 hrs of U87MG cells treated under AC magnetic field for 6 min 
(40Oe / 1 MHz). 
 
 
Figure 4.10 Morphology of U87MG cells treated for 6 minutes - hyperthermia 
treatment (40 Oe – 1 MHz) using MNPs-PMMA nanoparticles: Control: 
without application of magnetic field (a), one hour after hyperthermia (b) and 
24 h after hyperthermia (c). 
 
The impact of MNPs-PMMA nanoparticles on human red blood 
cells (RBCs) was evaluated by a hemolysis assay. The quantitation of 
hemoglobin in the supernatant of the nanoparticle-RBC mixture was 
done by recording the absorbance of hemoglobin at 540 nm. Treatment 
with 10 µl, 25 µl and 50 µl of MNPs-PMMA nanoparticles coated with 
0.1µg.mL
-1
 of MNPs was not able to cause hemolysis of RBCs, 
suggesting that these systems do not have hemolytic capacity, even 
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when administered at high concentrations (Figure 4.11). These results 
reveal that these nanoparticle formulations have high blood 
biocompatibility, making them an alternative to carry drugs 
administered intravenously.  
 
 
Figure 4.11 Hemolysis assay. Relative rate of hemolysis in human RBCs upon 
incubation with MNPs-PMMA nanoparticles at 10 µl, 25 µl and 50 µl volume. 
The presence of hemoglobin in the supernatant (red) was observed at 540 nm. 
Data are mean ± SD (n=3). 
4. CONCLUSION 
 
The encapsulation of MNPs loaded with PMMA by 
miniemulsion polymerization was efficient and resulted in stable MNPs-
PMMA nanoparticles in aqueous dispersion, with narrow average size 
distribution, superparamagnetic properties and biocompatibility. The 
high value of Ms and superparamagnetic properties of MNPs-PMMA 
nanoparticles make them attractive for drug delivery to specific cells or 
tissues without damaging healthy cells. The in vitro result showed that 
AC magnetic field application in U87MG cells treated with      MNPs-
PMMA nanoparticles decreased the cells viability and resulted in a 
region of hypoxia.   MNPs-PMMA nanoparticles presented high blood 
compatibility and have the potential to be used as carries of drugs in 
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cancer treatments, causing maximum tumor damage, with minimum 
side effects on healthy cells and tissues. 
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CHAPTER 5 
SIMULTANEOUS ENCAPSULATION OF MAGNETIC 
NANOPARTICLES AND ZINC PHTHALOCYANINE IN 
POLY(METHYL METHACRYLATE) NANOPARTICLES BY 
MINIEMULSION POLYMERIZATION AND IN VITRO 
STUDIES 
 
Abstract: The aim of this work was the simultaneous encapsulation of 
magnetic nanoparticles (MNPs) and zinc (II) phthalocyanine (ZnPc) in 
poly(methyl methacrylate) (PMMA) (MNPsZnPc-PMMA) 
nanoparticles (NPs)  by miniemulsion polymerization and to evaluate 
the photobiological activity and/or hyperthermia (HPT) against human 
glioblastoma cells (U87MG). MNPsZnPc-PMMA NPs presented an 
average diameter of 104 ±2.5 nm with a polydispersity index (PdI) of 
0.14 ±0.03 and negative surface charge - 47 ± 2.2 mV (pH 7.4 ±0.1). 
The encapsulation efficiency (EE%) of ZnPc was 85.7% ±1.30. The 
release of ZnPc from PMMA NPs was slow and sustained without the 
presence of burst effect, indicating a homogeneous distribution of the 
drug in the polymeric matrix. In the biological assay, MNPsZnPc-
PMMA NPs showed considerable cytotoxic effect on U87MG cells only 
after activation with visible light at 675 nm (photodynamic therapy, 
PDT) or after application of an alternating magnetic field. The 
simultaneous encapsulation of MNPs and ZnPc in a drug delivery 
system with sustained release can be a new alternative for cancer 
treatment leading to significant tumor regression after minimum doses 
of heat dissipation and light.    
 
Keywords: hyperthermia; miniemulsion polymerization; photodynamic 
therapy; polymeric nanoparticles. 
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5.1 INTRODUCTION  
 
The development of polymeric nanoparticles (NPs) loaded with 
hydrophilic drugs has been attracting considerable interest in recent 
years for cancer treatment through targeted administration to specific 
tissues or cells, with controlled drug delivery (DANHIER et al, 2010; 
KUMARI et al, 2010). Miniemulsion polymerization allows the 
production of polymeric NPs with unique characteristics of great interest 
for biomedical applications (LANDFESTER et al, 2010). The 
miniemulsion polymerization technique may be an advantageous 
encapsulation method, including the ability to control the particle size, 
directly dispersing the hydrophobic inorganic particles in the monomer 
phase with the aid of a stabilizer, the ability to nucleate all the droplets 
containing inorganic particles, as well as presenting a faster 
polymerization and, depending on the formulation, resulting in 
biocompatible NPs dispersions (MAHDAVIAN et al, 2008; 
LANDFESTER and MAILANDER et al, 2013; QIU et al, 2007). 
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Poly(methyl methacrylate) (PMMA) is a biocompatible and non-
biodegradable polymer prepared by miniemulsion polymerization that 
has been used for drug delivery (LANDFESTER et al, 2010; 
LANDFESTER and MAILANDER et al, 2013). Since it is non-
biodegradable, it can increase the circulation time in bloodstream, 
reaching therapeutic index and reducing side effects of the encapsulated 
drugs (FU and KAO, 2010). NPs are promising delivery systems for use 
in photodynamic therapy (PDT) and hyperthermia (HPT). PDT consists 
of therapeutic approaches involving the activation of photosensitized 
drugs by a visible light source, always associated with the generation of 
cytotoxic reactive oxygen species (ROS) and other free radicals, by type 
I or Type II photochemistry pathaway (FOOTE, 1991), to promote the 
selective destruction of target tissues (MARANHO et al, 2009; 
NAWALANY et al, 2012; RICCI-JÚNIOR and MARCHETTI, 2006; 
TRIESSCHEIJN et al, 2006). An efficient photosensitizer should have a 
high absorption cross-section at a wavelength suitable for the desired 
application (SAVOLAINEN et al, 2008), normally close the maximum 
absorption wavelength of the drug in question, avoiding interference 
with natural endogenous molecules. PDT has been widely used to treat 
superficial tumors such as skin, head and neck tumors (PRIMO and 
TEDESCO, 2013; RAI et al, 2010; ROCHA et al, 2012). Zinc (II) 
phthalocyanine (ZnPc) is a promising second-generation photosensitizer 
for PDT that belongs to the phthalocyanine class due to its high optical 
absorption coefficient (in the range of 600-800 nm). These 
photosensitizers are insoluble in water, leading to self-aggregation in 
aqueous solutions, which drastically reduces the photosensitizing 
efficiency when used directly in biological fluids. To avoid these 
problems, an advanced drug delivery system is needed (FOOTE, 1991; 
NUNES et al, 2004). Several kinds of polymeric nanoparticles and 
polymerization methods have been used to encapsulate magnetic 
nanoparticles (MNPs) inside polymers (FEUSER et al, 2015; HE et al, 
2009; HONG et al, 2008; LANDFESTER and MAILANDER, 2013). 
MNPs present low toxicity and are promising materials for cancer 
treatment (MUÑOS-BONILLA et al, 2012; DESHAYES and KASKO, 
2013). Additionally, induced hyperthermia as a procedure for cancer 
treatment involves raising the temperature of tumor tissues to 40–43 °C 
(ABULATEEFEH et al, 2011; BASEL et al, 2012; Zee, 2002). Solid 
tumors have been shown to have increased susceptibility to small 
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temperature rises compared to healthy tissue due to their increased rate 
of cell cycling, increased hypoxia, reducing fluid exchange, increased 
acidity (pH 2-4) (BASEL et al, 2012; Zee, 2002). Therefore, the 
combination of hyperthermia with treatment methods like radiotherapy, 
chemotherapy and PDT turns these methods much more effective. The 
combination of HTP and PDT has produced promising results indicating 
synergistic interaction and significant tumor regression (BOLFARINI et 
al, 2012; PRIMO and TEDESCO, 2013; XU and SU, 2013). The heat 
released by HPT induces changes in cell cycle, causing faster 
denaturation of malignant cells through aggregation of nuclear proteins, 
thereby enhancing the sensitivity of cells denatured previously with 
PDT (KUMAR and MOHAMAD, 2011).  
The simultaneous encapsulation of MNPs and ZnPc in the same 
system with controlled release is a promising new option for cancer 
treatment. Thus the objectives of this work were to encapsulate MNPs 
and ZnPc in PMMA NPs by miniemulsion polymerization and to 
evaluate their in vitro effect in the presence of alternating magnetic field 
and/or light on human glioblastoma cells (U87MG). These cells cause 
the most aggressive brain tumors, with low life cure rates after surgery 
associated with traditional therapies. Hence, this investigation can lead 
to promising new cancer treatments. 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
 
For the synthesis of magnetic nanoparticles (MNPs) coated with 
oleic acid (OA) the following reagents were used: ferrous sulfate 
(FeSO4⋅4H2O), iron (III) chloride hexahydrate (FeCl3⋅6H2O), 
ammonium hydroxide (99%), and oleic acid (OA), all purchased from 
Vetec. For the synthesis of MNPsZnPc loaded PMMA NPs, the 
following reagents were employed: the monomer methyl methacrylate 
(MMA), purchased from Arinos; azobisisobutylonitrile (AIBN), sodium 
dodecyl sulfate (SDS), NaH2PO4 (sodium phosphate monobasic) and 
Na2HPO4 (sodium phosphate dibasic), purchased from Vetec; lecithin 
(Alpha Aesar); miglyol 812 (Sazol) and zinc (II) phthalocyanine (ZnPc) 
and n-methylpyrrolidone (NMP), both purchased from Sigma Aldrich. 
Distilled water was used throughout the experiments. 
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5.2.2 METHODS 
5.2.2.1 Synthesis of magnetic nanoparticles coated with oleic acid 
(MNPs(OA))  
 
MNPs(OA) were prepared by the co-precipitation method. 
FeCl3.6H2O and FeSO4.7H2O (molar ratio of 1:1) were dissolved in a 
beaker containing distilled water under mechanical stirring at 800 rpm. 
Then, ammonium hydroxide was rapidly added to the solution. After 1 
hour, 20mL of OA was added and the stirring continued (800 rpm) for 
another 30 min.  Finally the MNPs(OA) solution was centrifuged and 
washed with ethanol three times to remove excess OA.  
5.2.2.2 Synthesis of PMMA nanoparticles 
 
The preparation of PMMA nanoparticles via miniemulsion 
polymerization was the same as described by Feuser and collaborates 
(2014). The aqueous phase was composed of 20 mL distilled water and 
the organic phase contained: 2 g of MMA (monomer), 0.1 g of lecithin 
(surfactant), 0.1 g of miglyol (costabilizer) and 0.04 g of AIBN 
(initiator). The organic phase was added dropwise under high shear 
using sonication with amplitude of 70% (Fisher Scientific, Sonic 
Dismembrator, 500 W). Sonication was mantained for 5 min (10 s on, 
and 1 s off) in a beaker immersed in an ice bath to avoid the temperature 
increase during sonication. The miniemulsion was transferred to glass 
tubes (10 mL) at 70 °C where the polymerization took place for 3 hours 
under protection from light. Afterwards, the material was cooled, 
centrifuged and washed several times with phosphate buffered saline 
solution (PBS) at pH 7.4. Subsequently nanoparticles were transferred to 
glass vials, frozen in liquid nitrogen and lyophilized (Lyophilizer, 
FreeZone 4.5-L Benchtop Freeze Dry System; Labconco, Kansas City, 
MO). The lyophilized powder was stored at room temperature (25 °C) 
before analysis. 
5.2.2.3 Simultaneous encapsulation of MNPs and ZnPc in PMMA 
NPs by miniemulsion polymerization (MNPsZnPC-PMMA) 
 
MNPsZnPc in PMMA NPs were prepared by miniemulsion 
polymerization. For encapsulation of MNPs and ZnPc, initially 1 mL of 
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NMP containing 6 mg of ZnPc was added dropwise in a beaker 
containing 20 mL of distilled water (aqueous phase) under sonication 
with an amplitude of 70% (Fisher Scientific, Sonic Dismembrator, 
500 W). Next, the organic phase (containing 2 g of MMA, 0.2 g of 
MNPs, 0.1 g of lecithin, 0.1 g of miglyol and 0.04 g of AIBN) was 
added dropwise under high shear to the previous aqueous ZnPc 
dispersion. The sonication was continued for 5 min (10 s on and 1 s off) 
in a beaker immersed in an ice bath to avoid temperature increase during 
sonication. The miniemulsion was transferred to glass tubes (10 mL) at 
70 °C, where the polymerization took place for 3 hours under protection 
from light. Afterwards, the material was cooled, centrifuged and washed 
several times with PBS at pH 7.4. Subsequently, NPs were transferred to 
glass vials, frozen in liquid nitrogen and lyophilized (FreeZone 4.5-L 
Benchtop Freeze Dry System; Labconco, Kansas City, MO). The 
lyophilized powder was stored at room temperature (25 °C) before 
analysis.  
5.3 Characterization  
 
Monomer consumption was measured by gravimetric analysis 
of samples withdrawn from the polymerization medium at different 
times and the reaction was stopped with the addition of 1% (w/w) 
hydroquinone solution. The determination of the residual monomer 
concentration after the miniemulsion polymerization was performed by 
GC (Shimadzu GC2010AF). Particle size, polydispersity index (PdI) 
and surface charge were measured by dynamic light scattering (DLS) 
using a Malvern Zetasizer Nano ZS analyzer. All samples were analyzed 
five times, from which we calculated the average and standard deviation 
(SD). The NPs morphology was observed using a JEOL, JEM 2100F, 
transmission electron microscope (TEM) operated at 100 kV. For this 
analysis, several drops of the diluted sample were placed on a 200 mesh 
Formvar/carbon copper grid (Electron Microscopy Science).  X-ray 
diffraction (XRD) experiments were performed to identify the 
crystallographic structure of free ZnPc, MNPs and MNPsZnPc-PMMA 
NPs. The crystalline phase of NPs was identified by XRD measurements 
using a XPert-Pro diffractometer, Cu-Kα radiation (45 kV/40 mA) in the 
2θ range of 20-80
o
. The average crystal size was calculated according to 
the Debye-Scherrer Eq. (1):  
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          ⁄                                                                                                                      
(1) 
where, D is the particle diameter, R is the Scherrer constant 
(0.89), λ is the wavenumber of incident X-ray beam, β is the half-
maximum peak width, and θ is the diffraction angle). The average 
crystallite size is obtained from the most intense peak (311). MNPs(OA) 
and MNPsZnPc-PMMA NPs were characterized  through 
thermogravimetric analysis (TGA) runs under nitrogen atmosphere at a 
heating rate of 10 °C/min. NPs chemical characterization was performed 
by Fourier transform infrared spectroscopy (FT-IR) using KBr pellets. A 
MicroSense model EV9 vibrating sample magnetometer (VSM) was 
used to measure the hysteresis loops of MNPs(OA) and MNPsZnPc-
PMMA NPs. The encapsulation efficiency (EE) of ZnPc was 
determined by UV-Vis spectrophotometry. 10 mg of NPs was dissolved 
in NMP, the common solvent for both drug and polymer. ZnPc 
concentration was measured at 670 nm (visible region of the 
electromagnetic spectrum) using a calibration curve with different 
concentrations of ZnPc dispersed in NMP. The determination coefficient 
(R
2
) exceeded 0.999, with excellent linearity (20 – 200 ng/mL). The 
EE% of ZnPc was calculated from Eq. (2): 
              ⁄                                                                                                              
(2) 
where EE is the ZnPc encapsulation efficiency, M1 is the mass 
of ZnPc in NPs and Mt is the mass of ZnPc used in the formulation. All 
samples were run in triplicate (n=3). 
5.4 In vitro studies 
5.4.1 Release profile 
 
The in vitro release studies followed the procedure described by 
Ricci-Junior and Marchetti (2006). NPs (5 mg) were weighed and added 
to 30 mL of the receptor medium, composed of PBS (pH 7.4) and 
2 wt.% SDS. The NPs suspension was continuously stirred (100 rpm) 
and the temperature was maintained at 37 
o
C in a thermostatically 
controlled water bath. At given time intervals, six samples (n = 6) of 
3 ml were withdrawn and centrifuged at 10,000 × g for 30 min 
(Beckman J-25 centrifuge, USA). The precipitates were re-suspended in 
3 ml of fresh medium and placed in the respective dissolution vessels. 
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The drug released in the receptor medium was quantified by 
spectrophotometry using the visible region of the spectrum (670 nm). 
The release profile was obtained by associating the percentage of drug 
released with time. The release data were fitted using the zero-order, 
first-order and Higuchi mathematical models, as described by Costa and 
Lobo (2002).  
5.4.2 In vitro cytotoxicity assay - Cell culture  
 
U87MG cells were seeded at 1x10
4 
cells/well in a 96-wells plate 
to assess the intrinsic cytotoxic effect of plain PMMA NPs and 
MNPsZnPc-PMMA NPs. After 24 h, U87MG cells were kept in the 
dark and incubated with a mixture of fresh medium and NPs at a final 
concentration of 50 µg of NPs, including 0.6 µg.mL
-1
 of MNPs and 
0.06 µg.mL
-1
 of ZnPc (5% CO2, 37 °C). After incubation, the medium 
containing the NPs was discarded and the cells were washed with PBS. 
Next, the cells were incubated with fresh medium for an additional 24 h, 
until the cell viability assay (MTT) was performed. Control cells were 
incubated with pure culture medium (untreated cells) or unloaded NPs 
mixed with medium, both in the dark. Cytotoxicity experiments in the 
dark were carried out in triplicate, with 36 wells for each condition. 
Murine fibroblast cells (L929) were cultivated in Dulbecco’s Modified 
Eagle Medium (DMEM) (GIBCO, São Paulo, SP, Brazil). DMEM was 
supplemented with 10% fetal bovine serum (FBS) (GIBCO, São Paulo, 
SP, Brazil), 100 U/mL penicillin-streptomycin (GIBCO, São Paulo, SP, 
Brazil) and 10 mM HEPES (GIBCO, São Paulo, SP, Brazil). Cells L929 
were treated with MNPsZnPc-PMMA NPs at the final concentration of 
50 µg.mL
-1
. Non-treated cells were considered as a control. Cells were 
incubated at 37 
o
C in a humidified atmosphere with 5% CO2, in plastic 
culture flasks. The cytotoxic effect was evaluated by measuring cell 
viability using the MTT assay.  
5.4.3 Photodynamic assay 
 
In order to evaluate the treatment of U87MG cells in vitro with 
MNPsZnPc-PMMA NPs, the cells were seeded at 1x10
5 
cells/well in a 
24-well plate. After 24 h, U87MG cells were treated with medium 
containing MNPsZnPc-PMMA NPs using 50 µg of NPs with 0.6µg.mL
-
1
 of MNPs and 0.06 µg.mL
-1
 of ZnPc (5% CO2, 37 °C). Following 
106
 
 
 
  
incubation (3 h), the medium loaded with NPs was removed, after which 
the cells were rinsed with PBS (1X) and incubated with conditioned 
medium. After 24 h, the cells were irradiated with visible light at 0.5, 1, 
3 and 5 J cm
-2
 in fresh medium without bovine serum. After the 
irradiation, U87MG cells were incubated (5% CO2, 37 °C) in fresh 
conditioned medium for 24 h more, when the MTT cell viability assay 
was performed. Control cells were incubated with culture medium alone 
without encapsulated MNPsZnPc-PMMA NPs and PDT, or 
encapsulated MNPsZnPc-PMMA NPs mixed with medium 
(encapsulated control). The cytotoxicity assay was carried out in 
triplicate, with 36 wells for each condition. 
5.4.4 Hyperthermia assay 
 
To evaluate the hyperthermia treatment of U87MG cells with 
MNPsZnPc-PMMA NPs in vitro, the cells were seed at 1x10
5 
cells/well 
in a 24-well plate. After 24 h, the U87MG cells were treated with 
medium containing MNPsZnPc-PMMA NPs using 50 µg of NPs with 
0.6µg.mL
-1
 of MNPs and 0.06 of ZnPc (5% CO2, 37 °C). Following 
incubation (3 h), the media loaded with NPs were removed, the cells 
were rinsed with PBS (1X) and incubated with conditioned medium. 
After 24 h, the cells were treated for 3 min or 6 min with an alternating 
magnetic field operating at 1 MHz and 40 Oe amplitude, in the presence 
of fresh medium without bovine serum. The magnetohyperthermia 
(MHT) was carried out on a portable apparatus operating at 1 MHz with 
40 Oe of field amplitude. The MHT system is composed by a metallic 
core with cylindrical cross-section (10.7 mm diameter) wounded by a 
coil of wire to concentrate the alternating magnetic flux. The solenoid 
core is linked to an adjustable support to apply the magnetic field in the 
targeted region (GUEDES et al, 2004;2005). The device details are 
described by patent INPI # PI 0204433-1 A2. 
After the hyperthermic application, U87MG cells were 
incubated (5% CO2, 37 °C) in fresh conditioned medium for an 
additional 24 h until the MTT cell viability assay was performed. 
Control cells were incubated with culture medium alone without 
encapsulated MNPsZnPc-PMMA NPs and magnetic field, or 
encapsulated MNPsZnPc-PMMA NPs mixed with medium 
(encapsulation control). The cytotoxicity assay was carried out in 
triplicate, with 36 wells for each condition. 
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5.4.5 Combined treatment – PDT and HPT 
 
In order to evaluate the synergy of the PDT and HPT, the 
U87MG cells were treated under the same conditions described above 
for PDT and HPT using the MNPsZnPc-PMMA-NPs. The light dose 
chosen was 3 J/cm
2 
and the magnetic field was applied for 6 min.  
5.4.6 MTT viability assay 
 
The cell MTT proliferation method was employed for 
assessment of cell viability after both the cytotoxic assays. Briefly, 
aliquots of 80 μl MTT solution (5 mg ml
− 1
) and 420 μl medium without 
phenol red were added to each well. The cells were then incubated for 
4 h, at 37 °C and 5% CO2 to allow the formazan formation reaction. 
Following incubation, the medium containing the MTT solution was 
removed and the formazan crystals were dissolved in 2-propanol. The 
optical density was measured at 570 and 690 nm using a Safire
2
 
microplate reader (Tecan Group Ltd.). Results are presented as 
percentage of survival, taking the control (untreated cells) as 100%.  
5.5 Statistical analysis 
 
Data are presented as the mean ± standard deviation of three 
determinations. One-way ANOVA followed by the Bonferroni post-hoc 
test were used to compare the cytotoxicity of the samples at different 
concentrations. Statistical analysis was performed using the Statistical 
Package for Social Sciences for Windows (SPSS Inc. version 13.0, 
USA). The statistical significance level was set at p < 0.05 for all 
analyses. 
5.6 RESULTS AND DISCUSSION   
5.6.1 Characterization of MNPs and ZnPc in PMMA NPs 
 
The addition of MNPs and ZnPc in the reaction medium to 
prepare MNPsZnPc-PMMA NPs by miniemulsion polymerization 
caused a reduction in the reaction rate (Figure 5.1a). One of the reasons 
for the decrease in the polymerization rate was the increase of the 
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average particle diameter when MNPs and ZnPc were added (from 
89 nm for PMMA NPs to 104 nm for MNPsZnPc-PMMA NPs), as it 
reduced the compartmentalization effect and the total number of free 
radicals present in the reaction medium (COSTA et al, 2013; FEUSER 
et al, 2014). Another reason was the reaction of the oxidizing initiator 
(AIBN) with part of the magnetite (Fe3O4) converting it to Fe2O3 
reducing the concentration of AIBN from the reaction medium (COSTA 
et al, 2013; FEUSER et al, 2015; HONG et al, 2008). No residual 
monomer was detected by GC analysis after lyophilization of the 
MNPsZnPc-PMMA NPs, allowing application of these NPs in the 
biomedical field (AYDIN et al, 2002; PRADEEP et al, 2012).  
Transmission electron microscopy images of the MNPs coated 
with oleic acid show particles with diameters between 5-13 nm (Figure 
5.1b). The polymer particles formed during miniemulsion 
polymerization of MMA were analyzed by TEM in order to verify the 
encapsulation of MNPs. Since PMMA decomposes under exposure to a 
strong electron beam (OKUBO et al, 1999; TIARKS et al, 2001), it was 
possible to degrade the polymer to reveal the magnetite NPs that had 
been encapsulated being the MNPs attributed to the darker points in the 
image (Figure5.1c). The extent of degradation depends on exposure time 
and intensity of the electron beam resulting in the appearance of hollow 
PMMA nanoparticles when the TEM sample was covered with a carbon 
film that preserved the size and shape of the PMMA particles whereas 
lighter internal regions were formed during TEM analyses (STAUDT et 
al, 2013). As can be seen from the TEM images in Figure1C, PMMA 
particles contained several MNPs in most of the particles.  
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Figure 5.1 Gravimetric conversion of the PMMA and MNPsZnPc-PMMA NPs 
(a) and TEM images of MNPs(OA) (b) and MNPsZnPc-PMMA NPs (c). 
 
The results of DLS analysis showed an intensity average 
diameter of 104nm ± 2.5 and polydispersity of 0.14 ± 0.03. The low PdI, 
around 0.1, indicates that the MNPsZnPc-PMMA NPs have narrow size 
distribution and that the osmotic pressure would be sufficient to prevent 
Ostwald ripening, increasing the stability of the small monomer droplets 
and of the miniemulsion (ASUA, 2002). TEM and DLS results show 
that the size distribution of the NPs is uniform, so it is likely that the 
dominant nucleation mechanism was the nucleation of the monomer 
droplets in preference to other possible mechanisms, such as micellar or 
homogeneous nucleation, as would be expected when employing a 
hydrophobic initiator (ASUA, 2002). Besides the size and morphology 
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of NPs, the zeta potential is another important characteristic of NPs, as it 
gives information about the colloidal stability and the possible 
interactions between NPs and the biological medium (HE et al, 2010; 
LANDFESTER and MAILANDER, 2010; PATIL et al, 2014;. The pH 
is a major factor affecting the zeta potential of a sample and therefore is 
an important parameter considered in the analysis. The empty PMMA 
NPs and MNPsZnPc-PMMA NPs exhibited negative zeta potential, -
 40 ± 4.3 mV and - 47 ± 2.2 mV (pH 7.4 ± 0.1), respectively. The 
increase of the negative charge of MNPsZnPc-PMMA NPs is associated 
with the presence of surfactant (lecithin) and OA adsorbed on the 
nanoparticle surface (FEUSER et al, 2014).  
X-ray powder diffraction (XRD) patterns for the naked 
MNPs(OA) and MNPsZnPc-PMMA NPs are shown in Figure 5.2. 
Figure 5.2a shows six characteristic peaks, observed at 2θ = (220), 
(311), (400), (422), (511) and (440) (FEUSER et al, 2015). These results 
demonstrate that the MNPs coated OA have the expected crystalline 
structure of Fe3O4 (FEUSER et al, 2015; PATIL et al, 2014; ZHENG et 
al, 2015). An additional broad peak for the ZnPcMNPs-PMMA NPs was 
observed at an angle between 10 and 20° due to amorphous polymer 
coating on the ZnPc and MNPs. Using the XRD results and Debye-
Scherrer equation, the average crystallite size of MNPs was estimated at 
10 nm. According to Mody and collaborates (2014), when MNPs have a 
critical diameter of about 5-10 nm it paves the way for them to become 
superparamagnetic NPs. XRD patterns of free ZnPc and PMMA are 
illustrated in Figure 5.2b. These data are useful in analyzing the degree 
of crystallinity of the MNPsZnPc-PMMA NPs. Free ZnPc exhibited a 
diffraction profile of crystalline material with several intense peaks. 
These results are similar to the results reported by Iwatsu and 
collaborates (1980) and Choi and collaborates (2014) for the 
polymorphic β-form of ZnPc.  The XRD profile of free ZnPc shows a 
crystalline form related to β-phase of monoclinic structure. However, 
these peaks were not observed in the XRD patterns of MNPsZnPc-
PMMA NPs. Therefore, the diffractograms of the MNPsZnPc-PMMA 
NPs indicate that the drug would be either molecularly dispersed in the 
polymers or distributed in an amorphous state or in very small crystals 
(LEKSHMI et al, 2010). 
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Figure 5.2 X-ray powder diffraction patterns of MNPs(OA) and  MNPsZnPc-
PMMA NPs (A) and free ZnPc and PMMA (B). 
 
TGA analysis (Figure 5.3a) shows that there was no mass loss 
in the temperature range from 0 to 100 °C, indicating that the material is 
free of impurities (HONG et al, 2008). Two mass losses occurred in the 
MNPs(OA). The first, of 30%, occurred between temperatures of 200 
and 280 ◦C, is related to free OA. The second mass loss, of about 13%, 
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was observed between 380 and 480 ◦C, corresponding to the OA 
adsorbed onto the MNPs (LANDFESTER and RAMIRES, 2013). In the 
case of MNPsZnPc-PMMA NPs, mass loss was gradual and it could be 
clearly seen that the PMMA NPs were completely degraded after 
reaching about 410 °C. The residual concentration of 11% corresponds 
to the MNPs. The other 89% correspond to the PMMA and AO present 
in MNPs. This analysis is very important to determine the total 
concentration of MNPs in the formulation. FT-IR spectrum of 
MNPsZnPc-PMMA NPs (Figure 5.3b) showed a band at 1736 cm
-1
 
corresponding to C=O groups of PMMA. In addition, the bands in the 
3000–2800 cm
-1
 region are attributed to the stretching of C
_
H bonds of 
the saturated alkane in PMMA. The peak at approximately 590 cm
-1
 
corresponds to Fe-O, which is attributed to the MNPs (FEUSER et al, 
2015; PATIL et al, 2014).  The free ZnPc presented characteristics 
peaks (718, 747 and 783 cm
-1
) of β-ZnPc (thermodynamically stable) 
(CHOI et al, 2014; HUSSEIN et al, 2011; IWATSU et al, 1980), 
corroborating with XRD analysis. The comparison between the FT-IR 
spectra of MNPsZnPc-PMMA NPs and free ZnPc confirmed that there 
is no significant interaction between ZnPc and the polymer showing that 
ZnPc was located in the polymeric matrix (molecularly dispersed) and 
not at the surface (LEKSHMI et al, 2010; ZHENG et al, 2005). These 
results also corroborate the XRD analysis. 
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Figure 5.3 TGA analysis of MNPs(OA) and MNPsZnPc-PMMA NPs and FTIR 
spectrum of free ZnPc, PMMA and MNPsZnPc-PMMA NPs. 
 
The magnetic properties of MNPs(OA) and MNPsZnPc-PMMA 
NPs were ascertained by VSM (Figure 5.4). Figure 5.4a shows the 
magnetization curves at room temperature. The MNPs coated with OA 
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and MNPsZnPc-PMMA NPs show typical superparamagnetic behavior 
at room temperature, with absence of hysteresis loop, and low value of 
the ratio remanent magnetization/saturation magnetization (Mr/Ms), 
3.8x10
-5
 and 8x10
-5 
emu/g of MNPs and of the coercive field (Hc), 
1.9 and 2.0 Oe. The superparamagnetic properties of NPs are very 
important for biomedical applications. In this way, without an external 
magnetic ﬁeld, their overall magnetization value is randomized to zero, 
avoiding interactive behavior of the particles when there is no applied 
field (BATTLE and LABARTA, 2002).
 
The Ms values in emu/g of 
MNPs were obtained considering the iron oxide mass determined by 
TGA (Figure 5.3a). The Ms value was 34 emu/g and 66 emu/g for 
MNPsZnPc-PMMA NPs and MNPs(OA), respectively. The decrease in 
Ms relative to the bulk value (Ms = 100 emu/g) may be due to oxidation 
processes during the sonication, leading to the formation of some 
nonmagnetic or low Ms iron oxide, since maghemite (𝛾-Fe2O3) has a 
lower Ms of 60–80 emu/g compared to 92-100 emu/g for magnetite 
(Fe3O4) (FEUSER et al, 2015; LANDFESTER and RAMIRES, 2003).
 
MNPsZnPc-PMMA NPs presented a significant reduction of Ms 
compared with the bulk values, due to finite-size effects (BATTLE and 
LABARTA, 2002). However, this Ms value is enough for encapsulated 
MNPs to move quickly and be easily separated from the aqueous phase 
by the action of an external magnetic field gradient, as can be seen in 
Figure 5.4b and c. Hence, MNPsZnPc-PMMA NPs can be directed 
towards a specific target in the human body, with application of an 
external magnetic field. 
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Figure 5.4 Magnetization curves of MNPs(AO) and MNPsZnPc-PMMA, for 
maximum applied field 20KOe and 4KOe (A). MNPsZnPc-PMMA NPs in PBS 
(7.4) without application of an external magnetic field (B) and with application 
of an external magnetic field (C). 
 
The spectroscopic results are presented in Figure 5.5. ZnPc did 
not suffer changes in its basic photophysical properties after the 
encapsulation. The soret and Q bands remain in the same position 
(Figure5.5a). Free ZnPc and ZnPc simultaneously encapsulated with 
MNPs in PMMA nanoparticles have similar spectroscopic behavior, 
with maximum wavelength at 670 nm for the one of the Q bands and 
ZnPc presented high encapsulation efficiency (85.7 ± 1.3%). The 
fluorescence emission of the photosensitizers is sensitive in their 
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environment, yielding much information (CUCCOVIA et al, 1982). The 
fluorescence emission spectra shown in Figure5B, indicates the position 
of the maximum emission (675 nm) of the classic ZnPc emission 
maximum, after light excitation at 610 nm in NMP. A slight reduction in 
the fluorescence intensity of the MNPsZnPc-PMMA NPs was observed 
considering the fluorescence quenching by PMMA NPs complexes. 
Similar results were shown by Chen and collaborates (2006) and 
Maranho and collaborates (2009). However, this behavior did not 
change the photochemical pathway and the production of the ROS and 
cytotoxic free radicals as expected (ZHEN et al, 2013). 
 
Figure 5.5 UV-Vis (a) and fluorescence spectrum (b): free ZnPc, MNPsZnPc-
PMMA NPs 
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5.6.2 In vitro Studies 
5.6.2.1 Release kinetics of ZnPc  
 
The release kinetics of ZnPc from the PMMA NPs showed a 
slow and sustained release profile. The amount of ZnPc released from 
PMMA NPs increased from 12% after 24 hours, to 50% and 80% after, 
respectively, seven and twelve days (Figure 5.6). In addition, it was not 
detected any “burst” effect indicating that ZnPc was entrapped within 
the PMMA NPs and possibly homogeneously dispersed in the polymeric 
matrix of the NPs and not at the surface  (KUMARI et al, 2010; 
HUANG, BRAZEL, 2001), corroborating the results previously 
evidenced by XRD and FTIR analyses. Thus, the results indicate that the 
drug release occurred by diffusion rather than desorption of the drug. 
The release of drugs from non-degradable polymeric delivery systems is 
more likely to be diffusion driven, which is associated with 
concentration gradient, diffusion distance and the swelling degree (FU 
and KAO, 2010). 
The zero-order, first-order and Higuchi models were evaluated 
in this work. The choice of the model was made by linear correlation 
(R 
2
). The Higuchi model showed the highest values of R
2
 (0.9378). 
This model is based on Fick’s law, whereby the release occurs by the 
diffusion of drugs within the delivery system (MATHEW et al, 2007). 
These results suggest that the release of ZnPc from MNPs-PMMA NPs 
is controlled by diffusion. 
 
Figure 5.6 Release profiles of ZnPc in MNPs-PMMA NPs. The error bars 
represent the standard deviation (SD) from the mean for a triplicate experiment 
(n=3). 
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5.6.3 In vitro cytotoxicity  
 
The biocompatibility of NPs was evaluated in L929 cells. The 
cells were treated with empty PMMA NPs and MNPsZnPc-PMMA NPs 
without magnetic field application and no light exposition, at a 
concentration of 50 µg.mL
-1
 of NPs (Figure 5.7a). The NPs did not 
show any cytotoxic effect on L929 cells, when compared with the 
control group (only cells) (p > 0.05). These results demonstrate the 
biocompatibility of the NPs in the absence of both magnetic field and 
light, preventing toxic effects on the healthy cells (FEUSER et al, 2015; 
DESHAYES and KASKO, 2013).  
Finally, cytotoxicity assays were performed on U87MG cells by 
HPT and PDT. HPT has been investigated in combination with PDT and 
the in vitro results show that HPT can act synergistically and have a 
photodynamic effect, which can be used for the treatment of solid 
tumors (BOLFARINI et al, 2012). The PDT is highly dependent on the 
photosensitizer’s cellular uptake mechanism. In aqueous medium, free 
ZnPc is generally absorbed by diffusion across the plasmatic membrane 
leading to a low intracellular concentration. Moreover, lipophilic ZnPc 
tends to aggregate in aqueous medium with reduction of its 
photodynamic activity (DEDA et al, 2009; ISELE et al, 1995; LEVY et 
al, 2008). Therefore, encapsulation of ZnPc in NPs improves the 
phototoxicity (RIICI-JÚNIOR and MARCHETI 2006). The HPT is 
highly dependent on nanosize and superparamagnetic property (DEDA 
et al, 2009). In all in vitro studies of this work, the concentration was 
50 µg of NPs with 0.6 µg.mL
-1
of MNPs and 0.06 µg.mL
-1
 of ZnPc. The 
in vitro synergic effect of both therapies and their separate application 
was investigated on U87MG cells. It is important to highlight that the 
MNPsZnPc-PMMA NPs without magnetic field application and no light 
exposition at a concentration of 50 µg.mL
-1
 of NPs did not present 
cytotoxic effect on U87MG cells when compared with the control group 
(only cells).  The in vitro cytotoxic effect of PDT was tested on U87MG 
cells incubated with MNPsZnPc-PMMA NPs. After incubation (3 h), 
the cells were irradiated using light doses of 0.5, 1.0, 3.0 and 5.0 Jcm
-2
 
and a decrease in cell viability, from 76  ± 1.23 to 68  ± 0.68, with 
increasing light dose could be observed (Figure 5.7b). For 3.0 and 
5.0 Jcm
-2
 light doses, the cell viability were very similar, therefore the 
lower light dose (3. 0 Jcm
-2
) was chosen for the combined treatment. For 
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the HPT assay, U87MG cells were treated with MNPsZnPc-PMMA NPs 
under alternating (AC) magnetic field activation for 3 and 6 min (40Oe 
– 1 MHz). As can be seen from Figure 5.7c, the cell viability 
significantly decreased (p < 0.05) after AC magnetic field application 
for 3 min (72.0 ± 1.29%) and 6 min (64.8 ± 1.17%). The exposure time 
(3 or 6 min) to the alternating magnetic field caused a significant 
difference (p < 0.05). For the combined treatments, U87MG cells were 
incubated for 24 h with MNPsZnPc-PMMA NPs and exposed to light 
doses of 3 J/cm
2
 followed by the application of the AC magnetic field 
for 6 min. In addition, the sequence of these treatments was also 
inverted, exposure to AC magnetic field followed by the application of 
the light doses. Figure 5.7d shows that cell viability decreased compared 
to that observed for the two therapies applied individually (p < 0.05). 
When the MNPsZnPc-PMMA NPs were exposed to light doses (3 J/cm
-
2
) followed the application of the AC magnetic field (6 min), the cell 
viability decreased to 48 ± 2.05. When the MNPsZnPc-PMMA NPs 
were exposed to alternating magnetic field (6 min) followed application 
of the light doses (3 J/cm
-2
), the cell viability decreased to 51 ± 1.97. As 
can be observed, the order of the treatments (PDT and HPT or HPT and 
PDT) did not present a significant difference (p < 0.05).  
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Figure 5.7 In vitro cytotoxicity assays in L929 cells (A). In vitro cytotoxicity 
assays of U87MG cells after treatment using MNPsZnPc-PMMA NPs irradiated 
with different light doses (B), after alternating (AC) magnetic field application 
(C) and combined therapies (D). ***p < 0.05 compared to control groups, using 
ANOVA followed by the Bonferroni post-hoc test. 
5.7. CONCLUSION 
 
The simultaneous encapsulation method of ZnPc and MNPs in 
PMMA NPs by miniemulsion polymerization resulted in stables 
MNPsZnPc-PMMA NPs, with an average size around 104 nm, 
superparamagnetic properties and high encapsulation efficiency of 
121
 
 
 
  
ZnPc. The dissolution profile test shows that the release of ZnPc from 
PMMA NPs is slow (12 days) and the mathematical models suggest that 
this release is controlled by diffusion, maintaining drug release for 
extended periods and allowing better treatment compliance. Therefore, 
MNPsZnPc-PMMA NPs can be applied to PDT and HPT for sustained 
drug delivery. The in vitro results showed that the application of light 
dose and AC magnetic field together can be more effective than each of 
the two treatments applied separately. The synergistic action of PDT and 
HPT in a drug delivery system can lead to a significant tumor regression 
after minimum doses of heat dissipation and/or photosensitization by 
light, in contrast to conventional treatments like chemotherapy and 
radiotherapy, where repeated administration of high drug doses is 
necessary to achieve a desired pharmacokinetic profile. 
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CHAPTER 6 
SUPERPARAMAGNETIC POLY(METHYL METHACRYLATE) 
NANOPARTICLES SURFACE MODIFIED WITH FOLIC ACID 
PRESENTING CELL UPTAKE MEDIATED BY ENDOCYTOSIS 
 
Abstract  
The encapsulation of superparamagnetic nanoparticles (MNPs) in 
polymeric nanoparticles (NPs) with modified surfaces can improve 
targeted delivery and induce cell death by hyperthermia. The goals of 
this study were to synthesize and characterize surface modified 
superparamagnetic poly(methyl methacrylate) with folic acid (FA) 
prepared by miniemulsion polymerization (MNPs-PMMA-FA) and to 
evaluate their in vitro cytotoxicity and cellular uptake in non-tumor 
cells, murine fibroblast (L929) cells and tumor cells that overexpressed 
folate receptor (FR) β, and chronic myeloid leukemia cells in blast crisis 
(K562). Lastly, hemolysis assays were performed on human red blood 
cells.  MNPsPMMA-FA presented an average mean diameter of 135 nm 
and a saturation magnetization (Ms) value of 37 emu/g of iron oxide, as 
well as superparamagnetic behavior. The MNPsPMMA-FA did not 
present cytotoxicity in L929 and K562 cells. Cellular uptake assays 
showed a higher uptake of MNPsPMMA-FA than MNPsPMMA in 
K562 cells when incubated at 37 °C. On the other hand, MNPsPMMA-
FA showed a low uptake when endocytosis mechanisms were blocked at 
low temperature (4 °C), suggesting that the MNPsPMMA-FA uptake 
was mediated by endocytosis. High concentrations of MNPsPMMA-FA 
showed hemocompatibility when incubated for 24 h in human red blood 
cells. Therefore our results suggest that these carrier systems can be an 
excellent alternative in targeted drug delivery via FR. 
 
Keywords: superparamagnetic; nanoparticles; poly(methyl 
methacrylate); folic acid; cell uptake 
 
The manuscript was was published in the Journal of Nanoparticles 
Research  
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6.1 INTRODUCTION  
 
Due to their unique physical properties, magnetic nanoparticles 
(MNPs), have been widely used in various biomedical applications, such 
as, targeted drug delivery (ZHAO et al, 2011; ZHENG et al, 2005), 
hyperthermia (FEUSER et al, 2015a; KUMAR et al, 2011 SIMIONI et 
al, 2007), and magnetic resonance imaging (MRI) (ABULATEEFEH et 
al, 2011; GUPTA and GUPTA, 2005). For these applications, MNPs 
must have combined properties of high magnetic saturation, 
superparamagnetic properties and biocompatibility (KUMAR et al, 
2011; ZHENG et al, 2005). MNPs represented by magnetite (Fe3O4) are 
often made in sizes smaller than 15 nm in diameter and their 
supepraramagnetic properties are sufficient to cause tumor cell death by 
hyperthermia (FEUSER et al, 2015a and 2015b). However, the use of 
pure MNPs for these applications are challenging due to the high surface 
to volume ratio and strong dipole–dipole interaction between the 
particles, which makes MNP agglomeration possible (KUMAR et al,. 
2014; TANG et al, 2013). The agglomeration of MNPs can be 
attenuated with the encapsulation of MNPs in polymeric nanoparticles 
(NPs). The encapsulation of MNPs in polymeric NPs improves their 
chemical and physical stability, solubility, biological stability, target 
delivery and reduces the side effects of the encapsulated material 
(AKBARZADEH et al, 2012; FAN et al, 2009; ZHANG et al, 2011). A 
large number of strategies have been proposed in the literature to 
encapsulate MNPs in polymeric colloidal particles including, inverse 
miniemulsion polymerization (ROMIO et al, 2013) and direct 
miniemulsion polymerization (FEUSER et al, 2015a; HE et al, 2009; 
YAN et al, 2011).  
Polymeric NPs can be prepared from natural or synthetic 
polymers (LANDFESTER and MAILANDER, 2013). They have been 
studied extensively as drugs carriers, where the main advantages are the 
protection of the drug, controlled release and the possibility of drug 
delivery within the targeted cell or tissue (LANDFESTER and 
MUSYANOVYCH, 2010; LANDFESTER and MAILANDER, 2013). 
Miniemulsion polymerization allows the production of polymeric NPs 
with unique characteristics of great interest for biomedical application, 
producing stable aqueous dispersions of droplets (50-500 nm) 
containing monomer, surfactant, ultrahydrophobe, initiator and water 
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insoluble compounds (e.g., hydrophobic MNPs) by applying high shear 
stress (ASUA, 2014; CRESPY and LANDFESTER 2010; HIGUCHI 
and MIRA, 1962; LANDFESTER 2009). The main advantage of the 
miniemulsion polymerization process is the ability to produce complex 
nanostructures, including inorganic nanoparticle encapsulation, in a 
single reaction step with fast polymerization rates (MAHDAVIAN et al, 
2008; QUIU et al, 2007).  
The NP surface modification with folic acid (FA) can increase 
drug uptake in tumor cells that express high levels of type α or β folate 
receptors (FR). The FR-α is significantly overexpressed on the surface 
of tumor cells, while the FR-β is overexpressed in leukemic cells and 
macrophages. FRs exhibit limited expression on non-tumor cells and 
tissues, where one of the main advantages is the targeted drug delivery 
by folate receptors (BHATTACHARYA et al, 2007; JIA-JYUN et al, 
2009; LEE et al, 2015; WIBOWO et al, 2013; YANG et al, 2014). 
FR-mediated drug delivery is facilitated by endocytosis, which may 
enable drug delivery (CHEN et al, 2013; PENGCHENG et al,. 2009; 
SUDIMACK and LEE, 2000). The NPs can be internalized across a 
plasmatic membrane (passive diffusion) and through endocytosis (NPs 
are engulfed by endocytic vesicles) (WANG et al, 2012). Several in 
vitro studies have demonstrated that the modified surface of 
nanoparticles with FA increases the cellular uptake in tumor cells that 
overexpressed FR (DUAN et al, 2012; SAHOO et al, 2013; YANG et 
al,. 2014; ZHANG et al, 2009). However, the functionalization or 
adsorption of the ligands cannot ensure drug delivery when it is 
intravenously administered (in vivo). When the functionalized 
nanoparticles enter the bloodstream they need to cross the blood vessel 
endothelial cells, which do not express FR, in order to reach the 
interstitial space of tumor sites (CHIN and FERREIRA, 1999; 
ANDHARIYA et al, 2013). To overcome this, a drug delivery system 
with superparamagnetic properties was proposed that could be guided 
by external magnetic field and uptake in vivo by FR mediated by 
endocytosis (XU et al,. 2014; ZHENG et at 2005). Furthermore, MNPs 
can also induce cell death by hyperthermia, when external alternating 
magnetic fields are applied (FEUSER et al,. 2015a and 2015b; MODY 
et al, 2014; XU et al, 2014). In a previous study, Feuser and collaborates 
(2015a) showed that superparamagnetic poly(methyl methacrylate) 
nanoparticles obtained by miniemulsion polymerization induced 
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glioblastoma (U87MG) cell death when alternating magnetic fields were 
applied for six minutes. 
The goal of this study was to synthesize and characterize 
superparamagnetic poly(methyl methacrylate) (PMMA) NPs obtained 
by miniemulsion polymerization surface modified with folic acid. In 
vitro cytotoxicity and cellular uptake assays were performed with the 
surface modified superparamagnetic poly(methyl methacrylate) 
(PMMA) with FA (MNPsPMMA-FA) and without FA (MNPsPMMA) 
on non-tumor cells, murine fibroblast cells (L929), cells that 
overexpressed FR-β, and chronic myeloid leukemia (K562) cells at two 
different temperatures (4 °C and 37 °C). Lastly, hemolysis assays was 
performed on human red blood cells.  
6.2 MATERIALS AND METHODS 
6.2.1 Materials 
 
For synthesis of magnetic nanoparticles coated with oleic acid 
(MNPsOA), the following reagents were used (high purity grade): 
ferrous sulfate (FeSO4⋅4H2O), iron (III) chloride hexahydrate 
(FeCl3⋅6H2O), ammonium hydroxide (99%), and oleic acid (OA), all 
purchased from chemistry Vetec. For the preparation of surface 
modified superparamagnetic PMMA NPs with FA (MNPsPMMA-FA), 
the following reagents were used: methyl methacrylate (MMA) obtained 
from chemistry Arinos, azobisisobutyronitrile (AIBN) and folic acid 
(FA) purchased from chemistry Vetec, lecithin obtained from Alpha 
Aesar, and Crodamol GTCC (as co-stabilizer) purchased from Croda. 
Distilled water was used throughout the experiments.6.2.2 Methods 
6.2.2.1 Synthesis of MNPsOA  
 
MNPsOA were prepared by co-precipitation in aqueous phase 
methods as described by Feuser and collaborates (2015a). Momentarily, 
FeCl3.6H2O and FeSO4.7H2O (mole ratio of 1:1.2) were dissolved in a 
beaker containing distilled water under mechanical stirring in the range 
of 800 rpm. Afterwards an ammonium hydroxide solution (11 mL) was 
rapidly added to the solution. After 1 h, 30 mL was added to the OA and 
the stirring process was continued (800 rpm) for 1 h. The MNPsOA 
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produced was centrifuged and washed three times with ethanol to 
remove the unreacted OA.  
6.2.2.2 Preparation of MNPsPMMA-FA by miniemulsion 
polymerization  
 
For encapsulation of MNPsOA by miniemulsion 
polymerization, an organic phase containing 2 g of MMA with 0.4 g of 
MNPsOA, 0.1 g of lecithin, 0.1 g of crodamol and 0.04 g of AIBN were 
added to a beaker containing 20 mL of distilled water and 0.02 g of FA 
(aqueous phase). The organic phase was added dropwise under higher 
shear with an amplitude of 70% (Fisher Scientific, Sonic Dismembrator, 
500 W). The high shear was maintained for 5 min (10 s on and 1 s off) 
in an ice bath immersed beaker to avoid an increased temperature during 
sonication. The miniemulsion product was transferred to glass tubes 
(10 mL) at 70 °C for polymerization during 3 h. Afterwards the material 
was cooled, centrifuged and washed three times with phosphate buffered 
saline (PBS) at pH 7.4. Subsequently, NPs were resuspended in 20 mL 
of PBS buffer. The magnetic fluid concentration used to produce the 
FA-MNPsPMMA was about 7x10
16
 particles.mL
-1
. For a comparative 
study, MNPs were prepared without folic acid (MNPsPMMA). The 
method of preparation was the same already described by Feuser and 
collaborates (2105a).  
6.2.2.3 Preparation of MNPsPMMA-FA by miniemulsion 
polymerization labeled with 6-coumarin  
 
A highly fluorescent molecule, 6-coumarin, was dissolved in 
Miglyol to form a uniform solution (0.5mg.mL
-1
). This solution (6-
coumarin/Miglyol) was used in the preparation of NPs to assess cellular 
uptake by fluorescence microscopy. In a beaker containing 20 mL of 
distilled water and 0.02 g of FA (aqueous phase) the organic phase was 
added (10 g of MMA with 0.5 g of MNPsOA, 0.1 g of lecithin, 0.1 g of 
solution Miglyol/6-coumarin and 0.04 g of AIBN) dropwise under 
higher shear. The following steps are the same as previously described. 
6.3 Characterization 
Monomer consumption was monitored by gravimetric analysis 
of samples withdrawn from the polymerization medium at different 
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times and the reaction was stopped with addition of a 1 % hydroquinone 
(w/w) solution. The determination of the concentration of residual 
monomer after the polymerization reaction in miniemulsion was 
performed by GC (Shimadzu GC2010AF). Particle size and surface 
charge were measured by dynamic light scattering (DLS) using a 
Malvern Zetasizer Nano ZS analyzer. The NPs morphology was 
observed using a JEM 2100F transmission electron microscope (TEM) 
operating at 80 kV. Average particle size and polydispersity index (PdI) 
were also measured by dynamic light scattering and the surface charge 
of the NPs was investigated through zeta potential measurements (in 
both cases using the same Zetasizer). All samples were analyzed three 
times, from which the average and standard deviation (SD) were 
calculated. Chemical characterization was performed by Fourier 
transform infrared spectroscopy (FT-IR) using KBr pellets. X-ray 
diffraction (XRD) experiments were performed to identify the 
crystallographic structure of MNPs and MNPsPMMA-FA NPs. The 
crystalline phase of NPs was identified by XRD measurements using an 
XPert-Pro diffractometer, Cu-Kα radiation (45 kV/40 mA) in the 2θ 
range of 20-80
o
. Thermogravimetric analysis (TGA) was performed. 
The MNPs(OA) and MNPsPMMA-FA NPs were measured through 
TGA runs under nitrogen atmosphere at a heating rate of 10 °C/min. A 
MicroSense model EV9 vibrating sample magnetometer (VSM) was 
used to measure the hysteresis loops of MNPs(OA) and MNPsPMMA-
FA NPs. All analyses were performed at room temperature. 
6.4 In vitro studies 
6.4.1 Cell culture and maintenance 
 
K562 cells were cultured in Roswell Park Memorial Institute 
Medium (RPMI) (GIBCO, São Paulo, SP, Brazil) supplemented with 
10 % heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 
100µg/ml streptomycin and 10 mM HEPES under 5 % CO2 humidified 
atmosphere in 75 cm
2
 flasks at 37 °C. Cell lines were purchased from 
American Type Culture Collection (ATCC, Rockville, MD, USA). L929 
cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
(GIBCO, São Paulo, SP, Brazil) supplemented with 10% heat-
inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml 
streptomycin and 10 mM HEPES under 5 % CO2 humidified 
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atmosphere in 75 cm
2
 flasks at 37 °C. Cell lines were purchased from 
American Type Culture Collection (ATCC, Rockville, MD, USA).  
6.4.2 Viability assay (MTT assay) 
 
The MTT cell proliferation assay was employed to assess cell 
viability after the cytotoxic assay. Briefly, 150μl of medium was 
removed and 50μl of MTT solution (5 mg.ml
−1
) was added to each well. 
The cells were then incubated for 4 h, at 37 °C and 5% CO2 to allow the 
formazan-formation reaction. Following incubation, the medium 
containing the MTT solution was removed, and the formazan crystals 
were dissolved in 2-propanol. The optical density was measured at 570 
nm and 690 nm using a Safire2 microplate reader (Tecan Group Ltd.). 
The results are presented as survival percentage, where the control 
(untreated cells) was 100%.  
6.4.3 Cellular uptake by fluorescence microscopy 
 
 The intracellular fate of carrier systems marked with 6-
coumarin (MNPsPMMA and MNPsPMMA-FA) were evaluated with 
fluorescence microscopy. L929 and K562 cells were cultured at a 
density of 5x10
5
 cells/mL, 200 mL/well. MNPsPMMA and 
MNPsPMMA-FA NPs were incubated at a low temperature (4°C), 
blocking receptor-mediated endocytosis mechanisms (LEAMON and 
LOW, 1991; GARCÍA-DÍAS et al, 2011), and at 37 °C with a 
concentration of 100 µg/mL. After 2 h of incubation, L929 were washed 
with PBS and the coverslips covering the bottom of the plate were 
removed and placed on a glass slide. The K562 cells were washed with 
PBS and placed on a glass slide. Cells were analyzed under a 
fluorescence microscope (Olympus BX41). Cell morphology and 
cellular uptake were evaluated by optical microscopy and the 
fluorescence of NPs was monitored by fluorescence microscopy. Cell 
images were acquired using emission mode with 20x objective after 
exciting the sample from 450 nm to 490 nm using barrier filters. 
Fluorescence imaging at a wavelength of 505 nm was collected. In order 
to quantify the 6-coumarin fluorescence, image analysis was performed 
using ImageJ software.  
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6.4.3 Hemolysis assay 
 
In order to analyze the effect of MNPsPMMA-AF in normal red 
blood cells (RBC), five human blood samples were collected according 
to the ethics committee requirements (CEPSH n° 913/2010). Briefly, 4 
mL of whole blood was added to 8 mL of a sterile solution of sodium 
chloride in water (saline) and the RBCs were isolated from serum by 
centrifugation at 10,000 × g for 5 min.  The RBCs were further washed 
five times with saline solution, after that, the RBCs were diluted in 2 mL 
of saline. Then 120 µL of the diluted RBC suspension was added to 880 
µL of water or saline. Samples were treated with MNPsPMMA-AF at a 
concentration of 50 and 100 µg.mL
-1
. All samples were prepared in 
triplicate and the suspension was briefly vortexed before undergoing a 
gentle stirring at 37 °C for 60 min. Afterwards, the mixture was briefly 
vortexed again and centrifuged at 10.000 × g for 5 min. 100 μL of 
supernatant was transferred to a 96-well plate. The absorbance value of 
hemoglobin at 570 nm was measured with the reference wavelength at 
540 nm. 120 µL of the diluted RBC suspension incubated with 880µL of 
water and saline were used as the positive and negative control, 
respectively (Yu et al,. 2011; Wang et al, 2009). Hemolysis percentage 
was calculated according to Eq. 2: 
 
          ( )  
                                  
                                 
                                       
Eq. (2) 
6.5 RESULTS AND DISCUSSION 
 
The polymerization kinetics of NPs with and without FA 
obtained by miniemulsion polymerization was verified by gravimetric 
conversion. Analysis of residual monomer is an important parameter to 
be evaluated, since the total conversion of the monomer to polymer 
avoids possible toxic effects of the residual monomer, allowing 
application of the PMMA NPs in the biomedical field 
(BETTENCOURT and ALMEIDA, 2010; GOSAVI et al, 2010).  The 
gravimetric conversion presented in Figure 6.1, showed that around 
200 min of reaction the conversion of MNPsPMMA and MNPsPMMA-
FA reached approximately 98%. As can be observed in Fig. 6.1, the 
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final conversion did not reach 100%, probably due to the loss of 
monomer (MMA) by evaporation during the emulsification and 
polymerization stages. Monomer evaporation can occur due to high 
vapor pressure of the MMA. It is important to mention that FA did not 
interfere in the polymerization rate.  
 
Figure 6.1 Gravimetric conversion analyses of the MNPsPMMA and 
MNPsPMMA-FA NPs obtained by miniemulsion polymerization. 
   
 
The results of the DLS and TEM analyses are presented in Fig. 
6.2. DLS analyses (Figure 6.2a and 2c) showed that the MNPsPMMA 
and MNPsPMMA-FA NPs have intensity average particle diameters of 
104 ± 3.9 nm and 134 ± 3.5 nm, and a polydispersity index of 
0.11 ± 0.02 and 0.14 ± 0.02, respectively. The FA adsorption on NPs 
surface increased the average size by approximately 30 nm, when 
compared to NPs without FA. The broadening of the particle size 
distribution and the increase in particle size can be attributed to the 
adsorption of FA on the NP surface. TEM images of MNPsPMMA-FA 
showed dark regions (black arrow) (Figure 6.2b and d), which are 
attributed to the presence of MNPs (5-13 nm in diameter) encapsulated 
in PMMA NPs. The MNPsPMMA-FA obtained by miniemulsion 
polymerization presented a sub micrometric size with a spherical 
morphology and unimodal size distribution. Other important factors in 
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the preparation of NPs for biomedical application is the zeta potential, 
since particle size can influence their ability to interact with cells. At pH 
7.4 the zeta potential of MNPsPMMA (-37mV± 4.8) and MNPsPMMA-
FA NPs (-38 mV ± 4.5) are not significantly different. The negative zeta 
potential can be attributed to the carboxylic groups of oleic acid and 
folic acid on the nanoparticle surface. The high negative values of zeta 
potential are related to the good colloidal stability of NPs and their 
possible interactions with biological medium (HE et al, 2010).  
 
 
Figure 6.2 a and c Dynamic light scattering; b and d transmission electron 
microscopy images of MNPsPMMA and MNPsPMMA-FA NPs, respectively. 
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The FTIR analyses (Figure 6.3) were performed, in order to 
evaluate possible chemical interactions of MNPs and FA on PMMA 
NPs. FTIR spectrum (Figure 6.3a) showed a band at 1736 cm
-1
 
corresponding to C=O groups of PMMA. In addition, the bands in the 
3000–2800 cm
-1
 region are attributed to the stretching of C-H bonds of 
the saturated alkane in PMMA. The peak at approximately 580 cm
-1
 
corresponds to asymmetric stretching vibrations of Fe-O ligands, which 
is attributed to the MNPs (ANDHARIYA et al, 2013; FEUSER et al, 
2015a). The absorption bands at 1694 (amide I), 1603 (amide II) and 
1482 cm
-1
 (ring phenyl) are characteristic peaks of FA (DUAN et al, 
2012; PAN et al, 2013; SAHOO et al, 2013; YOO et al, 2013; ZHANG 
et al, 2007). The FTIR spectrum of MNPsPMMA-FA NPs suggested an 
adsorption of FA onto NPs due to the appearance of an additional band 
at 1694 cm
-1
, as can be seen in Fig. 6.3b.               
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Figure 3 A FTIR spectrum: a MNPs(AO), PMMA, FA, MNPsPMMA and 
MNPsPMMA-FA and b FTIR spectrum at low scale: FA and MNPsPMMA-FA 
NPs. 
 
X-ray diffraction (XRD) patterns for the naked MNPs(OA) and 
MNPsPMMA-FA NPs are shown in Figure 6.4. Figure 6.4 shows six 
characteristic peaks from the cubic inverse spinel structure of bulk 
magnetite/maghemite, observed at 2θ = (220), (311), (400), (422), (511) 
and (440) (DORNIANI et al, 2012; YANG et al, 2014). These results 
demonstrate that the MNPsPMMA-FA have the expected crystalline 
structure of magnetite/maghemite. An additional broad peak for the 
MNPsPMMA-FA NPs was observed at an angle between 10 and 20°, 
which are characteristic of amorphous polymers. (FEUSER et al, 2015a; 
SAHOO et al, 2013).  
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Figure 6.4 XRD powder diffraction patterns of MNPs(OA) and  MNPsPMMA-
FA NPs 
 
TGA analysis was performed estimating the total concentration 
of MNPs in formulation. Figure 6.5 showed mass loss in the temperature 
range from 20 to 220 °C, which can be attributed to the evaporation of 
water. (NAN et al, 2013). The weight loss between 230 and 420 °C 
correspond to the polymer PMMA, which are completely degraded 
when reaching approximately 410 °C, co-stabilizer (Crodamol), OA and 
FA contribute to the major portion of the total weight. (FEUSER et al, 
2015a ; LANDFESTER and RAMIRES 2003; MOHAPATRA et al, 
2007). The residual weight of 16% corresponds to the encapsulated 
MNPs.  
 
Figure 6.5 TGA analyses of MNPsOA and MNPsPMMA-FA NPs. 
135
 
 
 
  
The magnetic properties of MNPs(OA) and MNPsPMMA-FA 
NPs were ascertained by VSM (Figure 6.6). The encapsulation of MNPs 
in PMMA NPs with FA modified surface showed typical 
superparamagnetic behavior at room temperature (Figure 6a and b), with 
the absence of hysteresis loop and a low remanent 
magnetization/saturation magnetization (Mr/Ms) ratio value, and a 
coercive field (Hc) of 5.0x10
-2
 and 0.4, respectively 
(CHANDRASEKHARANA et al, 2011; MODY et al, 2014; NAN et al, 
2013; YANG et al, 2014). The superparamagnetic properties are very 
important for biomedical field. Thus, when an external magnetic field is 
not applied, their overall magnetization value is randomized to zero, 
avoiding the interactive behavior of the nanoparticles (Mody et al, 
2014). The value of magnetization saturation (Ms) in emu/g of MNPs 
was obtained considering the iron oxide mass determined by TGA 
(Figure 5). The Ms value was 37 emu/g and 66 emu/g for MNPsPMMA-
FA NPs and MNPs(OA). The decrease in Ms value can be attributed to 
the dense coating of PMMA, as well as oxidation processes during the 
sonication, leading to the formation of some nonmagnetic or low Ms 
iron oxide, since maghemite (𝛾-Fe2O3) has a lower Ms of 60–80 emu/g 
compared to 92-100emu/g for magnetite (CHANDRASEKHARANA et 
al,. 2011; FEUSER et al,. 2015b; LANDFESTER and RAMIRES 2003). 
However, this Ms value was enough to move encapsulated MNPs 
quickly and can be easily separated from the aqueous phase by the 
action of an external magnetic field gradient, which can be seen in Fig. 
6.6c and 6d. Hence, MNPsPMMA-FA NPs can be directed towards a 
specific target in the human body, with application of an external 
magnetic field. 
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Figure 6.7 Cytotoxicity assay.  Cytotoxicity effects of different concentrations 
of MNPsPMMA-FA on L929 and K562 cells exposed 24h. The cell viability 
was monitored through MTT assay. (p>0.05) using one-way ANOVA followed 
by post-test Bonferroni’s. 
  
Fluorescence microscopy assay was performed in order to 
evaluate the morphology and cellular uptake on L929 (non-tumor) and 
K562 (tumor) cells overexpressing FR-β (SHI et al, 2013). The cells 
were treated with 13 ug.mL
-1
 of MNPsPMMA-FA and MNPsPMMA at 
two different temperatures (4°C and 37°C). As can be seen in Figure 8, 
L929 and K562 cells incubated for 24 h at 37 °C and 4 °C, and did not 
present significant changes in their morphology. The cellular uptake 
assays showed a higher internalization of MNPsPMMA-FA than 
MNPsPMMA at 37°C in K562 cells, which can be shown by their bright 
fluorescence (Figure 6.8). These results were corroborated with the 
quantification of fluorescence, which showed a significant increase in 
fluorescence intensity of MNPsPMMA-FA when compared with 
MNPsPMMA. These increases in cellular uptake suggested that 
MNPsPMMA-FA entered into cancer cells by folate receptor-mediated 
endocytosis (GARCÍA-DÍAS et al, 2011; KAM et al, 2005; ZHENG et 
al, 2014). On the other hand, when folate receptor-mediated endocytosis 
was blocked by low temperature at 4 °C, there was no significant 
difference in cellular uptake, as can be seen in Figure 6.8 and Figure 6.9. 
However, when L929 cells were used, similar results were observed for 
137
 
 
 
  
L929 cells at 37 °C and 4 °C (Fig. 6.8 and Fig. 6.9). These results were 
expected for L929 cells, since they do not express FR, suggesting that 
the NPs entered into cells by energy-independent mechanisms (KAM et 
al, 2005; ZHENG et al, 2014). All endocytosis pathways are energy and 
temperature dependent mechanisms, which involve the uptake of NPs in 
small invaginations of membrane vesicles (RASTOGI et al, 2014). 
Finally, our results showed that the superparamagnetic PMMA NPs with 
an FA modified surface are possibly an attractive target for cancer 
selective delivery by FR (MORIYAMA et al,. 1986; MOULIN et al, 
2007; QI AND RATNAM, 2006; VAN DER HEIJDEN et al, 2009; 
WIBOWO et al, 2013). 
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Figure 6.8 Optical and fluorescence microscopy images of L929 and K562 
cells. The cells were treated with MNPsPMMA or MNPsPMMA-FA at 
concentration of 100 µg.mL
-1 
and  incubated at 37 °C or at 4 °C for 2 h, after 
this period the cell morphology was evaluated by optical microscopy and the 
fluorescence of NPs was monitored by fluorescence microscopy (Olympus 
BX41). 
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Figure 6.9 Quantification of fluorescence intensity by ImajeJ software. Cells 
(K562 and L929) were incubated with MNPsPMMA and MNPsPMMA-FA 
NPs at 37 °C and 4 °C for 2 h, labeled with 6-coumarin at concentration of 
100 µg/mL. (**p < 0.01, ***p < 0.001) using one-way ANOVA followed by 
Bonferroni’s post-test. 
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In order, to evaluate the biocompatibility on human red blood 
cells, hemolysis assays were carried out, which can be seen in Figure 
6.10. The hemolysis assay is an important test to assess cytotoxicity in 
red blood cells (CHEN et al, 2012; ZHOU et al, 2011). According to the 
criterion of Standard Test Method for Analysis of Hemolytic Properties 
of Nanoparticles (ASTM E2524-08), a percentage hemolysis > 5% 
indicates that the test material causes damage. As can be seen in Figure 
10, high concentrations of MNPsPMMA-FA incubated for 24 h with 
human red blood cells, did not exceed 5%. The non-hemolytic character 
confirms the hemocompatibility of NPs obtained by miniemulsion 
polymerization, which can be an alternative for drug delivery systems 
administered systemically for leukemic treatment. 
 
 
Figure 6.10 Hemolysis Assay of MNPsPMMA-FA.  Relative rate of hemolysis 
in human RBCs upon incubation with MNPsPMMA-FA at concentration of 50 
and 100 µg.mL
-1
. The presence of hemoglobin in the supernatant (red) was 
observed at 540 nm. Data are mean ± SD (n=3). 
6.6 CONCLUSION 
 
The synthesis of surface modified superparamagnetic PMMA 
with FA obtained by miniemulsion polymerization resulted in a stable 
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polymeric system in aqueous dispersion, with good polydispersity index 
and biocompatibility. MNPsPMMA-FA presented a significant increase 
in the K562 cell uptake at 37°C, when compared with the MNPsPMMA, 
suggesting that it enters into cancer cells by folate receptor-mediated 
endocytosis. When the MNPsPMMA-FA were incubated at 4°C, there 
was a reduction in cellular uptake, demonstrating that the mechanism of 
entering into K562 cells is energy dependent (endocytosis). The 
hemolysis assay demonstrated the hemocompatibility of MNPsPMMA-
FA, which can be administered at 100 µg/mL without causing any 
damage to human red blood cells. Moreover, other studies are being 
performed, such as, drug encapsulation for cancer treatment and cellular 
uptake assays to improve and understand the entering mechanism of 
these NPs in cells overexpressing FR-α and FR-β.  
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CHAPTER 7 
 
SYNTHESIS OF FOLIC ACID-SUPERPARAMAGNETIC 
POLY(METHYL METHACRYLATE) NANOPARTICLES 
LOADED WITH LAURYL GALLATE BY MINIEMULSION 
POLYMERIZATION AND IN VITRO STUDIES 
 
Abstract: The goals of this study were to synthesize and characterize 
superparamagnetic poly(methyl methacrylate) (PMMA) nanoparticles 
(NPs) loaded with G12 (MNPsG12PMMA) and folic acid (FA) 
adsorbed on NPs (FA-MNPSG12PMMA) obtained by miniemulsion 
polymerization (MNPsG12PMMA-FA). In vitro cytotoxicity assay on 
L929 (murine fibroblast), HeLa (uterine colon cancer), and human red 
blood cells were performed. Lastly, an uptake cellular assay was 
performed, in order to verify the uptake of MNPsG12PMMA and FA-
MNPsG12PMMA NPs into HeLa cells. FA-MNPsG12PMMA and 
MNPsG12PMMA presented an average mean diameter of 129 nm and 
105 nm, respectively, with a saturation magnetization value of 38 emu/g 
of iron oxide and superparamagnetic behavior. FA-MNPsG12PMMA 
and MNPsG12PMMA did not present any cytotoxicity effects on L929 
and human red blood cells at the doses used, but significantly inhibited 
HeLa cell growth with a biphasic release profile. However, free G12 
presented cytotoxic effects on non-tumor cells and red blood cells. 
Cellular uptake assays demonstrated a higher uptake of 
FA-MNPsG12PMMA than MNPsG12PMMA when HeLa cells were 
incubated at 37 °C. On the other hand, when the NPs were incubated at 
low temperature (4 °C) no cellular uptake was observed, suggesting that 
the NPs are internalized by energy-dependent mechanism. The higher 
cellular uptake of FA-MNPsG12PMMA (2 times) after 24h of 
incubation in HeLa cells, suggests that those targeted Folate receptor-
mediated endocytosis. Therefore our results suggest that these carrier 
systems prepared with NPs can be an excellent alternative in targeted 
drug delivery by FR and in protection drugs, preventing possible toxic 
effects of free drug. 
 
Keywords: folic acid, lauryl gallate, polymeric nanoparticles, 
superparamagnetic, folate receptor. 
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7.1 INTRODUCTION 
 
Folic acid (FA) is a water-soluble vitamin and it has been 
targeted for therapy drugs in oncology (SCOMPARIN et al, 2015; 
SAHOO et al, 2013). The folate receptor is significantly overexpressed 
on the surface of different human cancer cells (DONG et al, 2014; 
LICCIARDI et al, 2005; SALTAN et al, 2011; SCOMPARIN et al, 
2015). Folate receptor-mediated drug delivery is based on conjugation 
with FA, which is internalized by folate receptor-mediated endocytosis 
(CHEN et al, 2012; ANDHARIYA et al, 2013; PENGCHENG et al, 
2013). The main advantage of FA adsorption or functionalization in 
polymeric nanoparticles (NPs) is their absent expression on non-tumor 
cells (LICCIARDI et al, 2005; SALTAN et al, 2011). However, the 
functionalization cannot ensure the delivery of the drug when it is 
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intravenously administered (in vivo). When the drug is administered in 
the bloodstream, the following occurs: distribution in the vascular space; 
penetration through the microvascular wall; movement through the 
interstitial space; interaction with the cell surface, and lastly cellular 
uptake (CHIN and FERREIRA, 1999). However, the transfer of 
bloodstream to the interstitial space of tumor sites is done through blood 
vessel endothelial cells that do not express the tumor-specific antigens 
(ANDHARIYA et al, 2013). In order to overcome these difficulties the 
preparation of a drug delivery system with superparamagnetic properties 
can be an attractive option in cancer treatment, in which the drug could 
be guided by an external magnetic field and internalized in vivo by 
receptor-mediated endocytosis (SALTAN et al, 2011, XU et al, 2013). 
Furthermore, the application of an external magnetic field can also 
induce cell death by hyperthermia (GUPTA and GUPTA 2005; XU et 
al, 2013; FEUSER et al, 2015b, 2015c). Magnetic nanoparticles (MNPs) 
have been widely used in various biomedical applications, due their 
excellent biocompatibility (GUPTA and GUPTA 2005; LAURENT et 
al, 2010; TEJA et al, 2009). For medical field applications, MNPs must 
have combined properties of high magnetic saturation, 
superparamagnetic properties and biocompatibility (KUMAR 2011; 
ZHENG et al, 2005).  
Several strategies have been proposed in the literature to 
encapsulate MNPs in NPs via in situ polymerization (CHIARADIA et 
al, 2015; He et al, 2009; FEUSER et al, 2015b). Miniemulsion 
polymerization allows the production of polymeric NPs with unique 
characteristics, which is of great interest in biomedical applications 
(LANDFESTER and MAILANDER, 2010). The miniemulsion 
polymerization technique may be an advantageous encapsulation 
method, which can control particle size, directly dispersing the 
hydrophobic inorganic particles into the monomer phase with the aid of 
a stabilizer, it has the ability to nucleate all the droplets containing 
inorganic particles, faster polymerization rate and biocompatibility 
(LANDFESTER, MUSYANOVYCH, MAILANDER, 2010; 
MAHDAVIAN et al, 2008; QUIU et al, 2007). 
The encapsulation of anticancer drugs in polymeric NPs with 
superparamagnetic properties can be an excellent strategy in cancer 
treatment, ensuring selective drug delivery and reducing side effects 
(DONG et al, 2014; LAPINA et al, 2013; MODY et al, 2014). Gallic 
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acid (GA) is a natural antioxidant, which is obtained from the hydrolysis 
of natural plant polyphenols (OW and STUPANS, 2003; WANG et al, 
2007). GA and its ester derivatives, such as octyl (G8) and lauryl gallate 
(G12), have been shown to be involved in a wide variety of biological 
actions. The biological activity of GA and its derivatives has been 
described in the literature as antimalarial (KLEIN and WEBER 2001), 
antioxidant (GRUNDHOFER and NIEMETZ, 2007; OW and 
STUPANS, 2003), anticancer (Zhao and Hu, 2013) and antibacterial 
(MANNA and KUO, 1999).  The only difference among the ester 
derivatives is found in the number of carbon atoms in the aliphatic side 
chain, giving them different physicochemical characteristics, especially 
lipophilicity evaluated by the partition coefficient value (LOCATELLI 
et al, 2013; OW and STUPANS, 2003; ROSSO et al, 2006). These ester 
derivatives, especially those with eight or more carbon atoms in the 
side-chain, were more efficient than GA in antiviral, antifungal, 
antioxidant and antitumoral activities (CORDOVA et al, 2011; 
LOCATELLI et al, 2013). These many biological activities have been 
correlated to the amphipathic character by increasing the cell 
membranes affinity and permeability (SAEKI et al, 2000; LOCATELLI 
et al, 2013). Although some of these ester derivatives showed a high 
cytotoxic activity, the chemical derivatization decreased their water 
solubility, constituting a disadvantage for intravenous administration 
(STELLA et al, 2007). According to Ximenes and collaborators (2010), 
GA and ester derivatives could interact and disrupt the erythrocyte 
membrane, another disadvantage for systemic administration. Another 
disadvantage involving in vivo administration of GA is poor 
pharmacokinetic profile (low bioavailability) (ALVES et al, 2016).  
Therefore the encapsulation of G12 in superparamagnetic polymeric 
nanoparticles (NPs) can increase site-specific drug concentration 
(increased bioavailability), reduce toxic effects on non-tumor cells or 
tissues, protecting and preventing possible aggregation of encapsulated 
drugs (DANHIER et al, 2012; SULISTIO et al, 2011). In addition, NPs 
can improve intravenous administration, when it is dispersed in an 
aqueous medium, providing an excellent strategy for cancer treatment 
(ORTEAG et al, 2011; SULISTIO et al, 2011).  
With the aim of improving target drug delivery, we synthetized 
and characterized superparamagnetic poly(methyl methacrylate) 
(PMMA) nanoparticles loaded with G12 (MNPsG12PMMA) and FA 
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adsorbed in NPs (FA-MNPsG12PMMA) by miniemulsion 
polymerization. The nanocarriers were developed and their polymeric 
structure characterized as: morphology by transmission electron 
microscopy; average particle size and polydispersity index; zeta 
potential; Fourier-transform infrared spectroscopy; thermogravimetric 
analysis; and determination of the superparamagnetic properties. A 
release study was performed to evaluate the profile and release kinetics. 
In vitro cytotoxicity, biocompatibility and uptake assays were 
performed.  
7.2 MATERIALS AND METHODS 
7.2.1 Materials  
 
For synthesis of magnetic nanoparticles coated with oleic acid 
(MNPsOA), the following reagents were used (high purity grade): 
ferrous sulfate (FeSO4⋅4H2O), iron (III) chloride hexahydrate 
(FeCl3⋅6H2O), ammonium hydroxide (99%), and oleic acid (OA), all 
purchased from Vetec. For the preparation of NPs, the following 
reagents were used: methyl methacrylate (MMA), obtained from Arinos 
Química Ltda, azobisisobutyronitrile (AIBN) and FA purchased from 
Vetec. G12 obtained from sigma-aldrich, lecithin obtained from Alpha 
Aesar and Crodamol (as co-stabilizer) purchased from Croda. Distilled 
water was used throughout the experiments. 
7.2.3 Methods 
7.2.3.1 Synthesis of magnetic nanoparticles coated with oleic acid 
(MNPs-OA) 
 
MNPs-OA nanoparticles were prepared by co-precipitation as 
described by Feuser and collaborators (2015b). Briefly, FeCl3.6H2O and 
FeSO4.7H2O (mole ratio of 1:1.2) were dissolved in a beaker containing 
distilled water under mechanical stirring in the 800 rpm range. Then an 
ammonium hydroxide solution (11 mL) was rapidly added to the 
solution. After 1 h, 30 mL was added to the OA and the stirring process 
continued (800 rpm) for 30 min. The MNPs-OA produced were 
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centrifuged and washed three times with ethanol to remove unreacted 
OA.  
7.2.3.2 Preparation of MNPSG12PMMA nanoparticles 
 
MNPsG12PMMA nanoparticles were prepared through 
miniemulsion polymerization. The simultaneous encapsulation of MNPs 
and G12 was the same as described by Feuser and collaborators (2015c). 
Initially 1 mL of NMP containing 40 mg of lauryl gallate was added 
dropwise into a beaker containing 20 mL of distilled water (aqueous 
phase) under sonication with an amplitude of 70% (Fisher Scientific, 
Sonic Dismembrator, 500 W). Then, the organic phase containing 2 g of 
MMA (monomer) coated with 0.2 g of MNPs (magnetic nanoparticles), 
0.1 g of lecithin (surfactant), 0.1 g of miglyol (costabilizer) and 0.04 g 
of AIBN (initiator) was added dropwise under higher shear to the 
previous aqueous lauryl gallate dispersion. The sonication was 
continued for 5 min (10 s on and 1 s off) in a beaker immersed in an ice 
bath to avoid a temperature increase during sonication. The 
miniemulsion was transferred to glass tubes (10 mL) at 70 °C, where 
polymerization took place for 3 hours under light protection. 
Afterwards, the material was cooled, centrifuged and washed several 
times and ressupended with phosphate buffered saline (PBS) at pH 7.4. 
The polymeric NP suspension was stored at room temperature.  
The process for the preparation of NPs loaded with G12 
(G12PMMA) was similar to the method described for MNPsG12PMMA 
(described above), however, MNPs were not added in the organic phase. 
7.2.3.3 Preparation of FA-MNPsG12PMMA nanoparticles 
 
FA-MNPsG12PMMA nanoparticles were prepared by 
miniemulsion polymerization. Initially 1 mL of NMP containing 40 mg 
of lauryl gallate was added dropwise into a beaker containing 20 mL of 
distilled water and 0.002 g of FA (aqueous phase) under sonication with 
an amplitude of 70% (Fisher Scientific, Sonic Dismembrator, 500 W). 
Next, the organic phase (containing 2 g of MMA (monomer) coated 
with 0.2 g of MNPs, 0.1 g of lecithin (surfactant), 0.1 g of miglyol 
(costabilizer) and 0.04 g of AIBN  (initiator) was added dropwise under 
higher shear to the previous aqueous lauryl gallate dispersion. The next 
steps are the same as previously described. For the preparation of G12 
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loaded in PMMA NPs with FA adsorbed in NPs (FA-G12PMMA) the 
procedure was the same (without the addition of MNPs in the organic 
phase).  
The preparation of FA adsorbed in PMMA NPs (FA-PMMA) 
was similar to that described by Feuser and collaborators (2014). The 
difference is the addition of FA (0.002 g) in the aqueous phase.   
7.2.4 Characterization  
 
The NPs morphology was observed using a JEM 2100F 
transmission electron microscope (TEM) operating at 100 kV. For TEM 
analysis, several drops of the diluted sample (1:10) was placed on a 200 
mesh Formvar/carbon copper grid (Electron Microscopy Science). After 
drying, samples were sputter-coated with a thin layer of carbon film to 
avoid the degradation of the PMMA under the electron beam and 
observed at 80 kV. Average particle size and polydispersity index (PdI) 
were also measured by dynamic light scattering and the surface charge 
of the NPs was investigated through zeta potential measurements (in 
both cases using the same Zetasizer). All samples were analyzed three 
times, from which we calculated the average and standard deviation 
(SD). Fourier-transform infrared spectroscopy (FT-IR) was used to 
confirm the chemical structure of the NPs using a KBr pellet. 
Ultraviolet-visible (UV-vis) spectrum was performed to verify the FA 
adsorption in NPs. The NPs were measured through TGA runs under a 
nitrogen atmosphere at a heating rate of 10 °C/min. A MicroSense 
model EV9 vibration sample magnetometer (VSM) was used to measure 
the hysteresis loops of NPs. For FTIR, TGA and VSM analyses the 
samples were centrifuged (13.400rpm) and lyophilized (Lyophilizer, 
FreeZone 4.5-L Benchtop Freeze Dry System; Labconco, Kansas City, 
USA)  
7.2.4.1 Encapsulation efficiency of G12 (EE) 
 
The EE of G12 was analyzed using UV-Vis spectrophotometry, 
where 10 mg of NPs were dissolved in NMP, the common solvent for 
both drug and polymer. The determination coefficient (R
2
) exceeded 
0.997, with excellent linearity (0.2 – 2µg/mL). The G12 concentration 
was measured at 273 nm (ultraviolet region of the electromagnetic 
spectrum) using a calibration curve with different concentrations of 
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lauryl gallate dispersed in NMP. The EE% of G12 was calculated from 
Eq. (1): 
  ( )  
  
  
⁄                                                                                                      
(1)    
where EE is the G12 encapsulation efficiency, M1 is the mass of G12 in 
NPs and Mt is the mass of G12 used in formulation. The experiments 
were run in triplicate (n=3). The NPs were measured through TGA runs 
under nitrogen atmosphere at a heating rate of 10 °C/min. A MicroSense 
model EV9 vibrating sample magnetometer (VSM) was used to measure 
the hysteresis loops of MNPs and superparamagnetic NPs.  
7.5 In vitro studies 
7.5.1 Controlled and kinetic release 
 
The release was carried out in the diffusion cell. NPs (15 mg) 
were weighed and placed in the donor compartment of the diffusion cell. 
A cellulose acetate membrane (cellulose membrane tubing Dialysis, 
Follow-Aldrich, Ref D9652-100TF) was used for separating donor 
compartments containing the nanoparticles of the receptor compartment 
that contained 20 ml of PBS pH 7.4 with 0.5 % SDS or PBS pH 5.5 with 
0.5 % SDS. A release study with acidic medium receptor (PBS pH 5.5 
with 0.5 % SDS) was carried out to simulate the medium lysosomal of 
tumor cells. The membrane is thin and porous allowing free diffusion of 
the solvent and drug. Receptor medium was continuously stirred 
(100 rpm) and the temperature was maintained at 37 
o
C in a 
thermostatically controlled water bath. The release studies followed the 
sink conditions. At 1, 2, 4, 6, 24, 48, 72, 96 and 120 h, an aliquot was 
withdrawn from the receptor medium of the release studies. The release 
study was performed in triplicate (n=3 determinações). The drug 
released in the receptor medium was quantified by spectrophotometry 
using the visible region of the spectrum (273 nm). The analytical curve 
was made in the concentration range from 1.6 to 8.8 µg.mL
-1
 with a 
determination coefficient of 0.999. The release profile was obtained by 
associating the percentage of drug released with time. The release data 
were fitted using the mathematical models of zero order (      
   ), first order (             ) and Higuchi (       
   ) 
described by Costa and Lobo (2002), and the determination coefficient 
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(R
2
) and straight line equation were determined using the software 
Excel. The mathematical model with best fit is the model that provides 
the highest value of determination coefficient. 
7.5.2 Biocompatibility assay on L929 (murine fibroblast) cells 
 
The L929 cell lines were selected to evaluate cytotoxicity as a 
direct contact test, as recommended by ISO 10993 for in vitro toxicity. 
The cells were cultured in Dulbecco’s Modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, penicillin (100 
units/ml), streptomycin (100 mg/mL), and 4 mM/L of glutamine at 
37 °C in tissue culture flasks with 5 % CO2. For experimental purposes, 
trypsinized cells were adjusted to a concentration of 1x10
4
 cells/well 
and plated in a 96 well flat bottom culture plate. After 24 h, the cells 
were treated with a medium containing G12 dissolved in DMSO (0.1%), 
MNPsG12PMMA, and FA-MNPsG12PMMA NPs dissolved in PBS 7.4 
at five concentrations: 1, 4, 8, 12 and 16 µg.mL
-1
 (5% CO2, 37 °C). 
After of incubation time (24h) the NPs were washed three times with 
PBS and cell viability was assessed using the classical MTT assay 
(Sigma, MO, USA). 
7.5.3 In vitro cytotoxicity assay on HeLa (human cervical cancer 
cells) cells 
 
HeLa cell lines were obtained from the Adolfo Lutz Institute 
(São Paulo). HeLa cells were grown in MEM medium containing 7.5% 
fetal bovine serum and maintained at 37 °C in a humidified incubator 
containing 5% CO2. The HeLa cells were seeded at 1x10
4 
cells/well in 
96-well plate. After 24 h, the cells were treated with a medium 
containing G12 dissolved in DMSO (0.1%), MNPsG12PMMA, and FA-
MNPsG12PMMA NPs dissolved in PBS 7.4 at five concentrations: 10, 
11, 12, 13 and 14 µg.mL
-1
 (5% CO2, 37 °C). After 24 h of incubation the 
cells were washed three times with PBS (7.4) and the MTT cell viability 
assay was performed.  The cytotoxicity assay was carried out in 
triplicate, with three wells for each condition.  
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7.5.4 MTT viability assay 
 
The MTT cell proliferation assay was employed to assess cell 
viability after both the cytotoxic assays. Briefly, 200μl aliquots of MTT 
solution (5 mg.ml
−1
) were added to each well and incubated for 3 h (37 
°C and 5% CO2), to allow the formazan-formation reaction. Following 
incubation, the medium containing the MTT solution was removed, and 
the formazan crystals were dissolved in DMSO. The absorbance was 
measured at 550nm using an Infinite 200 TECAN microplate reader. 
The results are presented as survival percentage (100%), where the 
control group contained 1% DMSO (v/v). 
7.5.5 Hemolysis assay 
 
This study was approved by the medical ethics committee of 
Polydoro Ernani de São Thiago University Hospital (Florianopolis, 
Brazil). Citrate-stabilized human blood was freshly collected and used 
within 3 h of being drawn. 4 mL of whole blood was added to 8 mL of a 
sterile solution of sodium chloride in water (saline) and the human red 
blood cells (RBCs) were isolated from serum by centrifugation at 
10.000 × g for 5 minutes. The RBCs were further washed five times 
with saline solution. Following the last wash, the RBCs were diluted in 
2 mL of saline solution and then 120 µL of the diluted RBC suspension 
was added to 880µL of water or saline. The G12, MNPsG12PMMA and 
FA-MNPsG12PMMA samples were treated at concentration 10, 25 and 
50µg.ml
-1
. All samples were prepared in triplicate and the suspension 
was briefly vortexed before gentle stirring at 37 °C for 60 minutes. After 
that, the mixture was briefly vortexed again and centrifuged at 10,000 × 
g for 5 minutes. 100 μL of supernatant from the sample tube was 
transferred to a 96-well plate. The absorbance value of hemoglobin at 
570 nm was measured with the reference wavelength at 540 nm. The 
120 µL of diluted RBC suspension incubated with 880 µL of water and 
saline was used as the positive and negative control, respectively. The 
hemolysis percentage (%) was calculated using Equation 1:  
Hemolysis (%) 
(sample absorbance-negative control) 
(positive control-negative control)
 100%                                                     
(1)    
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7.5.6 Cellular uptake assay by laser scanning confocal microscopy 
 
HeLa cells (5x104) were cultured on 13 mm diameter glass 
coverslips in 24 well plates for three days. Cells were then treated with 
10µg/mL of MNPsG12PMMA or FA-MNPsG12PMMA and incubated 
for 1 hour, at 37 ºC. In order to block the endocytotic pathways, NPs 
were also incubated for 1 h at 4 ºC (ZHENG et al, 2014). After the 
incubation, cells were washed 3 times with PBS, fixed with 2% 
paraformaldehyde (Electron Microscopy Science) in PBS for 20 minutes 
at 22 ºC, then mounted using Prolong Gold with DAPI (Thermo Fisher) 
and examined using laser scanning confocal microscopy A1RSi+MP 
(Nikon Corp). For images the 405 laser for DAPI excitation was used 
and 488 laser for NP excitation was used. For the study of cellular 
uptake by confocal microscopy, the polymeric NPs were marked with 6-
coumarin, a highly fluorescent molecule (green).  
7.5.7 Cellular uptake assay by flow cytometry  
 
HeLa cells (10
3
) were cultured in 12 well plates for 24h. Cells 
were then treated with 10 µg/mL of MNPsG12PMMA or FA-
MNPsG12PMMA, both incorporated with 6-coumarin, and incubated 
for 24 hours, at 37 ºC. Cells were collected by trypsinization and washed 
twice with PBS. Cellular uptake efficacy was evaluated by flow 
cytometry using a BD FACScalibur cytometer and analyzed using 
Flowing software.  
7.6 RESULTS AND DISCUSSION 
 
FA-MNPsG12PMMA nanoparticles were obtained successfully 
by miniemulsion polymerization. This technique showed a high EE of 
G12 (87 ± 2 %). TEM analysis (Figure 7.1) showed that the 
incorporation of G12 and MNPs didn’t affect the morphology and size 
of NPs. The NPs presented a mean size of 100nm approximately, a 
relatively narrow size distribution and spherical morphology. The 
superparamagnetic NPs presented some darker regions of very small 
size, around 5-14 nm in diameter, which are attributed to the core 
formed by MNPs, as can be observed in Fig 7.1B, E and F 
(FILIPPOUSI et al, 2013; ZHENG et al, 2005). DLS analyses 
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(Table 7.1) showed that the FA adsorption on polymeric NPs surface 
increased the average size by approximately 25 nm, when compared to 
polymeric NPs without FA. The broadening of the particle size 
distribution and the increase in particle size can be indicative of 
adsorption of FA on the NP surface. Observing Figure 7.1C, D, E and F, 
we can suggest that the FA was adsorbed on the surface of polymeric 
NPs (black arrow). Zeta potential analysis (Table 7.1) showed a 
negative surface charge, contributing to good colloidal stability (He et 
al, 2010). The negative surface charge of NPs can be attributed to the 
carboxylic groups (OA and PMMA) and the surfactant (lecithin) on the 
nanoparticle surface (FEUSER, 2015b). 
 
 
Figure 7.1 TEM analysis of NPs obtained by miniemulsion polymerization: (A) 
G12PMMA; (B) MNPsG12PMMA; (C and D) FA-G12PMMA; (E and F) FA-
MNPsG12PMMA. 
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Table 7.1 Analysis of average droplet (Dg) and particle (Dp) diameter, initial 
and final polydispersity index (PdIg and PdIp) and zeta potential of NPs obtained 
by Zetasizer 
Samples Dg 
(nm) 
Dp 
(nm) 
PdIg PdIp Zeta 
Potential 
(mV) 
PMMA 90 ± 3 98 ± 3 0.08 ± 0.0.1 0.11 ± 0.0.1 -37 ± 3 
G12PMMA 103 ± 4 106 ± 4 0.13 ± 0.02 0.13 ± 0.02 -38 ± 4 
MNPsG12PMMA 98 ± 3 105 ± 3 0.14 ± 0.02 0.18 ± 0.03 -42 ± 6 
FA-PMMA 112 ± 2 121 ± 3 0.14 ± 0.02 0.13 ± 0.01 -36 ± 2 
FA-G12PMMA 116 ± 3 126 ± 4 0.13 ± 0.02 0.16 ± 0.02 -34 ± 5 
FA-
MNPsG12PMMA 
117 ± 4 129 ± 4 0.19 ± 0.02 0.19 ± 0.02 -38 ± 4 
 
The XRD patterns of free G12, FA-PMMA, FA-
MNPsG12PMMA and MNPsG12PMMA are shown in Figure 7.2. The 
XRD profile of free G12 exhibited several characteristic peaks at 
diffraction angles of 15.94°, 18.91° and 22°, confirming the crystalline 
form of G12. However, these peaks were not observed in the 
diffractograms when the G12 was encapsulated in PMMA NPs, 
indicating that the drug (G12) can be molecularly dispersed in the 
polymeric matrix in its amorphous state (FEUSER et al, 2015c; ALVES 
et al, 2016). The peaks observed at 2θ: (220), (311), (400), (422), (511) 
and (440) in samples of MNPsG12PMMA and FA-MNPsG12PMMA 
are characteristic of magnetite (Fe3O4) encapsulated in PMMA NPs 
(DALLAS et al, 2006; FEUSER et al, 2015b; SAHOO et al, 2013). An 
additional broad peak for the FA-PMMA, FA-MNPsG12PMMA and 
MNPsG12PMMA was observed at an angle between 10 and 20°, which 
is characteristic of an amorphous polymer (LEKSHMI et al, 2010).   
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Figure 7.2 X-ray powder diffraction patterns of free G12, FA-PMMA (left), 
FA-MNPsG12PMMA and MNPsG12PMMA (right) 
 
FTIR analyses were performed to verify the incorporation of 
G12 and MNPs in the PMMA nanoparticles. In addition, the FTIR 
technique can indicate FA adsorption. In Figure 7.3A, the peaks at 
1736 cm
-1
 and 3000 – 2800 cm
-1
 correspond to C=O groups and 
stretching of C-H bonds, characteristic of PMMA nanoparticles 
(FEUSER et al, 2014). The peak at 577cm
-1
 is related to the vibration of 
the Fe-O bond, which matches well with the characteristic peak of 
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MNPs (CHIARADIA et al, 2015; GAO et al, 2010; SAHOO et al, 
2013). Comparing the FTIR spectra of PMMA nanoparticles and 
MNPsG12PMMA nanoparticles we confirmed that there is no 
significant interaction between drug (G12) and polymer, and the G12 is 
embedded into a polymeric matrix, corroborating with XRD analysis. 
FTIR spectrum of FA presented peaks at 1680, 1590, 3540, 3423 and 
3315cm
-1
 corresponding to amide I, amide II, ring O–H, NH2 and 
secondary NH groups (ANDHARIYA et al, 2012; MOHAPATRA et al, 
2007). The appearance of bands at 3400cm
-1 
and 1688cm
-1 
as can be 
seen in Figure 3B and D (small scale), can be indicative of FA 
adsorption, due to the interaction of hydrogen bonds (DONG et al, 2014; 
ZHANG et al, 2007). It is worth mentioning that the NPs without FA 
(Figure 7.3C) didn’t present bands at 3400 and 1688 cm
-1
. To confirm 
these results a UV spectrum (Figure 7.3E) was performed. The bands at 
284 nm reference the absorption of FA in UV spectrum (LICCIARDI et 
al, 2005; YANG et al, 2014; YOO et al, 2013), and confirms the FA 
adsorption onto the surface PMMA nanoparticles.  
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Figure 7.3 FTIR spectra of NPs without FA (A and C); FA adsorbed on NPs (B 
and D) and UV-vis spectra of FA adsorbed on NPs (E). 
 
TGA analyses (Figure 7.4) were performed to determine the 
total concentration of MNPs in the formulation (GAO et al, 2010). The 
MNPs-OA presented a weight loss at around 200 and 440 °C (40 %), 
attributed to the OA on the surface of MNPs (RAMIRES and 
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LANDFESTER, 2003). The total concentration of MNPs obtained by 
the co-precipitation method was of 60%. In the case of 
MNPsG12PMMA and FA-MNPsG12PMMA mass loss is gradual and it 
can be clearly observed that the polymer is completely degraded when 
reaching about 430 °C (Feuser et al, 2014). The residual concentration 
of approximately 19 %, corresponds to the MNPs. The other 81% 
corresponds to the PMMA and AO on the surface of MNPs.  
 
 
Figure 7.4 TGA analyses of MNPs-OA (FEUSER et al, 2015b) and FA-
MNPsG12PMMA 
 
The magnetic properties of NPs were studied by VSM. Figure 
7.5 shows that all NP coated MNPs presented a high value of saturation 
magnetization. The samples presented a saturation magnetization value 
of approximately 38 emu/g of iron oxide (Figure 7.5A). The FA 
adsorbed onto NPs and the incorporation of G12 didn’t affect the 
saturation magnetization value. However, the saturation magnetization 
decrease of values bulks (90-100emu/g of Fe3O4 and 60-80 emu/g of 
maghemite (𝛾-Fe2O3) when MNPs are encapsulated in NPs. This 
decrease of saturation magnetization can be attributed to the dense 
coating of the non-magnetic polymer, or because during polymerization, 
some of the Fe3O4 convert to another type of iron oxide, like 𝛾-Fe2O3, 
due to the presence of the oxidizing initiator fragments 
(CHANDRASEKHARAN et al, 2011; DALLAS et al, 2006; FEUSER 
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et al, 2015b; RAMIRES and LANDFESTER, 2003). All analyzed 
samples showed superparamagnetic behavior at room temperature, with 
an absence of hysteresis loop, low remanent magnetization/saturation 
magnetization ratio and small coercive field values (Figure 7.5B) 
(CHANDRASEKHARAN et al, 2011).  The superparamagnetic 
properties of NPs are very important for biomedical applications, which, 
without an external magnetic field their overall magnetization value is 
randomized to zero, preventing active behavior of the particles when 
there is no applied field (GAO et al, 2010; XU and SU, 2013), resulting 
in an excellent strategy to drug delivery by influence of an external 
magnetic field (Mody et al, 2014).  
 
  
Figure 7.5 VSM analyses of magnetic properties of FA-MNPsG12PMMA and 
MNPsG12PMMA nanoparticles, with magnetic field of 20 KOe and 4 KOe. 
7.6.2 In vitro studies 
7.6.2.1 Release kinetics of G12 from FA-superparamagnetic PMMA 
NPs 
 
A release study was performed at both physiological and 
lysosomal pH conditions (tumor cells are slightly acidic) (NOWICKA et 
al, 2013; SAHOO et al, 2013) at 37
 o
C, in order to evaluate the release 
163
 
 
 
  
profile of G12 incorporated into NPs with AF. The release profiles for 
pH 7.4 and 5.5 exhibited rapid release with initial burst effect from 0 to 
1 h. At 1 h, the release profile followed a biphasic pattern in both 
samples (FA-G12PMMA and FA-MNPsG12PMMA) and pH conditions 
(7.4 and 5.5): release was slow and linear from 1 to 6 h and very slow 
and sustained from 24 to 120 h (Figure 7.6). The release of G12 from 
NPs was accelerated in pH 5.5 that simulates the lysosomal medium of 
the tumor cells (Sahoo et al, 2013) in comparison with physiological pH 
(pH 7.4). Results also indicated that G12 was released more quickly 
from FA-MNPsG12PMMA NPs in comparison with FA-G12PMMA 
NPs (Figure 7.6). Thus, the polymer matrix resistance to diffusion G12 
was lower in FA-MNPsG12PMMA NPs. The biphasic pattern can be an 
excellent strategy in the development of targeted drug systems, where 
the drug is released during two periods: (I) immediate drug release to 
maintain the constant drug concentration in the blood plasma for a 
prolonged period, followed by a slow and sustained release in the target 
tissue, consequently improving patient compliance (decreases the 
number of daily administrations) and therapeutic efficacy (LI et al,. 
2014; YU et al,. 2013; GAO et al, 2011; HUANG and BRAZEL 2001).  
  
 
Figure 7.6 Release profiles of G12 loaded in NPs with FA. Data refers to 
mean ± standard deviation (n = 3) in different experiments at 37
 o
C with 
differing pH (pH 7.4 and pH 5.5). 
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The zero order, first order, and Higuchi mathematical models 
were used in this study to evaluate the release kinetics. Mathematical 
models were applied to the release data. The choice of model was based 
on the highest coefficient of determination (r
2
). The kinetics of release 
was best explained by Higuchi model followed by the zero-order model 
and finally the first order model. The Higuchi model describes the 
release drugs from a solid matrix by diffusion based on Fick's law 
(COSTA and LOBO, 2001; LEKSHMI et al, 2010). Generally, diffusion 
is the mechanism that controls the drug release in delivery systems 
produced with non-biodegradable polymers such as PMMA, and 
consequently, factors such as concentration gradient, location of the 
drug in the polymer matrix, diffusion distance, and the degree of 
swelling can influence the profile and the release rate (FU and KAO 
2010, GAO et al, 2011; RAO and GECKELER, 2011). Thus, we can 
conclude that the release of G12 from the nanocarriers followed the 
Higuchi model and the mechanism that controls the release is diffusion.  
7.6.2.2  In vitro cytotoxicity on L929 cells and hemolys  is assay 
 
Mouse fibroblast (L929) is a popular cell line recommended by 
ISO 10993-5 in many experimental aspects for polymer cytotoxicity 
testing. In this study the biocompatibility of free G12 and NPs was 
evaluated in L929 cells. The cells were treated with five different 
concentrations (1, 4, 8, 12 and 16 µg.mL
-1
 of G12). As shown in Figure 
7.7, free G12 significantly inhibited L929 cell growth in a dose-
dependent manner when these cells were treated for 24 h. Cell viability 
was 76% and 44% when the cells were treated with 4 and 16 µg.mL
-1
, 
respectively. Other studies also have demonstrated the cytotoxic effect 
of GA derivatives on L929 cells (LOCATELLI et al, 2013; SERRANO 
et al,; 1998). However, when the G12 was encapsulated in 
superparamagnetic PMMA NPs with and without FA no cytotoxic 
effects were observed on L929 cells at the same doses. Therefore we can 
conclude that the encapsulation of G12 into the polymer matrix provides 
a decrease in cytotoxic effects on L929 non-tumor cells at the used 
doses (DANHEIR et al, 2012). 
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Figure 7.7 In vitro cytotoxicity assays of free G12, MNPsG12PMMA and FA- 
MNPsG12PMMA in L929 cells at different concentrations (1 – 12µg.mL
-1
). 
Values represent the mean ± SD of the percentage of viable cells in comparison 
with the DMSO control considered as 100%. Data represent three independent 
experiments, each being performed in triplicate. Significant differences: 
* p < 0.05. 
 
In order, to evaluate the biocompatibility of red blood cells, 
hemolysis assays were carried out, as can be seen in Figure 7.8. The 
hemolysis assay is an important test for assessment of cytotoxicity on 
red blood cells (CHEN et al, 2012; ZHOU et al, 2011). According to the 
criterion of Standard Test Method for Analysis of Hemolytic Properties 
of Nanoparticles (ASTM E2524-08), a percentage hemolysis > 5% 
indicates that the test material causes damage. Hemocompatibility 
assays of free G12 on human red blood cells demonstrated a high 
hemolytic percentage at all tested concentrations. The hemolytic 
percentage reached 16, 25, 33 and 99 % when the red blood cells were 
treated with 10, 20, 40 and 80 µ.mL
-1
. On the other hand, G12 
encapsulated in FA-superparamagnetic PMMA NPs did not exceed 5% 
at concentrations of 10 (3.5 %) 20 (4.2 %), and 40 µg.mL
-1
 (4.8 %). 
When the red blood cells were exposed to high concentrations the 
hemolytic percentage reached 17%. The results obtained corroborate 
with the cytotoxicity assay. The non-hemolytic character confirms the 
hemocompatibility of NPs, which ensure the protection of G12 when 
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encapsulated in PMMA NPs.  In others words FA-MNPsG12PMMA are 
similar to the original plasma, which indicates that the NPs have no 
obvious activation or coagulation factors and thrombin generation 
(ZHOU et al, 2011). The good biocompatibility of NPs on human red 
blood cells is due main their negative surface charge. Recent studies 
reported in literature have demonstrated that the preparation of NPs with 
positive surface charges tend to cause hemolysis (JONG and BORM, 
2008; FORNAGUERA et al, 2015).  Lastly, we can affirm that the 
encapsulation of the G12 into the polymer matrix provides protection to 
the drug, which can decrease cytotoxic effects on non-tumor cells and 
offer possibility of specific targeting (cancer) when intravenously 
administered with a sustained release.        
  
 
Figure 7.8 Hemolysis assay. Relative rate of hemolysis in human RBCs upon 
incubation with Free G12 and FA- MNPsG12PMMA at concentrations:  10, 20, 
40 and 80µg.mL
-1
. Data represent mean ± SD (n = 3). (* p < 0.05) one way 
ANOVA followed by Tukey's test. 
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7.6.2.3 In vitro anticancer activity of G12 on HeLa cells 
 
The cytotoxic effects of free G12, MNPsG12PMMA and FA-
MNPsG12PMMA NPs were evaluated on HeLa cells and examined 
through the MTT assay. The aim of this study was to compare the 
cytotoxic effects of free G12 and NPs with and without FA. As can be 
seen in Figure 7.9 the free G12 did not present any cytotoxic effects on 
HeLa cells at concentrations of 10 and 11 µg.mL
-1
. MNPsG12PMMA 
NPs, induced a decrease in cell viability (19%) at a concentration of 
11 µg.mL
-1
. The cytotoxic effect using 10 and 11 µg.mL
-1
 of G12 was 
more pronounced in FA-MNPsG12PMMA NPs, which promoted 
significant reduction in cell viability, 14% and 30%, respectively. The 
free G12 induced cell death from concentrations of 12 µg.mL
-1
, with a 
reduction in cell viability of 18% (12 µg.mL
-1
) to 39% (14 µg.mL
-1
). 
However, a higher reduction in cell viability was observed when FA-
MNPsG12PMMA was exposed to HeLa cells at concentrations of 12, 13 
and 14 µg.mL
-1
, which decreased cell viability to 59%, 48% and 41%, 
respectively. FA-MNPsG12PMMA NPs, presented a higher cytotoxic 
effect than MNPsG12PMMA NPs at concentrations of 11 - 14 µg.mL
-1
. 
The optical microscopy analysis of FA-MNPsG12PMMA NPs 
(13 µg.mL
-1
) incubated at 24 h on HeLa cells, showed a significant 
change in cell morphology (Figure 7.9C), when compared with the 
control group (Figure 7.9B), resulting in a loss of cell membrane 
integrity (white arrow) and inducing cell death. Lastly, our results 
suggest that the higher cytotoxic effect of the FA-MNPsG12PMMA 
NPs can be related with an increase in cellular uptake due to the 
interaction between the folate groups adsorbed on NPs and FR of HeLa 
cells (LAPINA et al, 2013; SABHARANJAK and MAYOR, 2004; 
WIBOWO et al, 2013). 
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Figure 7.9 In vitro cytotoxicity of free G12, MNPsG12PMMA and FA-
MNPsG12PMMA at different concentrations (10 - 14µg.mL
-1
) (A). Optical 
microscopy analysis (100x) of HeLa cells: Control (B) and FA-MNPsPMMA 
(IC50) (C) after 24 h of incubation. Values represent the mean ± SD of the 
percentage of viable cells in comparison with the DMSO control considered as 
100%. Data represent three independent experiments, each being performed in 
triplicate. Significant differences: ***p< 0.0001; **p< 0.0001 and *p< 0.0001. 
7.6.2.4 Cellular uptake study by confocal microscopy and flow 
cytometry  
 
To evaluate binding to the cell surface or uptake of 
MNPsG12PMMA and FA-MNPsG12PMMA NPs, HeLa cells were 
treated with NPs marked with 6-coumarin at 37 ºC or 4 ºC (Figure 
7.10A). Assuming that at 4 ºC endocytosis is inhibited (TRINDADE et 
al, 2008; ZHENG et al, 2014), the diffusion capacity was evaluated 
across the plasmatic membrane. As can be observed in Figure 7.10, both 
NPs were not able to diffuse at 4 ºC, suggesting that some energy-
dependent process in endocytotic pathways internalized the NPs 
(PANARITI et al, 2012; ZHANG et al, 2009; ZHENG et al, 2014). 
When NPs were incubated at 37ºC, a higher cellular uptake was 
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observed in NPs with FA, as can be seen in Figure 7.10. The orthogonal 
images of MNPsG12PMMA and FA-MNPsG12PMMA NPs uptake by 
cells at 37 ºC (Fig 7.10B and C) show that those NPs were at same level 
as the nucleus of cells (observed in blue), which indicates that NPs were 
internalized, and not just binding on the cell surface. Lastly, the flow 
cytometry assay showed that FA improved the internalization of NPs 
into HeLa cells (Fig 7.10 D and E), suggesting that those were targeted 
HeLa cells by FR-mediated endocytosis, corroborating with data 
previously described.  
 
 
Figure 7.10 Cellular uptake of MNPsG12PMMA and FA-MNPsG12PMMA 
NPs. (A) Cells treated with MNPsG12PMMA or FA-MNPsG12PMMA, at 4ºC 
or 37ºC. (B) Orthogonal view of cells treated with MNPsG12PMMA at 37ºC, 
(C) Orthogonal view of cells treated with FA-MNPsG12PMMA at 37ºC. 
Observe the nuclei in blue and the compounds in green. (D) Histogram of 
fluorescence of HeLa cells treated with MNPsG12PMMA and FA-
MNPsG12PMMA NPs. (E) Quantification of cells that uptake 
MNPsG12PMMA and FA-MNPsG12PMMA NPs. 
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7.7 Conclusion 
 
In conclusion this work has demonstrated that FA-
MNPsG12PMMA NPs are suitable for encapsulation and controlled 
release of G12. The NPs were able to reduce cytotoxicity of 
encapsulated G12 in non-tumor L929 cells and red blood cells, 
protecting the drug inside the polymeric matrix, as shown in DRX and 
FTIR analysis. The FA adsorption on NPs increased the cellular uptake 
suggesting that those were targeted HeLa cells by FR-mediated 
endocytosis.  Lastly, our studies demonstrated that the FA adsorption in 
PMMA NPs obtained by miniemulsion polymerization could be an 
excellent alternative in cancer treatment with targeted drug delivery and 
controlled release of encapsulated drugs.      
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CHAPTER 8 
8. GENERAL CONCLUSION 
 
The synthesis of PMMA NPs loaded with drugs and MNPs 
obtained by miniemulsion polymerization technique, resulted in stable 
NPs, with nanometric size, superparamagnetic properties, high 
encapsulation efficiency, prolonged drug release drug protection and 
biocompatibility on tumor and non-tumor cells. The encapsulated drugs, 
ZnPc and G12, were more effective than free drugs. The incorporation 
of MNPs in PMMA NPs was effective against U87MG cells when AC 
magnetic field was applied resulting in cells death by HPT. Similar 
results were observed when ZnPc and MNPs were simultaneously 
encapsulated in PMMA NPs. In this study the synergic effect was 
demonstrated by simultaneous treatment of PDT and HPT. The FA 
adsorption on PMMA NPs presented biocompatibility in non-tumor 
cells and a higher cellular uptake on cells that overexpress FR type β 
(K562). The simultaneous encapsulation of G12 and MNPs in PMMA 
NPs with FA-modified surface, presented a higher cytotoxic on HeLa 
cells than NPs without FA. Finally, uptake assay shown that the higher 
cytotoxic effect of G12 and MNPs loaded in PMMA NPs with FA-
modified surface on HeLa cells was due to uptake cellular by FR-
mediated endocytosis. 
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